WO1991005545A1 - Liposome microreservoir composition and method - Google Patents
Liposome microreservoir composition and method Download PDFInfo
- Publication number
- WO1991005545A1 WO1991005545A1 PCT/US1990/006034 US9006034W WO9105545A1 WO 1991005545 A1 WO1991005545 A1 WO 1991005545A1 US 9006034 W US9006034 W US 9006034W WO 9105545 A1 WO9105545 A1 WO 9105545A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liposome
- liposomes
- composition
- compound
- vesicle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a liposome composition and method for administering a therapeutic compound into the bloodstream over an extended period.
- Liposomes have been proposed as a carrier for intraven ⁇ ously (IV) administered compounds.
- IV intraven ⁇ ously
- the use of lipo ⁇ somes for slow release of liposome-entrapped material into the bloodstream has been severely restricted by the rapid clear ⁇ ance of liposomes from the bloodstream by cells of the reti- culoendothelial system (RES) .
- the RES will remove 80-95% of IV injected liposomes within one hour, and effec ⁇ tively remove circulating liposomes from the bloodstream within of 4-6 hours.
- the invention includes, in one aspect, a liposome compo ⁇ sition effective to extend to at least 24 hours, the period of effective activity of an therapeutic compound which can be administered intravenously in a therapeutically effective amount, and which has a blood halflife, in free form, of less than about 4 hours.
- the composition includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole per ⁇ cent of a vesicle-forming lipid derivatized with a biocompa- tible hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range between about 0.1 to 0.4 microns, and the compound in liposome-entrapped form.
- the composition is intended for intravenous administration at a dose which contains an amount of the liposome-entrapped compound which is at least three times the therapeutically effective dose for the compound in free form.
- the hydrophilic polymer is polyethyleneglycol having a molecular weight between about 1,000-5,000 daltons, and the polymer is derivatized with the polar head roup of a phospholipid, such a phosphatidylethanol- amine (PE) .
- a phospholipid such as a phosphatidylethanol- amine (PE)
- the polymer may be other suitable biocompatible hydrophilic polymers, such as polylactic acid and polyglycolic acid.
- the composition is effective to extend to at least 48 hours, the period of thera ⁇ Chamberic activity of an intravenously injected polypeptide which can be administered intravenously in a therapeutically effec ⁇ tive amount.
- the polypeptide may be a peptide or protein, such as superoxide dismutase, glucocerebrosidase, asparagi- nase, adenosine deaminase, interferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor
- TNF - alpha, beta colony stimulating factors
- M-CSF macro- phage
- G-CSF granulocyte
- GM-CSF granulocyte, macrophage
- TPA prourokinase
- urokinase HIV-1 vaccine
- hepatitis B vaccine hepatitis B vaccine
- malaria vaccine hepatitis B vaccine
- melanoma vaccine erythropoietin
- EPO ribosome inhibitor pro- tein
- factor VIII factor VIII
- bone growth factor fibroblast growth factor
- insulin-like growth factor nerve growth factor
- platelet-derived growth factor tumor growth factors (alpha, beta), somatomedin C (IGF-1)
- IGF-1 tumor growth factors
- ribosome inhibitor pro- tein ribosome inhibitor pro- tein
- the composition is effective to deliver a therapeutically effective amount of the peptide into the bloodstream for a period of between 5-10 days.
- Also forming part of the invention is a method for exten ⁇ ding to at least 24 hours, the period of effective activity of an therapeutic compound which can be administered intravenous ⁇ ly in a therapeutically effective amount, and which has a halflife in the blood, in free form, of less than about 4 hours.
- a liposome composition of the type described above is administered intravenously to a subject at a dose which contains an amount of the compound which is at least three times such therapeutically effective amount.
- a liposome composition effective to extend to at least one week, the period of effective activity of an therapeutic compound which can be administered intra ⁇ venously in a therapeutically effective amount.
- the composi- tion includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid deri ⁇ vatized with a biocompatible hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range between about 0.07-.15 microns, and the compound in liposome- entrapped form.
- the composition is intended for subcutaneous administration at a dose which contains an amount of the lipo ⁇ some-entrapped compound which is at least ten times such therapeutically effective intravenously administered amount.
- the liposome composition is used in a method for extending the period of release of a therapeutic compound, preferably a polypeptide, in a therapeutically active amount, for a period of at least 2 weeks.
- the invention includes a liposome composition composed of vesicle-forming lipids and a vesicle- forming lipid derivatized with polylactic acid or polyglycolic acid, and a lipid composition composed of a vesicle-forming lipid having a polar head group, and a polylactic acid or polyglycolic acid moiety derivatized to the lipid's head group.
- Figure 1 illustrates a general reaction scheme for derivatizing a vesicle-forming lipid amine with a polyalkyl- 5 ether
- Figure 2 is a reaction scheme for preparing phosphati- dylethanolamine (PE) derivatized with polyethyleneglycol via a cyanuric chloride linking agent;
- PE phosphati- dylethanolamine
- Figure 3 illustrates a reaction scheme for preparing 10 phosphatidylethanolamine (PE) derivatized with polyethylene ⁇ glycol by means of a diimidazole activating reagent
- Figure 4 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polyethylene ⁇ glycol by means of a trifluoromethane sulfonate reagent
- Figure 5 illustrates a vesicle-forming lipid derivatized with polyethyleneglycol through a peptide (A) , ester (B) , and disulfide (C) linkage;
- Figure 6 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polylactic 20 acid
- Figure 7 is a plot of liposome retention time in the blood, expressed in terms of percent injected dose as a function of hours after IV injection, for PEG-PE liposomes containing different amounts of phosphatidylglycerol; 25 Figure 8 is a plot similar to that of Figure 7, showing retention times in the blood of liposomes composed of predomi ⁇ nantly unsaturated phospholipid components;
- Figure 9 is a plot similar to that of Figure 1 , showing retention times in the blood of PEG liposomes (solid tri ⁇
- Figure 10 is a plot of blood lifetimes of PEG-liposomes sized by extrusion through 0.1 micron (solid squares), 0.2 micron (solid circles), and 0.4 micron (solid triangles) polycarbonate membranes;
- Figure 11 is a plot of blood retention times in liposomes containing a vesicle-forming lipid derivatized with polylactic acid (solid squares) and polyglycolic acid (open triangles) ;
- Figure 12 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of aqueous solutions of vasopressin at total doses of 0.2 ⁇ g (closed squares), 0.8 ⁇ g (closed triangles) , and 2 ⁇ g (closed circles) ;
- Figure 13 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of PEG-liposomes containing entrapped vasopressin at total doses of 2 ⁇ g (closed squares) , 8 ⁇ g (closed triangles) , and 24 ⁇ g (closed circles) ;
- Figure 14 shows urine
- Figure 15 shows the blood clearance kinetics of free macrophage-colony stimulating factor (M-CSF) (solid triangles) , PEG-liposomes containing 30 mole percent cholesterol (solid triangles) , and M-CSF associated with the PEG-liposomes (solid circles) ;
- M-CSF free macrophage-colony stimulating factor
- Figure 16 shows the blood clearance kinetics of free M-CSF (solid triangles) , cholesterol-free PEG-liposomes (solid triangles) , and M-CSF associated with the PEG-liposomes (solid circles) ;
- Figure 17 is a plot of percent release of M-CSF into the blood from PEG liposomes containing 30 (solid, circles) and 0 (solid triangles) mole percent cholesterol;
- Figure 18A shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous administra ⁇ tion of saline (control, open circles) and free vasopressin, in an amount 2 ⁇ g (solid triangles) , 25 ⁇ g " (solid circles) , and 50 ⁇ g (solid diamonds) ; and
- Figure 18B shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous administra ⁇ tion of saline (control, open circles) and vasopressin en ⁇ trapped in PEG-liposomes, in an amount 25 ⁇ g (solid triang- les) , 100 ⁇ g (solid circles) , and 400 ⁇ g (solid diamonds) .
- FIG. 1 shows a general reaction scheme for preparing vesicle-forming lipid derivatized a biocompatible, hydrophili polymer, as exemplified by polyethylene glycol (PEG) , poly lactic acid, and polyglycolic acid, all of which are readil water soluble, can be coupled to vesicle-forming lipids, an are tolerated in vivo without toxic effects.
- the hydrophili polymer which is employed, e.g., PEG is preferably capped b a methoxy, ethoxy or other unreactive group at one end, or i one in which one end is more reactive than the other, such a polylactic acid.
- the polymer is activated at one end by reaction with suitable activating agent, such as cyanuric acid, diimadozle, anhydride reagent, or the like, as described below. Th activated compound is then reacted with a vesicle-formin lipid, such as phosphatidylethanol (PE) , to produce th derivatized lipid.
- suitable activating agent such as cyanuric acid, diimadozle, anhydride reagent, or the like
- Th activated compound is then reacted with a vesicle-formin lipid, such as phosphatidylethanol (PE) , to produce th derivatized lipid.
- PE phosphatidylethanol
- the polar group in the vesicle-formin lipid may be activated for reaction with the polymer, or th two groups may be joined in a concerted coupling reaction, according to known coupling methods.
- PEG capped at one end with a methoxy or ethoxy group can be obtained commercially in a variety of polymer sizes, e.g., 500-20,000 ' dalton molecular weights.
- the vesicle-forming lipid is preferably one having two hydrocarbon chains, typically acyl chains, and a polar head group. Included in this class are the phospholipids, such as phosphatidylcholine (PC) , PE, phosphatidic acid (PA) , phospha- tidylinositol (PI) , and sphingomyelin (SM) , where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation. Also included in this class are the glycolipids, such as cere- broside and gangliosides. Another vesicle-forming lipid which may be employed is cholesterol and related sterols.
- PC phosphatidylcholine
- PA phosphatidic acid
- PI phospha- tidylinositol
- SM sphingomyelin
- glycolipids such as cere- broside and gangliosides.
- cholesterol may be less tightly anchored to a lipid bilayer membrane, particu ⁇ larly when derivatized with a high molecular weight polyalkyl- ether, and therefore be less effective in promoting liposome evasion of the RES in the bloodstream.
- vesicle-forming lipid is intended to include any amphipathic lipid having hydrophobic and polar head group moieties, and which (a) by itself can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids, or (b) is stably incorporated into lipid bilayers in combination with phospholipids, with its hydrophobic moiety in contact with the interior, hydro- phobic region of the bilayer membrane, and its polar head group moiety oreinted toward the exterior, polar surface of the membrane.
- An example of a latter type of vesicle-forming lipid is cholesterol and cholesterol derivatives, such as cholesterol sulfate and cholesterol hemisuccinate.
- the vesicle-forming lipid may be a relatively fluid lipid, meaning that the lipid phase has a relatively low liquid-to-liquid crystal phase-transition temperature, e.g., at or below room temperature, or relatively rigid lipid, meaning that the lipid has a relatively high melting temperature, e.g., up to 50°C.
- relatively rigid lipid meaning that the lipid has a relatively high melting temperature, e.g., up to 50°C.
- the more rigid, i.e., saturated lipids contribute to greater membrane rigidity in a lipid bilayer structure and also contribute to greater bilayer stability in serum.
- Other lipid components, such as cholesterol are also known to contribute to membrane rigidity and stability in lipid bilayer structures.
- Phospholipids whose acyl chains have a variety of degrees of saturation can be obtained commercially, or prepared according to published methods.
- FIG. 2 shows a reaction scheme for producing a PE-PEG lipid in which the PEG is derivatized to PE through a cyanuric chloride group. Details of the reaction are provided in Example 1. Briefly, ethoxy-capped PEG is activated with cyanuric chloride in the presence in sodium carbonate under conditions which produced the activated PEG compound IV in the figure. This material is purified to remove unreacted cyanuric acid. The activated PEG compound is reacted with PE in the presence of triethyl a ine to produce the desired PE- PEG compound shown at VII in the figure. The yield is about 8-10% with respect to initial quantities of PEG. The method just described may be applied to a variety of lipid amines, including PE, cholesteryl amine, and glycolipids with sugar-amine groups.
- lipid amines including PE, cholesteryl amine, and glycolipids with sugar-amine groups.
- a second method of coupling a polyalkylether, such as capped PEG to a lipid amine is illustrated in Figure 3.
- the capped PEG is activated with a carbonyl diimidazole coupling reagent, to form the activated imidazole compoun shown at X in Figure 3.
- Reaction with a lipid amine, such as PE leads to PEG coupling to the lipid through an amide linkage, as illustrated in the PEG-PE compound shown at XI in the figure. Details of the reaction are given in Example 2.
- a third reaction method for coupling a capped poly ⁇ alkylether to a lipid amine is shown in Figure " 4.
- PEG is first protected at its OH end by a trimethylsilane group.
- the end-protection reaction is shown at A in the figure, and involves the reaction of trimethylsilylchloride with PEG in the presence of triethylamine.
- the protected PEG is then reacted with the anhydride of trifluoromethyl sulfonate (compound XVI in Figure 4) to form the PEG compound activated with trifluoromethyl sulfonate.
- the trimethylsilyl protective group can be released by acid treatment, as indicated at H+ in the figure, or by reaction with a quaternary amine fluoride salt, such as the fluoride salt of tetrabutylamine. It will be appreciated that a variety of known coupling reactions, in addition to those just described, are suitable for preparing vesicle-forming lipids derivatized with hydro ⁇ philic polymers such as PEG.
- the sulfonate anhydride coupling reagent illustrated in Figure 4 can be used to join an activated polyalkylether to the hydroxyl group of an amphipathic lipid, such as the 5'-OH of cholesterol.
- Other reactive lipid groups such as an acid or ester lipid group may also be used for coupling, according to known coupling methods.
- the acid group of phosphatidic acid can be activated to form an active lipid anhydride, by reaction with a suitable anhydride, such as acetic anhydride, and the reactive lipid can then be joined to a protected polyalk 1- amine by reaction in the presence of an isothiocyanate reagent.
- the derivatized lipid component are prepared to include a labile lipid-polymer linkage, suc as a peptide, ester, or disulfide linkage; which can b cleaved under selective physiological conditions, such as i the presence of peptidase or esterase enzymes present in th bloodstream.
- Figure 5 shows exemplary lipids which are linke through (A) peptide, (B) , ester, and (C) , disulfide containin linkages.
- the peptide-linked compound can be prepared, fo example, by first coupling a polyalkylether with the N terminal amine of the tripeptide shown, e.g., via the reactio shown in Figure 3.
- the peptide carboxyl group can then b coupled to a lipid amine group through a carbodiimide couplin reagent conventionally.
- the ester linked compound can b prepared, for example, by coupling a lipid acid, such a phosphatidic acid, to the terminal alcohol group of a poly alkylether, using alcohol via an anhydride coupling agent.
- a lipid acid such as a phosphatidic acid
- an anhydride coupling agent Alternatively, an short linkage fragment containing an inter nal ester bond an suitable end groups, such as primary amin groups can be used to couple the polyalkylether to the amphi pathic lipid through amide or carbamate linkages.
- the linkage fragment may contain an internal disulfide link age, for use in forming the compound shown at C in Figure 5.
- Figure 6 illustrates a method for derivatizing polylacti acid with PE.
- the polylactic acid is reacted, in the presenc of PE, with dicyclohexylcarboimide (DCCI) , as detailed i Example 4.
- DCCI dicyclohexylcarboimide
- a vesicle-forming lipid derivatize with polyglycolic acid may be formed by reaction of polygly colic acid or glycolic acid with PE in the presence of suitable coupling agent, such as DCCI, also as detailed i Example 4.
- the vesicle-forming lipids derivatized with eithe polylactic acid or polyglycolic acid form part of the inven tion herein.
- liposome containing these derivatized lipids in a 1-20 mole percent.
- lipid components used in forming the liposomes of the invention may be selected from a variety of vesicle-forming lipids, typically including phospholipids and sterols. As will be seen, one requirement of the liposomes of the present invention is long blood circulation lifetime. It is therefore useful to establish a standardized measure of blood lifetime which can be used for evaluating the effect of lipid component on blood halflife.
- One method used for evaluating liposome circulation time in vivo measures the distribution of IV injected liposomes in the bloodstream and the primary organs of the RES at selected times after injection.
- RES uptake is measured by the ratio of total liposomes in the bloodstream to total liposomes in the liver and spleen, the principal organs of the RES.
- age and sex matched mice are injected intravenously (IV) through the tail vein with a radiolabeled liposome composition, and each time point is determined by measuring total blood and combined liver and spleen radiolabel counts, as detailed in Example 6.
- the liposomes of the present invention include 1-20 mole percent of the vesicle-forming lipid derivatized with a hydro ⁇ philic polymer, described in Section I.
- the phospholipid components may be composed of predominantly of fluidic, relatively unsaturated, acyl chains, or of more saturated, rigidifying acyl chain components.
- Example 7 which examines blood/RES ratios in liposomes formed with PEG-PE, cholesterol, and PC having varying degrees of saturation (Table 4) .
- the vesicle-forming lipids may be selected to achieve a selected degree of fluidity or rigidity, to control the stability of the liposomes in serum and the rate of release of entrapped drug from the liposomes in the blood ⁇ stream and/or tumor.
- the vesicle-forming lipids may also be selected, in lipid saturation characteristics, to achieve desired liposome preparation properties. It is generally the case, for example, that more fluidic lipids are easier to formulate and down size by extrusion or homogenization than more rigid lipid components. In general, more fluidic lipids
- Cholesterol, or related cholesterol derivatives may be important, however, in regulating the rate of release of lipo ⁇ some entrapped therapeutic compounds into the bloodstream.
- PEG-liposome formulations containing high cholesterol (e.g., 30 mole percent or greater) released very little peptide or protein into serum in vitro, whereas decreasing amounts of cholesterol producing increasing loss of encapsulated poly- peptide.
- the rate of release of compound from long-circulating liposomes can be controlled by the percent cholesterol included in the liposomes.
- the vesicle-forming lipid derivatized with a hydrophilic polymer is present in an amount preferably between about 1-20 mole percent, on the basis of moles of derivatized lipid as a percentage of total moles of vesicle-forming lipids. It will be appreciated that a lower mole ratio, such as 0.1 mole percent, may be appropriate for a lipid derivatized with a large molecular weight polymer, such as one having a molecular weight greater than 100 kilodaltons.
- the hydrophilic polymer in the derivatized lipid preferably has a molecular weight between about 200-20,000 daltons, and more preferably between about 1,000-5,000 daltons.
- Example 8B which examines the effect of very short ethoxy ether moieties on blood/RES ratios indicates that polyether moieties of greater than about 5 carbon ether are required to achieve significant enhancement of blood/RES ratios.
- the liposomes may be prepared by a variety of techniques, such as those detailed in Szoka et al, 1980.
- One method for preparing drug-containing liposomes is the reverse phase evaporation method described by Szoka et al and in U.S. Patent No. 4,235,871.
- the reverse phase evaporation vesicles (REVs) have typical average sizes between about 2-4 microns and are predominantly oligolamellar, that is, contain one or a few lipid bilayer shells.
- the method is detailed in Example 5A. This method is generally preferred for preparing liposomes with encapsulated proteins high encapsulation efficiencies (up to 50%) are possible, and thus protein loss or problems of recovery and purification of non-encapsulated protein are reduced.
- Multilamellar vesicles can be formed by simple lipid-film hydration techniques. In this procedure, a mixtur of liposome-forming lipids of the type detailed above dis solved in a suitable solvent is evaporated in a vessel to for a thin film, which is then covered by an aqueous medium, a detailed in Example 5B. The lipid film hydrates to form MLVs, typically with sizes between about 0.1 to 10 microns.
- the liposomes for intravenous injection are prepared to have substantially homogeneous sizes in a selected size range between about 0.1 and 0.4, and preferably 0.1 to 0.2 micron size ranges. Liposomes in this size range have sufficiently high encapsulation volumes for carrying therapeutically effec ⁇ tive amounts of the compound to be administered. At lower liposome sizes, the ratio of liposome-encapsulated compound to free compound may too low to achieve a requisite initial dose level of liposome-encapsulated compound in the bloodstream or may not remain in circulation due to extravasation. At the same time, 0.1-0.4 micron liposomes are small enough to give long blood circulation times, as discussed below, and also to allow sterilization by sterile filtration.
- One effective sizing method for REVs and MLVs involves extruding an aqueous suspension of the liposomes through a polycarbonate membrane having a selected uniform pore size, typically 0.4, 0.2, and/or 0.1 micron pore sizes.
- the pore size of the membrane is proportional to the largest sizes of the liposomes which are produced, particularly where the pre ⁇ paration is extruded two or more times through the same size membrane.
- This method of liposome sizing is used in preparing homogeneous-size REV and MLV compositions described in the examples below.
- a more recent method involves extrusion through an asymmetric ceramic filter. The method is detailed in U.S. patent application for Liposome Extrusion Method, Serial No. 829,710, filed February 13, 1986. Homogenization methods are also useful for down-sizing liposomes.
- the composition of the invention is used for slow-release delivery into the bloodstream or a poly ⁇ peptide (peptide or protein) which is therapeutically active in the bloodstream when administered IV, but which in free form has a short blood halflife, typically 4 ' hours or less.
- polypeptides examples include hormones, such as vaso ⁇ pressin, calcitonin, oxytocin, somatotropin, human growth hormone, atrial naturectic factor (ANF) , and insulin; enzymes, such as superoxide dismutase, glucocerebrosidase, asparagin- ase, and adenosine deaminase; immunomodulators, such as inter- ferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta) , and colony stimu ⁇ lating factors (M-CSF (macrophage) , G-CSF (granulocyte) , GM- CSF (granulocyte, macrophage) ; anticoagulants, such as TPA, prourokinase, and urokinase; vaccines, such as HIV-1 vaccine, hepatitis B vaccine, malaria vaccine
- polypeptides useful in the invention typically hav relatively short blood halflives, on the order of 2-4 hours o less, and are active in the picogram/ml to nanogram/ml concen tration range in the blood.
- polypeptide is preferably loaded passivel by the reverse-phase emulsion method for preparing liposomes, although many other methods, such as solvent injection o lipid hydration may be employed.
- liposome formation an sizing, free (unbound) drug can be removed by a variety o methods, for example, by gel filtration or ion exchang chromatography or diafiltration.
- the amount of fre peptide in the final sterilized composition is less than abou 20%, and preferably less than 10% of the total polypeptide contained in the composition.
- the encapsulated compound is preferably present in an amount which, in a selected liposome dose, is between 3-20 times the amount of compound which would be given as a therapeutic dose in free form by IV administration.
- a selected liposome dose will pre ⁇ ferably contain between about 3-20 ⁇ g of the peptide. Since 10-20% of this compound, e.g., 2-4 ⁇ g, may be in non-encapsu ⁇ lated form, it will be appreciated that the total amount of liposome which can be administered may be limited by the maxi- mum tolerated dose of the free compound.
- liposomes can be administered by achieving higher ratios of encapsulated to non-encapsulated compound. In general, this ratio is increased with larger liposomes, more complete free drug removal from the liposome composition, and greater liposome stability on storage.
- composition is also useful for slow-release delivery of a variety of non-peptide, water-soluble compounds which are effective in treating circulating cancers such as leukemias, for example, cytarabine, cyclophosphamide, carmustine, thio- guanine, bleomycin, daunorubicin, vinblastine, vincristine, and asparaginase.
- leukemias for example, cytarabine, cyclophosphamide, carmustine, thio- guanine, bleomycin, daunorubicin, vinblastine, vincristine, and asparaginase.
- antibiotics such as gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and streptomycin, cefotaxime, ceftizoxi e, and ceftriaxone
- anti-viral agents such as AZT (zidovidine) , DDI (dideoxyinosine) , DDC (didioxycytidine) , ganciclovir, D4T (didehydrodeoxythymidine) , phosphonoformate, ribavirin, and acyclovir.
- anti-viral agents such as AZT (zidovidine) , DDI (dideoxyinosine) , DDC (didioxycytidine) , ganciclovir, D4T (didehydrodeoxythymidine) , phosphonoformate, ribavirin, and acyclovir.
- Such compounds may be encapsulated by passive loading, as above, during liposome
- drugs which form weak bases at physiological pH may be actively loaded into the liposomes at high drug concentration in the liposomes.
- One method for active loading drugs into liposomes is described in co-owned U.S. patent application Serial No. 413,037, filed September 28, 1988.
- liposomes are prepared in the presence of a relatively high ammonium ion, such as 0.125 M ammonium sulfate. After sizing the liposomes to a desired size, the liposome suspension is treated to create an inside- to-outside ammonium ion gradient across the liposomal membranes.
- the gradient may be created by dialysis against a non-ammonium containing medium, such as an isotonic glucose medium, or by gel filtration, such as on a Sephadex G-50 column equilibrated with 0.15 M NaCl or KC1, effectively replacing ammonium ions in the exterior phase with sodium or potassium ions.
- a non-ammonium containing medium such as an isotonic glucose medium
- gel filtration such as on a Sephadex G-50 column equilibrated with 0.15 M NaCl or KC1
- ammonium concentration inside the liposomes is preferably at least 10 times, and more preferably at least 100 to 1000 times that in the external liposome phase.
- a rela ⁇ tively dilute suspension of the liposomes e.g., less than about 50 mM lipid
- an aqueous solution of the drug e.g., less than about 50 mM lipid
- the mixture is allowed to equilibrate over an extended period, e.g., 24 hours at room temperature.
- a suspension of liposomes having a lipid con ⁇ centration of 25 mg/ml is mixed with an equal volume of anthracycline drug at a concentration of about 10 mg/ml. At the end of the incubation period, the suspension is treated to remove free (unbound) drug,
- A. Extended Lifetime in the Bloodstream One of the requirements for extended compound release into the bloodstream, in accordance with the invention, is an extended liposome lifetime in the bloodstream with IV liposome administration.
- One measure of liposome lifetime in the bloodstream in the blood/RES ratio determined at a selected time after liposome administration, as discussed above.
- Blood/RES ratios for a variety of liposome compositions are given in Table 3 of Example 6. In the absence of PEG- derivatized lipids, blood/RES ratios were 0.03 or less.
- the blood/RES ratio ranged from 0.2, for low-molecular weight PEG, to between 1.7- 4 for several of the formulations, one of which lacks cholesterol, and three of which lack a charged phospholipid (e.g., PG) .
- the blood/RES values reported above can be compared with blood/RES values reported in co-owned U.S. Patent No. 4,920,016, which used blood/RES measurement methods identical to those used in for the data presented in Tables 3 and 5.
- the best 24-hour blood/RES ratios which were reported in the above-noted patent was 0.9, for a formulation composed of GM lf saturated PC, and cholesterol.
- the next best formulations gave 24-hour blood/RES values of about 0.5.
- typical 24- hour blood/RES ratios obtained in a number of the current formulations were more than twice as high as the best formula ⁇ tions reported which have been reported to date.
- ability to achieve high blood/RES with GM X or HPI lipids was dependent on the presence of predominantly saturated lipids in the liposomes.
- Plasma kinetics of a liposomal marker in the bloodstream can provide another measure of the enhanced liposome lifetime which is achieved by the liposome formulations of the present invention.
- Figure 7 and 8 discussed above show the slow loss of liposomal marker over a 24 hour period in typical PEG-lipo- some formulations, substantially independent of whether the marker is a lipid or an encapsulated water-soluble compound
- Figure 9 shows the kinetics of liposome loss from the bloodstream for a typical PEG-lipsome formulation and the same liposomes in the absence of a PEG-derivatized lipid. After 24 hours, the percent marker remaining in the PEG-liposomes was greater than about 20%, whereas the conventional liposomes showed less than 5% retention in the blood after 3 hours, and virtually no detectable marker at 24 hours.
- liposome size was been investigated by comparing loss of liposomal marker in intra- venously injected liposomes having selected sizes between about 0.1 and 0.25 microns. Experimental details are given in Example 10. The results, given in Figure 10, show about 10% or greater liposome marker present in the blood after 24 hours for each of the liposome formulations. Highest blood life- times were achieved with the smallest liposomes. Thus, although all of the liposome preparations give high blood lifetimes, it is also clear that liposome size can be selected to produce desired increase or decrease in total drug release time.
- the liposome size between 0.1 and 0.4 microns allows relatively high compound loading in the lipo ⁇ somes, for effective compound release as the percentage of liposomes in the bloodstream even at relatively low liposome concentrations in the bloodstream. This is typically an important consideration since the total amount quantity of liposomes which can be administered will be limited, due to the unavoidable presence of some free compound in injected composition.
- Example 16 The study reported in Example 16 demonstrates a simila ability to control release rates of large proteins from long- circulating liposomes.
- PEG-liposomes containing encapsu ⁇ lated M-CSF (a 55 kilodalton protein) were examined for per- cent retention in the bloodstream, of both lipid and protein components.
- the data plotted in Figure 15 show liposome lipi (solid triangles) and protein (solid circles) kinetics 24 hours after IV injection for a PEG-lipsome formulation con ⁇ taining 30 mole percent cholesterol. The data indicate about 20% loss of encapsulated material over 24 hours, as discusse in Example 16.
- Figure 17 shows a similar plot for PEG-liposomes without cholesterol.
- the data here show a 40-50% loss of M-CSF after 24 hours.
- the plots o protein release from cholesterol (solid circles) and no cholesterol (solid triangles) PEG-liposomes are obtained.
- the plots illustrate the markedly different protein release kinetics which can be obtained with long circulating lipo- somes, by varying cholesterol content of the liposomes.
- Another feature of the data shown in Figure 17 is th relatively high percent (at least 3%) of initially injecte protein which is released at 24 hours in both formulations. IV. Intravenous Liposome Treatment
- the invention includes, in one aspect, a method for extending to at least 24 hours, the period of effective activity of an therapeutic compound.
- the compound is one which can be administered intravenously in a therapeutically effective amount, and which has a halflife in the bloodstream, in free form, of less than about 4 hours.
- a liposome composition such as described above, containing the compound in liposome-entrapped form.
- the size, lipid composition, and extent compound loading of the drug are selected, according to the desired release rates and total release times, as con ⁇ sidered in Section III above.
- the composition is injected intravenously to a subject at a dose which contains an amount of the compound which is at least 3, and typically 5-20 times the therapeutically effec ⁇ tive dose.
- a therapeutically effective dose of a compound is 10 ⁇ g/Kg body weight
- the liposome com- position would be injected at a liposome dose of at least 30 ⁇ g compound/Kg, and typically between 50-200 ⁇ g compound/Kg body weight.
- the amount of material which can be injected is generally limited by the maximum tolerated dose of free compound, since 5-20% or more of the compound may be in free (non-entrapped) form when the composition is admi ⁇ nistered.
- the maximum tolerated dose of a compound in free form is 2 ⁇ g/Kg body weight
- the lipo ⁇ some composition contains 10% non-entrapped compound
- the highest dose of liposome composition which can be given is 20 ⁇ g/Kg body weight.
- Figure 13 shows the effect, measured in percent predosage urine flow, of IV injection of free vaso ⁇ pressin at dose levels of 0.2 ⁇ g (solid squares), 0.8 ⁇ g (solid triangles) and 2.0 ⁇ g (solid circles) .
- the reduction in urine flow is maximum after 1 day, but returns to control levels (open circles) by day 2.
- Figure 14 shows the effect on urine flow by vasopressin administered IV in PEG-liposomes, at dosage levels of 2 ⁇ g (solid squares) , 8 ⁇ g (solid triangles) and 24 ⁇ g (solid cir ⁇ cles) .
- a pronounced reduction in urine flow was observed within one day, with a slight rebound toward control values by day 2 — an effect likely due, in part, to free peptide in the liposome formulation.
- a marked reduction in urine flow was observed for at least 7 days following IV administration. It is noted that the long-term therapeutic effect is saturated at an 8 ⁇ g dose, with no further effect observed at 24 ⁇ g.
- the long-live liposome composition of the invention is also effective for slow release of a liposome- entrapped compound from a subcutaneous (SubQ) site into the bloodstream.
- a subcutaneous site into the bloodstream.
- therapeutic effects of up to 3 weeks or more can be achieved by a single subcutaneous injection of the liposome composition of the invention.
- the experimental model used to demonstrate this method is the vasopressin model described above, and detailed in Example 17. Briefly, a treatment method involving SubQ injection of free vasopressin was compared, for duration of physiological effect, with vasopressin administered SubQ in PEG-liposomes.
- Figure 18A shows the depression in urine production observed with SubQ administration of free vasopressin at doses of 2 ⁇ g
- FIG. 18B shows the effect of SubQ administration of the peptide in PEG liposomes. The lowest does administered, 25 ⁇ g (closed triangles) gave a slight prolongation of activity, to about 8 days. A vasopressin dose of 100 ⁇ g (closed circles) showed a significant reduction in urine output out to about 20 days. An even longer effect, of at least 24 days, was observed at a dose of 400 ⁇ g (closed squares) .
- the treatment method employing vasopressin is designed for treatment of diabetes insipidus, by long-term administration of vasopressin from a SubQ site. More generally, the method is designed for extending to at least one week, the period of effective activity of an therapeutic compound which can be administered intravenously in a therapeutically effective amount.
- the method utilizes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range preferably between about 0.07-.15 microns, and having the compound in liposome-entrapped form.
- the liposome composition is administered subcutaneously at a dose of the composition which contains an amount of the liposome-entrapped compound which is at least ten times the therapeutically effective intravenously administered amount.
- the method can be used for therapeutic delivery of the compound over a several- week period.
- the ability of the liposome composition of the invention to produce a long-term therapeutic effect from a SubQ site suggests that the liposomes taken up from this site through the lymphatics may be able to successfully evade the normal lymphatic clearance mechanisms, including Kupfer cells.
- This mechanism is supported by studies on araC administration by the interperitoneal (IP) route by PEG-liposomes. Briefly, it was found that PEG-liposomes containing entrapped araC and administered by IP route produced a 250-300% increase in survial in animals having L1210 leukemias, compared with about 120% increase in survival with the free drug given by the IP route. The results suggests that PEG-liposomes are capable of migrating from the peritoneum through the lymphatics into the bloodstream.
- Cholesterol Cholesterol (Choi) was obtained from Sigma (St. Louis, MO) .
- Sphingomyelin (SM) egg phosphatidylcholine (lecithin or PC), partially hydrogenated PC having the composition IV40, IV30, IV20, IV10, and IV1, phosphatidylglycerol (PG) , phospha- tidylethanolamine (PE) , dipalmitoyl-phosphatidyl glycerol (DPPG) , dipalmitoyl PC (DPPC) , dioleyl PC (DOPC) and distear- oyl PC (DSPC) were obtained from Avanti Polar Lipids (Birming ⁇ ham, AL) or Austin Chemical Co (Chicago, II) .
- Cyanuric chloride (5.5 g; 0.03 mol) was dissolved in 400 ml of anhydrous benzene containing 10 g of anhydrous sodium carbonate, and PEG-1900 (19 g; 0.01 mol) was added and the mixture was stirred overnight at room temperature. The solu ⁇ tion was filtered, and 600 ml of petroleum ether (boiling range, 35-60°) was added slowly with stirring. The finely divided precipitate was collected on a filter and redissolved in 400 ml of benzene.
- the activated PEG was analyzed for nitrogen and an appropriate correction was applied in selecting the quantity of reactant to use in further synthetic steps.
- the quantity of material used in the next synthetic step was increased by 100/20, or 5-fold.
- the product contained 50% of the theoretical amount of nitrogen only 100/50 or a 2-fold increase was needed.
- the solid compound was taken up in 24 ml of ethanol/- chloroform; 50/50 chloroform and centrifuged to remove insoluble material. Evaporation of the clarified solution to dryness under vacuum afforded 21 mg (7.62 ' micromoles) of colorless solid.
- the reaction mixture was cooled and the clear solution formed at room temperature.
- the solution was diluted to 50.0 ml with dry benzene and stored in the refrigerator as a 100 micromole/ml stock solution of the imidazole carbamate of PEG ether 1900.
- the solvent from the remaining reaction mixture was evapo rated under vacuum.
- the residue was taken up in 10 m methylene chloride and placed at the top of a 21 mm x 270 m chromatographic absorption column packed with Merck Kieselge 60 (70-230 mesh silica gel) , which has been first rinsed wit methylene chloride.
- the mixture was passed through th column, in sequence, using the following solvents.
- Air from the reaction vessel was displaced with nitrogen.
- the vessel was closed and heated in a sand bath 110°C for 22 hours.
- the solvent was evaporated under vacuum to obtain 1.58 grams of brownish- colored oil.
- the crude product was dissolved in 3 ml of the same solvent and transferred to the top of the chromatography column.
- the chromatogram was developed with the same solvent and sequential 30 ml portions of effluent were assayed each by TLC.
- the TLC assay system used silica gel coated glass plates, with solvent combination butanone/acetic acid/water; 40/25/5; v/v/v. Iodine vapor absorption served for visualization.
- the desired N-1-trimethylsilyloxy polyethylene glycol 1500 PE was a chief constituent of the 170-300 ml portions of column effluent. When evaporated to dryness under vacuum these portions afforded 111 mg of pale yellow oil of compound.
- PE compound was dissolved in 2 ml of tetrahydrofuran. To this, 6 ml acetic acid and 2 ml water was added. The resulting solution was let to stand for 3 days at 23°C. The solvent from the reaction mixture was evaporated under vacuum and dried to constant weight to obtain 75 mg of pale yellow wax. TLC on Si-C18 reversed-phase plates. developed with a mixture of 4 volumes ethanol, 1 volume water indicated that some free PE and some polyglycol-like materia formed during the hydrolysis.
- N-Polyethylene glycol 1500 P.E. by fluorid deprotection.
- 500 mg of crude N-1-trimethylsilyloxy polyethylene glyco PE was dissolved in 5 ml tetrahydrofuran and 189 mg (0.60 millimoles) of tetrabutyl ammonium fluoride was added an agitated until dissolved.
- the reactants were let to stan over night at 20°C.
- the solvent was evaporated under reduced pressure and th residue was dissolved in 10 ml chloroform, washed with tw successive 10 ml portions of water, and centrifuged t separate chloroform and water phases.
- the chloroform phas was evaporated under vacuum to obtain 390 mg of orange-brown wax, which was determined to be impure N-polyethylene glycol 1500 PE compound.
- the wax was re-dissolved in 5 ml chloro ' form and trans- ferred to the top of a 21 X 270 mm column of silica gel moistened with chloroform.
- the column was developed by passing 100 ml of solvent through the column.
- the Table 2 solvents were used in sequence:
- the tube was cooled to room temperature, and 6 ml of chloroform added.
- the chloroform solution wa washed with three successive 6 ml volumes of water, centrifuged after each wash, and the phases separated with Pasteur pipette.
- the remaining chloroform phase was filtere with suction to remove suspended distearolyphosphatidyl ethanola ine.
- the filtrate was dried under vacuum to obtai 212 mg of semi-crystalline solid.
- This solid was dissolved in 15 ml of a mixture of volumes ethanol with 1 volume water and passed through a 50 m deep and 21 mm diameter bed of H + Dowex 50 cation exchang resin, and washed with 100 ml of the same solvent.
- Phosphate analysis suggests a molecular weight of 924,000.
- Example 5 Preparation of REVs and MLVs A. Sized REVs A total of 15 ⁇ moles of the selected lipid components, in the mole ratios indicated in the examples below, were dis ⁇ solved in chloroform and dried as a thin film by rotary evapo ⁇ ration. This lipid film was dissolved in 1 ml of diethyl ether washed with distilled water. To this lipid solution was added 0.34 ml of an aqueous buffer solution containing 5 ⁇ i Tris, 100 mM NaCl, 0.1 mM EDTA, pH 7.4, and the mixture was emulsified by sonication for 1 minute, maintaining the tempe rature of the solution at or below room temperature. Wher the liposomes were prepared to contain encapsulated [1251] tyraminyl-inulin, such was included in the phosphate buffer at a concentration of about 4 ⁇ Ci/ml buffer.
- the ether solvent was removed under reduced pressure at room temperature, and the resulting gel was taken up in 0.1 ml of the above buffer, and shaken vigorously.
- the resulting REV suspension had particle sizes, as determined by microscopic examination, of between about 0.1 to 20 microns, and was com ⁇ posed predominantly of relatively large (greater than 1 micron) vesicles having one or only a few bilayer lamellae.
- the liposomes were extruded twice through a polycarbonate filter (Szoka, 1978), having a selected pore size of 0.4 microns or 0.2 microns. Liposomes extruded through the 0.4 micron filter averaged 0.17+ (0.05) micron diameters, and through the 0.2 micron filter, 0.16 (0.05) micron diameters. Non-encapsulated [1251] tyraminyl-inulin was removed by passing the extruded liposomes through Sephadex G-50 (Phar ⁇ macia) .
- Multilamellar vesicle (MLV) liposomes were prepared according to standard procedures by dissolving a mixture of lipids in an organic solvent containing primarily CHC1 3 and drying the lipids as a thin film by rotation under reduced pressure.
- a radioactive label for the lipid phase was added to the lipid solution before drying.
- the lipid film was hydrated by addition of the desired aqueous phase and 3 mm glass beads followed by agitation with a vortex and shaking above the phase transition temperature of the phospholipid component for at least 1 hour.
- a radioactive label for the aqueous phase was included in the buffer.
- the hydrated lipid was repeatedly frozen and thawed three times to provide for ease of the following extrusion step.
- the size of the liposome samples was controlled by extru ⁇ sion through defined pore polycarbonate filters using pres ⁇ surized nitrogen gas.
- the ' liposomes were extruded one time through a filter with pores of 0.4 ⁇ m and then ten times through a filter with pores of 0.1 ⁇ m.
- the liposomes were extruded three times through a filter with 0.2 ⁇ m pores followed by repeated extrusion with 0.05 ⁇ m pores until the mean diameter of the particles was below 100 nm as determined by DLS.
- Unencapsu- lated aqueous components were removed by passing the extruded sample through a gel permeation column separating the lipo ⁇ somes in the void volume from the small molecules in the included volume.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and l-palmitoyl-2-oleyl-PE (POPE) was prepared as in Example 2.
- the PEG-POPE lipid was combined with and partially hydrogen- ated egg PC (PHEPC) in a lipid:lipid mole ratio of about 0.1:2, and the lipid mixture was hydrated and extruded through a 0.1 micron polycarbonate membrane, as described in Example 4, to produce MLVs with average size about 0.1 micron.
- the MLV lipids included a small amount of radiolabeled lipid marker 14 C-cholesteryl oleate, and the encapsulated marker 3 H- inulin.
- the liposome composition was injected and the percent initial injected dose in mice was determined as described in Example 4, at 1, 2, 3, 4, and 24 after injection.
- the time course of loss of radiolabeled material is seen in Figure which is a plot of percent injected dose for encapsulate inulin (solid circles), inulin marker corrected to the initia injection point of 100% (open circles) , and lipid marke (closed triangles), over a 24-hour period post injection. A seen, both lipid and encapsulated markers showed greater tha 10% of original injected dose after 24 hours.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and distearylPE (DSPE) was prepared as in Example 2.
- the PEG-PE lipids were formulated with selected lipids from among sphin- gomyelin (SM) , fully hydrogenated soy PC (PC) , cholesterol (Choi) , partially hydrogenated soy PC (PHSPC) , and partially hydrogenated PC lipids identified as PC IV1, IV10, IV20, IV30, and IV40 in Table 4.
- SM sphin- gomyelin
- PC fully hydrogenated soy PC
- PHSPC partially hydrogenated soy PC
- PC lipids identified as PC IV1, IV10, IV20, IV30, and IV40 in Table 4.
- the lipid components were mixed in the molar ratios shown at the left in Table 5, and used to form MLVs sized to 0.1 micron as described in Example 4.
- the blood and L+S (RES) values were used to calculate a blood/RES value for each composition.
- the column at the right in Table 4 shows total amount of radioactivity recovered.
- the two low total recovery values in the table indicate anomalous clearance behavior.
- the results from the table demonstrate that the blood/RES ratios are largely independent of the fluidity, or degree of saturation of the phospholipid components forming the lipo ⁇ somes. In particular, there was no systematic change in blood/RES ratio observed among liposomes containing largely saturated PC components (e.g., IV1 and IV10 PC's), largely unsaturated PC components (IV40) , and intermediate-saturation components (e.g., IV20) .
- largely saturated PC components e.g., IV1 and IV10 PC's
- IV40 largely unsaturated PC components
- IV20 intermediate-saturation components
- the PEG-PE lipids were formulated with selected lipids from among sphin- gomyelin (SM) , fully hydrogenated soy PC (PC) , and cholesterol
- Methoxy-ethyoxy-cholesterol was prepared by coupling methoxy ethanol to cholesterol via the trifluorosulfonate coupling method described in Section I.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6.
- the PEG-PE lipids were formulated with selected lipids from among distearylPC (DSPC) , partially hydrogenated soy PC (PHSPC) , cholesterol, and ethoxylated cholesterol, as indicated at the right in Table 7.
- DSPC distearylPC
- PHSPC partially hydrogenated soy PC
- cholesterol ethoxylated cholesterol
- Example 9 Effect of Charged Lipid Components on Blood/RES Ratios in PEG-PE Liposomes
- PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6.
- the PEG- PE lipids were formulated with lipids selected from among egg PG (PG) , partially hydrogenated egg PC (PHEPC) , and choleste ⁇ rol (Choi), as indicated in the Figure 6.
- the two formula ⁇ tions shown in the figure contained about 4.7 mole percent (triangles) or 14 mole percent (circles) PG.
- the lipids were prepared as MLVs, sized to 0.1 micron as in Example 4.
- the percent of injected liposome dose present 0.25, 1, 2, 4, and 24 hours after injection are plotted for both formula ⁇ tions in Figure 6. As seen, the percent PG in the composition had little or no effect on liposome retention in the bloodstr ⁇ eam. The rate of loss of encapsulated marker seen is also similar to that observed for similarly prepared liposomes containing no PG.
- PEG-DSPE prepared as above with PEG-1900, was formulated with partially hydrogenated egg PC (PHEPC) , and cholesterol (Choi), at a mole ratio of 0.15: 1.85: 1.
- PHEPC partially hydrogenated egg PC
- Choi cholesterol
- the liposomes were sized by extrusion through 0.25, 0.15 or 0.1 micron polycarbo ⁇ nate filters, to produce liposome sizes of about 0.4, 0.2, and 0.1 microns, respectively.
- Non-encapsulated 3 H-inulin was removed by gel filtration.
- each of the three liposome were injected intravenously, and the percent of injected liposome marker in the blood was measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 10. All three formulations show long blood half- lives, as evidence by at least about 10% liposome marker remaining after 24 hours.
- the 0.1 micron formulation (solid squares) is longer lived than the 0.2 micron formulation (solid circles) which is in turn longer lived than the 0.4 micron formulation.
- Example 11 Effect of Other Hydrophilic Polymers on Blood Lifetime Polylactic acid-DSPE or polyglycolic acid-DSPE, prepared as above, was formulated with lipids selected from among hydrogenated soy PC (HSPC) , and cholesterol (Choi) , at a weight ratio of either 2: 3.5: 1 or 1: 3.5: 1.
- the liposomes were sized by extrusion through a 0.1 micron polycarbonate filter.
- the liposomes were labeled by Ga-DF as described in Example 5.
- These liposome formulations were injected intravenously, and the percent of injected liposome marker in the blood was measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 11.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and distearyl PE (DSPE) was prepared as in Example 2.
- the PEG-PE lipids were formulated with PHEPC, and cholesterol, in a mole ratio of 0.15:1.85:1.
- a second lipid mixture contained the same lipids, but without PEG-PE.
- Liposomes were prepared from the two lipid mixtures as described in Example 5, by lipid hydration in the presence of DF followed by sizing to 0.1 micron, removal of non-entrapped DF by gel filtration, and Ga labeling as described in Example 5. Both compositions contained 10 ⁇ M lipid/ml in 0.15 M NaCl, 0.5 mM desferal.
- the two liposome compositions (0.4 ml) were injected IV in animals, as described in Example 6. At time 0.25, 1, 3 or 5, and 24 hours after injection, blood samples were removed and assayed for amount inulin remaining in the blood, expressed as a percentage of the amount measured immediately after injection. The results are shown in Figure 9. As seen, the PEG-coated liposomes have a blood halflife of about 11 hours, and nearly 30% of the injected material is present in the blood after 24 hours. By contrast, uncoated liposomes showed a halflife in the blood of less than 1 hour. At 24 hours, the amount of injected material was undetectable.
- the vein was nicked and a bevelled 6-inch section of poly ⁇ ethylene catheter tubing (PE_50 Clay-Adams) filled with normal saline (0.9%) or 5% dextrose was inserted into the vein. Correct placement was verified by venous drawback and flush using a 1 cc syringe. The catheter was anchored loosely to the vein by passing a small tie under the vessel and knotting it around the cannula.
- PE_50 Clay-Adams poly ⁇ ethylene catheter tubing
- test solution 150-1000 ⁇ l of test solution was administered intravenously.
- the dose volume administered was adjusted to give the desired total amount of vasopressin, for example 0.2, 0.8, and 3 ⁇ g of aqueous vaso- pressin.
- the venous catheter was then removed, the femoral vein was tied off, and both leg incisions were closed. The animals were allowed to regain consciousness.
- Figure 12 shows the percent predosage urine flow in animals treated with saline (open circles) or 0.2 ⁇ g (solid squares) 0.8 ⁇ g (solid triangles), and 2 ⁇ g (solid circles) vasopressin solution.
- urine production showed a dose-dependent drop.
- urine production was substantially back to control levels.
- lipid composition used in preparing the liposomes was PEG-DSPE, PC, sphingomyelin, and cholesterol, in a mole ratio 0.2: 1: 1: 1.
- Lipid mixtures for a 1 ml final volume of liposomes with a phospholipid concentration of 10 ⁇ mol/ml were dissolved in chloroform and evaporated to dryness under reduced pressure. After residual solvent was removed by high vacuum for 1 hour the mixture was dissolved in ethyl ether freshly washed with phosphate buffer at pH 7.
- aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM EDTA) containing sufficient arginine vasopressin to give a final drug concentration of 510 ⁇ g/ml was added to the lipids in ether.
- a trace amount of 3 H-labeled vasopressin was added to the vasopressin solution for determination of protein concentrations.
- the ether was removed by controlled rotoevaporation, and additional drug-free buffer added to give a 1 ml solution immediately after gel dispersion.
- the vasopressin content of the resulting liposomes was determined by separating free from liposome-bound by gel filtration on Bio-Gel A15.
- the liposomes were extruded through 0.4 ⁇ m Nuclepore filters (Olsen et al., 1979) and particle size distribution measured by dynamic light scattering with a Nicomp model 200. Mean diameter ranged between 0.2 ⁇ m and 0.5 ⁇ m and showed a low polydispersity. Unbound vasopressin was removed by dialysis and monitored by gel chromatography as above.
- PEG-liposome preparations from above were administered intravenously to rats prepared as in Example 13, at liposomal doses 2 ⁇ g (solid squares) 8 ⁇ g (solid triangles) , and 24 ⁇ g (closed circles) vasopressin solution.
- Percent predosage urine flow was measured as above, with the results shown in Figure 14.
- the data show the substantially the same dose- dependent depression in urine production in the first day after drug administration, presumably resulting predominantly from non-entrapped vasopressin in the lipsome formulations. In contrast to free peptide administration, however, all three formulation produced a significant inhibition in urine production with respect to control (open circles) over a 2-8 day period after liposome administration.
- Example 15 Treatment with PEG-Liposomal Vasopressin: Effect of Liposome Cholesterol Concentration Large unilamellar liposomes were prepared as in Example 14, with liposomes containing either 33, 16, or 0 mole percent cholesterol. Vasopressin encapsulation, lipsome sizing, and free peptide removal was carried out as in Example 14.
- the three PEG-liposome preparations were administered intravenously to rats prepared as in Example 13, at liposomal doses giving 8 ⁇ g vasopressin, and the percent predosage urine production was measured over a 9 day period following liposome administration.
- the results are shown in Figure 15, for saline control (open circles) and PEG-liposomes with 0 (solid squares) , 16 (solid triangles) , and 33 (solid circles) mole percent cholesterol.
- the day-1 response shows a marked dependence on percent cholesterol, with the greatest effect on urine flow being produced in liposomes with the lowest mole ratio of choleste ⁇ rol.
- This result is consistent with in vitro stability studies of vasopressin release from PEG-liposomes in serum: In the presence of serum, little release of vasopressin was seen in liposomes containing greater than 30 mole percent cholesterol. By contrast, formulations containing reduced amounts of cholesterol showed increasingly higher release rates of encapsulated peptide. Thus, it would appear that the significantly higher diuretic effect seen after 1 day with low and no cholesterol formulations is due to the presence of free peptide released from the liposomes in serum.
- Example 16 Blood Clearance Kinetics of M-CSF from PEG-Liposomes A lipid film containing PEG-DSPE, PHEPC IV-40, cholesterol, and ⁇ -tocopherol, in a mole ratio 5:61:33:1, was hydrated with distilled water, and the resulting MLVs were sonicated for 30 minutes to form SUVs. M-CSF was concentrated and a portion of the protein was labeled with U125I-iodine.
- Equal volumes (2 ml) of the protein solution and SUVs were mixed, and the mixture was frozen in an acetone/dry bath, and lyophilized overnight.
- the dried material was rehydrated in 0.8 ml of distilled water, and the resulting liposome suspension was extruded 1 time through a 0.4 ⁇ polycarbonate filter, and 3 times through a 0.2 ⁇ filter.
- the sized liposomes were diluted to 10 ml in distilled water, washed washed two times with high speed centrifugation, and the washed pellet was resuspended in 0.9 ⁇ l of sterile buffer, to a final concentration of 40 ⁇ ol lipid/ml and between 0.5 and 1.25 mg protein/ml.
- PEG-liposome preparations from above were administered intravenously to animals as in Example 6, and the blood levels of M-CSF were measured at 1, 2, 4, and 24 hours after rats prepared as in Example 14, at liposomal doses 2 ⁇ g (solid squares) 8 ⁇ g (solid triangles) , and 24 ⁇ g (closed circles) vasopressin solution. Similar measurements were made for an equivalent amount of M-CSF administered in solution form.
- the plasma kinetics for the PEG-liposome formulation containing 30 mole percent cholesterol are shown in Figure 15. The data show rapid clearance of free protein (solid triangles) with less than 1% protein remaining in the blood at 24 hours, compared with about 8% for liposome-associated protein (solid circles) .
- Percent liposomes remaining in the bloodstream was slightly greater than 10%.
- a comparison of the clearance of rates of the lipid and pro ⁇ tein markers indicates that about 20% of the protein marker was released from the liposomes by 24 hours post injection.
- the plasma kinetics obtained with cholesterol-free PEG- liposomes is shown in Figure 16.
- Percent liposomes remaining after 24 hours was about 8.5 (solid triangles) compared with about 4.5% for liposome-associated M-CSF.
- the radioactive counts in the liposome lipid marker and in the encapsulated protein were normalized to 100% initial values, and the percent injected dose released into the blood ⁇ stream over time was then determined from the ' difference be- tween the normalized protein and normalized liposome marker radioactivity levels.
- a plot of the calculated values of percent protein released at 1, 2, 4, and 24 hours post injec ⁇ tion is shown in Figure 17.
- the plot for the cholesterol-free formulation shows a protein release peak at 2 hours, with a gradual decline in amount released in the 2-24 hour period in the no-cholesterol formulation (solid triangles) .
- the amount of protein released from the liposomes at 24 hours was between 3-4 percent of the total administered.
- the plot for the formulation containing 30 mole percent cholesterol shows a gradual increase in release protein release rate over 24 hours.
- the amount of protein released from the liposomes at 24 hours was about 3 percent of the total administered.
- both formulations showed relatively high levels of protein release (3% or greater) at 24 hours.
- Example 17 Subcutaneously Administered Liposomes
- the lipid composition of the thin film was PEG- DSPE, HEPC, and cholesterol, in a mole ratio 0.15:1.85:1.
- the thin film was hydrated with an aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM EDTA) containing arginine vasopressin at 7.5 mgs/ml.
- the MLVs were sized by repeated extrusion through a 0.1 micron polycarbonate membrane, and free (non-encapsulated) peptide was removed by gel filtration, as in Example 15. The final concentration of PEG-liposomes in the suspension was 100 ⁇ M/ml.
- Vasopressin in free form was administered subcutaneously (1 ml) to Brattleboro rats, as in Example 13.
- the site of subcutaneous injection was the dorsal neck region.
- the doses administered were 2 ⁇ g (solid triangles) , 25 ⁇ g (solid circles) , 50 ⁇ g (solid squares) , and 100 ⁇ g (solid diamonds) .
- the percent of predosage urine flow observed is plotted in Figure 18A.
- the percent of predosage urine flow observed is plotted in Figure 18B.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69015207T DE69015207T2 (en) | 1989-10-20 | 1990-10-19 | LIPOSOME MICRORESERVOIR COMPOSITION AND METHOD. |
KR1019920700919A KR920703013A (en) | 1989-10-20 | 1990-10-19 | Liposomal Microretent Compositions and Methods |
EP90916409A EP0496813B1 (en) | 1989-10-20 | 1990-10-19 | Liposome microreservoir composition and method |
KR1019920700918A KR0134982B1 (en) | 1989-10-20 | 1990-10-19 | Lipsome microreservoir composition and method |
NO92921213A NO921213L (en) | 1989-10-20 | 1992-03-27 | LIPOSOM MICROR RESERVE COMPOSITION AND PROCEDURE |
FI921763A FI921763A0 (en) | 1989-10-20 | 1992-04-21 | MIKRORESERVOARKOMPOSITION OCH FOERFARANDE FOER LIPOSOM. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/425,224 US5013556A (en) | 1989-10-20 | 1989-10-20 | Liposomes with enhanced circulation time |
US425,224 | 1989-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991005545A1 true WO1991005545A1 (en) | 1991-05-02 |
Family
ID=23685679
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006211 WO1991005546A1 (en) | 1989-10-20 | 1990-10-19 | Solid tumor treatment method and composition |
PCT/US1990/006034 WO1991005545A1 (en) | 1989-10-20 | 1990-10-19 | Liposome microreservoir composition and method |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006211 WO1991005546A1 (en) | 1989-10-20 | 1990-10-19 | Solid tumor treatment method and composition |
Country Status (18)
Country | Link |
---|---|
US (2) | US5013556A (en) |
EP (2) | EP0496835B1 (en) |
JP (4) | JP2667051B2 (en) |
KR (2) | KR0134982B1 (en) |
AT (2) | ATE122229T1 (en) |
AU (2) | AU642679B2 (en) |
CA (2) | CA2067133C (en) |
DE (3) | DE69019366T2 (en) |
DK (1) | DK0496835T3 (en) |
ES (1) | ES2071976T3 (en) |
FI (2) | FI921763A0 (en) |
GR (1) | GR3017060T3 (en) |
HK (1) | HK14097A (en) |
IL (2) | IL96069A (en) |
LU (1) | LU88854I2 (en) |
NL (1) | NL960031I2 (en) |
NO (3) | NO304637B1 (en) |
WO (2) | WO1991005546A1 (en) |
Cited By (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007537A1 (en) * | 1992-10-05 | 1994-04-14 | Stichting Voor De Technische Wetenschappen | Pharmaceutical composition for site-specific release of a clot-dissolving protein |
WO1994007466A1 (en) * | 1992-10-07 | 1994-04-14 | Liposome Technology, Inc. | Compositions for treatmewnt of inflamed tissues |
WO1994020073A1 (en) * | 1993-03-03 | 1994-09-15 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
WO1994026251A1 (en) * | 1993-05-07 | 1994-11-24 | Sequus Pharmaceuticals, Inc. | Subcutaneous liposome delivery method |
WO1996010391A1 (en) * | 1994-09-30 | 1996-04-11 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
WO1997021429A1 (en) * | 1995-12-11 | 1997-06-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid |
WO1998008489A1 (en) * | 1996-08-26 | 1998-03-05 | Transgene S.A. | Cationic lipid-nucleic acid complexes |
WO1998016202A2 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome composition and method |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
WO1999027908A1 (en) * | 1997-12-04 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US6083923A (en) * | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
US6096720A (en) * | 1995-08-01 | 2000-08-01 | Novartis Ag | Liposomal oligonucleotide compositions |
WO2000066126A2 (en) * | 1999-04-29 | 2000-11-09 | Alza Corporation | Liposome compositions for improved drug retention |
WO2001011069A1 (en) | 1999-08-06 | 2001-02-15 | Celltech R&D Limited | Freeze/thawed lipid complexes and their preparation |
US6224903B1 (en) | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
US6316024B1 (en) | 1996-10-11 | 2001-11-13 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6673364B1 (en) | 1995-06-07 | 2004-01-06 | The University Of British Columbia | Liposome having an exchangeable component |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
EP1651187A2 (en) * | 2003-07-31 | 2006-05-03 | The Board Of Regents, The University Of Texas System | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
WO2007115168A2 (en) | 2006-03-31 | 2007-10-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 gene |
US7358068B2 (en) | 2002-09-13 | 2008-04-15 | Replicor, Inc. | Antiviral oligonucleotides |
EP2003207A2 (en) | 2000-01-18 | 2008-12-17 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2140872A2 (en) | 2008-07-02 | 2010-01-06 | Kenneth Wileford | Composition for the treatment of skin conditions comprising sea water with additional magnesium |
US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
EP2174945A1 (en) | 2001-08-01 | 2010-04-14 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
WO2010042281A2 (en) | 2008-08-25 | 2010-04-15 | Excaliard Pharmaceuticals | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US7718632B2 (en) | 2007-06-15 | 2010-05-18 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
WO2010068816A1 (en) | 2008-12-10 | 2010-06-17 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
EP2221376A2 (en) | 2001-06-21 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
WO2010099341A1 (en) | 2009-02-26 | 2010-09-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of mig-12 gene |
WO2010105209A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
EP2246443A1 (en) | 2001-05-14 | 2010-11-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP2270231A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2270230A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
EP2272985A1 (en) | 2001-08-07 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (A) expression |
EP2280019A1 (en) | 2001-07-25 | 2011-02-02 | ISIS Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US7888498B2 (en) | 2006-05-22 | 2011-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
EP2284267A2 (en) | 2003-08-18 | 2011-02-16 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US7960350B2 (en) | 2003-10-24 | 2011-06-14 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
EP2332955A2 (en) | 2001-07-30 | 2011-06-15 | ISIS Pharmaceuticals, Inc. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
EP2336318A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2336319A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
EP2388318A1 (en) | 2001-12-10 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
EP2392583A1 (en) | 2006-05-19 | 2011-12-07 | Alnylam Europe AG. | RNAi modulation of Aha and therapeutic uses thereof |
US8148344B2 (en) | 2008-03-27 | 2012-04-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for mediating RNAi in vivo |
WO2012064824A1 (en) | 2010-11-09 | 2012-05-18 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
WO2012078967A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (epo) production |
WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
EP2468865A1 (en) | 2004-02-06 | 2012-06-27 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of stat3 expression |
WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
US8293719B2 (en) | 2004-03-12 | 2012-10-23 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
WO2012166903A1 (en) | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
WO2012177949A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
WO2012177947A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
WO2012177906A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
WO2013003112A1 (en) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
EP2617828A1 (en) | 2007-12-10 | 2013-07-24 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of factor VII gene |
US20130224121A1 (en) * | 2012-02-23 | 2013-08-29 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
WO2013155204A2 (en) | 2012-04-10 | 2013-10-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
EP2690175A2 (en) | 2008-09-02 | 2014-01-29 | Alnylam Pharmaceuticals | Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression |
EP2712926A2 (en) | 2008-03-05 | 2014-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
WO2014107731A1 (en) | 2013-01-07 | 2014-07-10 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
WO2014160871A2 (en) | 2013-03-27 | 2014-10-02 | The General Hospital Corporation | Methods and agents for treating alzheimer's disease |
WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
EP2810643A2 (en) | 2009-08-14 | 2014-12-10 | Alnylam Pharmaceuticals Inc. | Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus |
US8926955B2 (en) | 2008-12-22 | 2015-01-06 | Creabilis S.A. | Synthesis of polymer conjugates of indolocarbazole compounds |
WO2015050990A1 (en) | 2013-10-02 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
EP2905336A1 (en) | 2007-03-29 | 2015-08-12 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
EP2937418A1 (en) | 2008-10-20 | 2015-10-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
EP2944646A1 (en) | 2005-09-29 | 2015-11-18 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
WO2016094897A1 (en) | 2014-12-12 | 2016-06-16 | The Jackson Laboratory | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
WO2016100716A1 (en) | 2014-12-18 | 2016-06-23 | Vasant Jadhav | Reversirtm compounds |
EP3109321A1 (en) | 2008-09-25 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
WO2017015109A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017048843A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
EP3252068A2 (en) | 2009-10-12 | 2017-12-06 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
EP3456827A2 (en) | 2010-06-02 | 2019-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
US10485764B2 (en) | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
WO2020037125A1 (en) | 2018-08-16 | 2020-02-20 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
WO2020113135A1 (en) | 2018-11-29 | 2020-06-04 | Flagship Pioneering Innovations V, Inc. | Methods of modulating rna |
EP3674409A1 (en) | 2011-03-29 | 2020-07-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of tmprss6 gene |
EP3693463A1 (en) | 2013-10-04 | 2020-08-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2021046122A1 (en) | 2019-09-03 | 2021-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
EP3797789A1 (en) | 2015-01-20 | 2021-03-31 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
WO2021087325A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
WO2021163066A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021207167A1 (en) | 2020-04-06 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Families Citing this family (1491)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5456663A (en) * | 1984-05-25 | 1995-10-10 | Lemelson; Jerome H. | Drugs and methods for treating diseases |
US5882330A (en) * | 1984-05-25 | 1999-03-16 | Lemelson; Jerome H. | Drugs and methods for treating diseases |
US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
JPH0720857B2 (en) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US5153000A (en) * | 1988-11-22 | 1992-10-06 | Kao Corporation | Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US20010051183A1 (en) * | 1989-10-20 | 2001-12-13 | Alza Corporation | Liposomes with enhanced circulation time and method of treatment |
US5843473A (en) * | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5441746A (en) * | 1989-12-22 | 1995-08-15 | Molecular Bioquest, Inc. | Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5305757A (en) * | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US6001335A (en) * | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5882678A (en) * | 1990-01-12 | 1999-03-16 | The Liposome Co, Inc. | Interdigitation-fusion liposomes containing arachidonic acid metabolites |
US5162361A (en) * | 1990-04-10 | 1992-11-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method of treating diseases associated with elevated levels of interleukin 1 |
US6465188B1 (en) * | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US20060084797A1 (en) * | 1990-06-11 | 2006-04-20 | Gilead Sciences, Inc. | High affinity TGFbeta nucleic acid ligands and inhibitors |
US20030113369A1 (en) * | 1991-01-16 | 2003-06-19 | Martin Francis J. | Liposomes with enhanced circulation time and method of treatment |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) * | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
JP3220180B2 (en) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
GB9111611D0 (en) * | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
DE69333434T2 (en) | 1992-04-03 | 2005-03-03 | The Regents Of The University Of California, Oakland | SELF-ORGANIZING SYSTEM FOR THE ADMINISTRATION OF POLYNUCLEOTIDES CONTAINING AN AMPHIPHATIC PEPTIDE |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
DK0656368T4 (en) * | 1992-08-05 | 2003-09-29 | Meito Sangyo Kk | Small diameter composite material containing a water-soluble carboxypolysaccharide and magnetic iron oxide |
DE4236237A1 (en) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, their preparation and use as medicines |
US6764693B1 (en) * | 1992-12-11 | 2004-07-20 | Amaox, Ltd. | Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants |
JP3351476B2 (en) * | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | Phospholipid derivatives and liposomes containing the same |
WO1994021281A1 (en) * | 1993-03-23 | 1994-09-29 | Liposome Technology, Inc. | Polymer-polypeptide composition and method |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US20050181976A1 (en) * | 1993-05-10 | 2005-08-18 | Ekwuribe Nnochiri N. | Amphiphilic oligomers |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
WO1994027580A1 (en) * | 1993-05-21 | 1994-12-08 | The Liposome Company, Inc. | Reduction of liposome-induced adverse physiological reactions |
WO1995011670A1 (en) * | 1993-10-25 | 1995-05-04 | The Liposome Company, Inc. | Liposomal defensins |
US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5468499A (en) * | 1993-11-15 | 1995-11-21 | Ohio State University | Liposomes containing the salt of phosphoramide mustard and related compounds |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
JPH09506866A (en) * | 1993-12-14 | 1997-07-08 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | Controlled release of pharmaceutically active substances for immunotherapy |
US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
US20010055581A1 (en) * | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
DE4423131A1 (en) * | 1994-07-01 | 1996-01-04 | Bayer Ag | New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4 |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5512294A (en) * | 1994-08-05 | 1996-04-30 | Li; King C. | Targeted polymerized liposome contrast agents |
US6132764A (en) * | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
DE69527206T2 (en) * | 1994-09-30 | 2003-02-27 | Inex Pharmaceuticals Corp | AGENT FOR INSERTING POLYANIONIC MATERIALS IN CELLS |
US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
ES2153053T3 (en) * | 1994-10-14 | 2001-02-16 | Liposome Co Inc | LIPOSOMAS OF ETER-LIPIDO AND ITS THERAPEUTIC USE. |
CN1080575C (en) * | 1994-10-14 | 2002-03-13 | 蛋白质传送股份有限公司 | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5827531A (en) * | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
IL112834A (en) * | 1995-03-01 | 2000-12-06 | Yeda Res & Dev | Pharmaceutical compositions for controlled release of soluble receptors |
US5658588A (en) * | 1995-03-31 | 1997-08-19 | University Of Cincinnati | Fibrinogen-coated liposomes |
GB9509016D0 (en) * | 1995-05-03 | 1995-06-21 | Royal Free Hosp School Med | Tissue entrapment |
US8071737B2 (en) * | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
US5997898A (en) * | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
DE69634084T2 (en) * | 1995-06-07 | 2005-12-08 | Inex Pharmaceuticals Corp. | PREPARATION OF LIPID NUCLEIC ACID PARTICLES A HYDROPHOBIC LIPID NUCLEIC ACID COMPLEX INTERMEDIATE PRODUCT AND FOR THE USE IN THE TRANSFER OF THE INVENTION |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6033645A (en) * | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6051600A (en) * | 1995-09-12 | 2000-04-18 | Mayhew; Eric | Liposomal hydrolysis-promoting hydrophobic taxane derivatives |
US6107332A (en) | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US5858397A (en) * | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
EP0863748A4 (en) * | 1995-10-11 | 1999-11-03 | Kevin Jon William | Liposomal compositions and methods of using them |
US20030040467A1 (en) * | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US5626654A (en) | 1995-12-05 | 1997-05-06 | Xerox Corporation | Ink compositions containing liposomes |
JP2000503204A (en) | 1996-01-08 | 2000-03-21 | ジェネンテック インコーポレーテッド | WSX receptor and ligands |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US5908624A (en) * | 1996-06-27 | 1999-06-01 | Albany Medical College | Antigenic modulation of cells |
USRE39042E1 (en) * | 1996-02-16 | 2006-03-28 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
US5942246A (en) * | 1996-02-16 | 1999-08-24 | The Liposome Company, Inc. | Etherlipid containing multiple lipid liposomes |
US6007839A (en) * | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
US6667053B1 (en) | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
US5965159A (en) | 1996-02-16 | 1999-10-12 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
CA2250219C (en) | 1996-03-28 | 2008-10-07 | Hayat Onyuksel | Materials and methods for making improved liposome compositions |
EP0935415B1 (en) | 1996-05-01 | 2006-11-22 | Imarx Pharmaceutical Corp. | In vitro methods for delivering nucleic acids into a cell |
WO2005121371A2 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20050042647A1 (en) * | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20070275921A1 (en) * | 1996-06-06 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Oligomeric Compounds That Facilitate Risc Loading |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US5919480A (en) | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
US8007784B1 (en) | 1996-06-27 | 2011-08-30 | Albany Medical College | Antigenic modulation of cells |
US7368129B1 (en) | 1996-08-14 | 2008-05-06 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
US6284267B1 (en) | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
WO1998007409A1 (en) * | 1996-08-23 | 1998-02-26 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
ATE366588T1 (en) * | 1996-09-11 | 2007-08-15 | Imarx Pharmaceutical Corp | METHOD FOR DIAGNOSTIC IMAGING OF THE KIDNEY REGION USING A CONTRAST AGENT AND A VASODILATOR |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
EP0932390A1 (en) | 1996-10-11 | 1999-08-04 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
NZ336539A (en) * | 1996-10-15 | 2000-09-29 | Liposome Co Inc | Peptide-lipid conjugates, liposomes and liposomal drug delivery |
US6339069B1 (en) | 1996-10-15 | 2002-01-15 | Elan Pharmaceuticalstechnologies, Inc. | Peptide-lipid conjugates, liposomes and lipsomal drug delivery |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US20070036722A1 (en) * | 1996-10-28 | 2007-02-15 | Pal Rongved | Separation processes |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
NZ335596A (en) * | 1996-10-28 | 2000-10-27 | Nycomed Imaging As | Diagnostic and therapeutic agents comprising microbubbles of a reporter, a surfactant and a vector |
US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
US6207186B1 (en) * | 1997-02-14 | 2001-03-27 | The Regents Of The University Of California | Lamellar gels and methods for making and using |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
HUP0001256A3 (en) | 1997-04-03 | 2002-12-28 | Univ Johns Hopkins Med | Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, method for making the same and using them |
EP1787999B1 (en) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF antibodies |
DK0971959T3 (en) | 1997-04-07 | 2006-05-15 | Genentech Inc | Humanized antibodies and methods for producing humanized antibodies |
WO1998044910A1 (en) * | 1997-04-09 | 1998-10-15 | Philipp Lang | NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO) |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
DE69841002D1 (en) * | 1997-05-14 | 2009-09-03 | Univ British Columbia | Highly effective encapsulation of nucleic acids in lipid vesicles |
DE19724796A1 (en) * | 1997-06-06 | 1998-12-10 | Max Delbrueck Centrum | Antitumor therapy agents |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6663899B2 (en) * | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6217886B1 (en) | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
DE69841598D1 (en) | 1997-09-18 | 2010-05-20 | Pacira Pharmaceuticals Inc | RETARDANT RELEASE OF LIPOSMAL ANESTHETIC COMPOSITIONS. |
US7229841B2 (en) * | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
CA2309548A1 (en) | 1997-11-14 | 1999-05-27 | Skyepharma Inc. | Production of multivesicular liposomes |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
EP1481990B1 (en) | 1997-11-21 | 2007-06-06 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
US6787132B1 (en) * | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
EP1947119A3 (en) | 1997-12-12 | 2012-12-19 | Genentech, Inc. | Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
DK1510579T3 (en) | 1998-02-04 | 2009-11-30 | Genentech Inc | Use of heregulin as an epithelial cell growth factor |
CA2319433C (en) * | 1998-02-09 | 2008-04-22 | Bracco Research S.A. | Targeted delivery of biologically active media |
US6312685B1 (en) | 1998-03-13 | 2001-11-06 | Timothy C. Fisher | Red blood cells covalently bound with two different polyethylene glycol derivatives |
US6942859B2 (en) | 1998-03-13 | 2005-09-13 | University Of Southern California | Red blood cells covalently bound with polymers |
EP1064382B1 (en) | 1998-03-17 | 2008-08-20 | Genentech, Inc. | Polypeptides homologous to vegf and bmp1 |
US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
JP2002507567A (en) * | 1998-03-25 | 2002-03-12 | ラージ スケール バイオロジー コーポレイション | Benzoic acid derivatives for inhibiting angiogenesis |
US6858706B2 (en) * | 1998-04-07 | 2005-02-22 | St. Jude Children's Research Hospital | Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
US6593294B1 (en) * | 1998-04-27 | 2003-07-15 | Opperbas Holding B.V. | Pharmaceutical composition comprising Factor VIII and neutral liposomes |
US6986902B1 (en) * | 1998-04-28 | 2006-01-17 | Inex Pharmaceuticals Corporation | Polyanionic polymers which enhance fusogenicity |
US6448224B1 (en) | 1998-05-06 | 2002-09-10 | St. Jude Children's Research Hospital | Antibiotics and methods of using the same |
US6331407B1 (en) | 1998-05-06 | 2001-12-18 | St. Jude Children's Research Hospital | Antibiotics and methods of using the same |
US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
AU740405B2 (en) | 1998-05-15 | 2001-11-01 | Genentech Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP2058334B1 (en) | 1998-06-12 | 2012-10-31 | Genentech, Inc. | Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
ATE428371T1 (en) | 1998-07-17 | 2009-05-15 | Pacira Pharmaceuticals Inc | BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF ENCLOSED SUBSTANCES |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
CA2346879A1 (en) * | 1998-09-16 | 2000-04-27 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6419709B1 (en) | 1998-10-02 | 2002-07-16 | Guilford Pharmaceuticals, Inc. | Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same |
US6153212A (en) * | 1998-10-02 | 2000-11-28 | Guilford Pharmaceuticals Inc. | Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same |
MY126795A (en) | 1998-10-23 | 2006-10-31 | Amgen K A Inc | Dimeric thrombopoietic peptide mimetics binding to mp1 receptor and having thrombopoietic activity. |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
EP2075335A3 (en) | 1998-12-22 | 2009-09-30 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
WO2000037502A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
US6350464B1 (en) | 1999-01-11 | 2002-02-26 | Guilford Pharmaceuticals, Inc. | Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
US6818227B1 (en) * | 1999-02-08 | 2004-11-16 | Alza Corporation | Liposome composition and method for administration of a radiosensitizer |
US6537585B1 (en) | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
US6379698B1 (en) | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
CA2270600A1 (en) | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania |
EP1645291A1 (en) | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
AU4430200A (en) * | 1999-05-11 | 2000-11-21 | Sankyo Company Limited | Liposome preparation of fat-soluble antitumor drug |
US20040229779A1 (en) * | 1999-05-14 | 2004-11-18 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040023874A1 (en) * | 2002-03-15 | 2004-02-05 | Burgess Catherine E. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US6974684B2 (en) * | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
EP1978029A3 (en) | 1999-06-15 | 2008-10-15 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
EP1190705A4 (en) * | 1999-06-24 | 2009-03-18 | Kyowa Hakko Kogyo Kk | Method of regulating leakage of drug encapsulated in liposomes |
MXPA01013458A (en) | 1999-06-25 | 2002-07-30 | Genentech Inc | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES. |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
KR20090024308A (en) | 1999-08-27 | 2009-03-06 | 제넨테크, 인크. | Dosages for treatment with anti-erbb2 antibodies |
KR20050004240A (en) * | 1999-08-31 | 2005-01-12 | 제넨테크, 인크. | Compositions and Methods for the Treatment of Tumor |
KR20010085996A (en) * | 1999-09-03 | 2001-09-07 | 스티븐 엠. 오드레 | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
WO2001026625A2 (en) | 1999-10-08 | 2001-04-19 | Alza Corp | Neutral-cationic lipid for nucleic acid and drug delivery |
IT1315253B1 (en) * | 1999-10-22 | 2003-02-03 | Novuspharma Spa | LIPOSOMIAL PREPARATION OF 6,9-BIS- (2-AMINOXYL) AMINO | BENZOG | ISOCHINOLIN-5,10-DIONE DIMALEATO |
US7067111B1 (en) * | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
EP1690872A3 (en) | 1999-12-01 | 2006-08-23 | Genentech, Inc. | Composition and methods for the diagnosis of tumours |
US6593308B2 (en) | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
AU2136501A (en) * | 1999-12-10 | 2001-06-18 | Celator Technologies Inc. | Lipid carrier compositions with protected surface reactive functions |
DK1897945T3 (en) | 1999-12-23 | 2012-05-07 | Genentech Inc | IL-17 homologous polypeptides and therapeutic uses thereof. |
JP2003520210A (en) * | 2000-01-05 | 2003-07-02 | イマレックス セラピューティクス, インコーポレイテッド | Pharmaceutical formulations for delivery of drugs with low water solubility |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
IL150676A0 (en) * | 2000-01-13 | 2003-02-12 | Genentech Inc | NOVEL STRa6 POLYPEPTIDES |
DK1274399T3 (en) * | 2000-01-28 | 2005-08-08 | Alza Corp | Liposomes containing an encapsulated compound in supersaturated solution |
US20030176385A1 (en) * | 2000-02-15 | 2003-09-18 | Jingfang Ju | Antisense modulation of protein expression |
JP4922824B2 (en) * | 2000-04-03 | 2012-04-25 | 参天製薬株式会社 | Delivery substance and drug delivery system using the same |
WO2001077342A1 (en) | 2000-04-11 | 2001-10-18 | Genentech, Inc. | Multivalent antibodies and uses therefor |
DK1272225T3 (en) * | 2000-04-12 | 2006-12-27 | Liplasome Pharma As | Lipid-based systems for targeted delivery of diagnostic agents |
MXPA02010324A (en) | 2000-04-21 | 2003-04-25 | Amgen Inc | Apo ai aii peptide derivatives. |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
AU2001258106A1 (en) * | 2000-05-11 | 2001-11-20 | Celator Technologies Inc. | Lipid carrier compositions for improved drug retention |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
PL212211B1 (en) * | 2000-06-02 | 2012-08-31 | Regents Board Of | Ethylenedicysteine (ec)-drug conjugates |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
AU6836301A (en) | 2000-06-20 | 2002-01-02 | Idec Pharma Corp | Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
EP2042597B1 (en) | 2000-06-23 | 2014-05-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
CA2648048A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20040023259A1 (en) * | 2000-07-26 | 2004-02-05 | Luca Rastelli | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
DE60136281D1 (en) | 2000-08-24 | 2008-12-04 | Genentech Inc | METHOD FOR INHIBITING IL-22-INDUCED PAP1 |
EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030133972A1 (en) * | 2000-10-11 | 2003-07-17 | Targesome, Inc. | Targeted multivalent macromolecules |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
DK2174954T3 (en) | 2000-10-18 | 2016-07-04 | Robert Sackstein | HEMATOPOIETIC CELL E-selectin / L-SELEKTINLIGAND polypeptides and methods of use thereof |
WO2002036073A2 (en) * | 2000-11-02 | 2002-05-10 | Smithkline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
DE10056136A1 (en) * | 2000-11-07 | 2002-05-16 | Nemod New Modalities | Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound |
AU2002248190A1 (en) * | 2000-11-30 | 2002-08-12 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
US20020132982A1 (en) * | 2000-11-30 | 2002-09-19 | Balasubramanian Sathyamangalam V. | AHF associated dispersion system and method for preparation |
US8110218B2 (en) * | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
US7625584B2 (en) * | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
CN1982330B (en) * | 2000-12-18 | 2012-01-25 | 卡比斯特制药公司 | Methods for preparing purified lipopeptides |
WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
US20040077604A1 (en) * | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20040043928A1 (en) * | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
AR035779A1 (en) | 2001-02-06 | 2004-07-14 | Genetics Inst Llc | FUSION POLYPEPTIDES DERIVED FROM GLICOPROTEIN IB PLATE ALFA AND METHODS OF USE OF THE SAME |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
EP1372739A4 (en) * | 2001-03-08 | 2005-10-19 | Targesome Inc | Stabilized therapeutic and imaging agents |
IL158160A0 (en) * | 2001-03-26 | 2004-03-28 | Alza Corp | Liposome composition for improved intracellular delivery of a therapeutic agent |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
WO2002087541A1 (en) * | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
EP1383480A4 (en) * | 2001-04-30 | 2006-05-24 | Targeted Genetics Corp | Lipid-comprising drug delivery complexes and methods for their production |
GB0111279D0 (en) * | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
ATE549354T1 (en) | 2001-05-11 | 2012-03-15 | Amgen Inc | PEPTIDES AND ASSOCIATED TALL-1 BINDING MOLECULES |
WO2002092554A1 (en) * | 2001-05-15 | 2002-11-21 | Transgene S.A. | Complexes for transferring substances of interest into a cell |
AU2002310046A1 (en) * | 2001-05-22 | 2002-12-03 | Duke University | Compositions and methods for inhibiting metastasis |
US20020197253A1 (en) * | 2001-05-22 | 2002-12-26 | Cheek Dennis J. | Compositions and methods for promoting or inhibiting NDPK |
NZ544410A (en) | 2001-05-30 | 2008-04-30 | Genentech Inc | Anti-ngf antibodies for the treatment of various disorders |
AU2002322024B2 (en) * | 2001-05-31 | 2008-05-08 | Pacira Pharmaceuticals, Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
JP2005501011A (en) * | 2001-06-08 | 2005-01-13 | ユタ ベンチャー ザ セカンド リミテッド パートナーシップ | Tissue-specific inner membrane protein |
US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
DK2000545T3 (en) | 2001-06-20 | 2011-11-28 | Genentech Inc | Compositions and methods for diagnosis and treatment of lung tumor |
CN1827766B (en) | 2001-06-28 | 2010-08-25 | 徐荣祥 | In vitro cell cultivation method |
US20030087274A1 (en) * | 2001-07-05 | 2003-05-08 | Anderson David W. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040029790A1 (en) * | 2001-07-05 | 2004-02-12 | Meera Patturajan | Novel human proteins, polynucleotides encoding them and methods of using the same |
WO2003007914A2 (en) * | 2001-07-19 | 2003-01-30 | Guilford Pharmaceuticals, Inc. | Biocompatible polymer containing composition for treatment of prostate cancers |
WO2003007915A2 (en) * | 2001-07-19 | 2003-01-30 | Guilford Pharmaceuticals, Inc. | Compositions for treatment of head and neck cancers, and methods of making and using the same |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
IL160016A0 (en) * | 2001-07-29 | 2004-06-20 | Yissum Res Dev Co | Osteogenic growth oligopeptides as stimulants of hematopoiesis |
US20040030096A1 (en) * | 2001-08-02 | 2004-02-12 | Linda Gorman | Novel human proteins, polynucleotides encoding them and methods of using the same |
WO2003015707A2 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
KR20040066788A (en) | 2001-08-31 | 2004-07-27 | 더 락커펠러 유니버시티 | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
EP2174953A1 (en) | 2001-09-18 | 2010-04-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
DE10148065A1 (en) * | 2001-09-28 | 2003-04-17 | Max Planck Gesellschaft | (Ester) -lysolecithins in liposomes |
WO2003026588A2 (en) * | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Methods and apparatus for extrusion of vesicles at high pressure |
US20030199442A1 (en) * | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
IL161733A0 (en) | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
WO2003039595A2 (en) * | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
US20040219201A1 (en) * | 2001-12-06 | 2004-11-04 | Yechezkel Barenholz | Tempamine compositions and methods of use |
AU2002367318B2 (en) | 2002-01-02 | 2007-07-12 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
JP4508645B2 (en) | 2002-01-04 | 2010-07-21 | ザ ロックフェラー ユニバーシティー | Compositions and methods for the prevention and treatment of amyloid-beta peptide related diseases |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
EP1487273B1 (en) | 2002-02-13 | 2009-01-21 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
JP2005536190A (en) | 2002-04-16 | 2005-12-02 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
EP1517923A2 (en) * | 2002-04-22 | 2005-03-30 | Recopharma AB | Compositions and methods for inhibiting microbial adhesion |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
EP2338478B1 (en) | 2002-06-28 | 2014-07-23 | Protiva Biotherapeutics Inc. | Method for producing liposomes |
AU2003241598B2 (en) * | 2002-07-02 | 2009-11-05 | Nanotx Corp. | Radiolabeled compounds and liposomes and their methods of making and using the same |
AU2003267984A1 (en) * | 2002-07-03 | 2004-01-23 | Receptor Biologix, Inc. | Liposomal vaccine |
US20040247661A1 (en) * | 2002-07-03 | 2004-12-09 | Dov Michaeli | Liposomal vaccine |
US20050169979A1 (en) * | 2002-07-03 | 2005-08-04 | Dov Michaeli | Liposomal vaccine |
EP1572130A4 (en) | 2002-07-08 | 2008-07-02 | Genentech Inc | Compositions and methods for the treatment of immune related diseases |
EP1585966B8 (en) | 2002-07-15 | 2012-03-07 | F. Hoffmann-La Roche AG | Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4 |
EP1537146B9 (en) * | 2002-07-15 | 2011-07-06 | Board Of Regents, The University Of Texas System | Antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
CA2492654A1 (en) * | 2002-07-16 | 2004-01-22 | University Of South Florida | Human immunosuppressive protein |
US20040161423A1 (en) * | 2002-07-18 | 2004-08-19 | Sanjeev Kumar (Mendiratta) | Polymer modified anti-angiogenic serpins |
MXPA05001312A (en) * | 2002-08-02 | 2005-08-03 | Transave Inc | Platinum aggregates and process for producing the same. |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
EP1393720A1 (en) * | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicle-encapsulated corticosteroids for treatment of cancer |
PL376536A1 (en) | 2002-08-28 | 2006-01-09 | Immunex Corporation | Compositions and methods for treating cardiovascular disease |
AR036316A1 (en) * | 2002-08-29 | 2004-08-25 | Monte Verde S A | A PHARMACEUTICAL COMPOSITION OF SMALL SIZE LIPOSOMES AND PREPARATION METHOD |
US20070231379A1 (en) * | 2002-08-29 | 2007-10-04 | Slater James L | Liposome-entrapped topoisomerase inhibitors |
US7655772B2 (en) | 2002-09-06 | 2010-02-02 | University Of South Florida | Materials and methods for treatment of allergic diseases |
US20050272650A1 (en) * | 2004-02-17 | 2005-12-08 | Mohapatra Shyam S | Materials and methods for treatment of inflammatory and cell proliferation disorders |
US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
WO2004024068A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
EP1578373A4 (en) | 2002-09-11 | 2007-10-24 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
EP2444409A2 (en) | 2002-09-16 | 2012-04-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
JP2006513700A (en) | 2002-09-25 | 2006-04-27 | ジェネンテック・インコーポレーテッド | Novel compositions and methods for the treatment of psoriasis |
WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20060147450A1 (en) * | 2002-10-04 | 2006-07-06 | Shelton David L | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
AU2003304238A1 (en) | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
EP1633786A4 (en) * | 2002-10-09 | 2007-07-25 | Rinat Neuroscience Corp | Methods of treating alzheimer s disease using antibodies directed against amyloid beta peptide and compositions thereof |
JP2006517785A (en) | 2002-10-29 | 2006-08-03 | ジェネンテック・インコーポレーテッド | Novel compositions and methods for the treatment of immune related diseases |
EP1560597A4 (en) * | 2002-10-29 | 2007-06-27 | Pharmacia Corp | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
AU2003290598A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
AU2003287505A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US20040093198A1 (en) * | 2002-11-08 | 2004-05-13 | Carbon Design Systems | Hardware simulation with access restrictions |
EP1581169A4 (en) | 2002-11-08 | 2008-09-17 | Genentech Inc | Compositions and methods for the treatment of natural killer cell related diseases |
WO2004043396A2 (en) * | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
US20050158375A1 (en) * | 2002-11-15 | 2005-07-21 | Toshikiro Kimura | Pharmaceutical composition containing liposomes for treating cancer |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
PL377813A1 (en) | 2002-11-26 | 2006-02-20 | Biocon Limited | Modified naturetic compounds, conjugates, and uses thereof |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
KR20050090987A (en) * | 2002-12-19 | 2005-09-14 | 알자 코포레이션 | Method of treating angiogenic tissue growth |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
ES2382918T3 (en) | 2002-12-24 | 2012-06-14 | Rinat Neuroscience Corp. | Anti-NGF antibodies and procedures using them |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
ES2337563T3 (en) | 2002-12-31 | 2010-04-27 | Zydus Bsv Pharma Private Limited | UNPEGLATED LIPOSOMES OF LASTING CIRCULATION. |
US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
EP1583713B1 (en) * | 2003-01-07 | 2009-03-25 | Ramot at Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
EP1591450A4 (en) * | 2003-01-10 | 2006-05-17 | Yamanouchi Pharma Co Ltd | Conjugate for retention in blood and cancer tissue-specific drug delivery |
US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
US7468356B2 (en) | 2003-02-11 | 2008-12-23 | Antisense Therapeutics Ltd. | Modulation of insulin like growth factor I receptor expression |
EP1594441B1 (en) | 2003-02-19 | 2010-12-15 | Rinat Neuroscience Corp. | Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US7968115B2 (en) | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
US20060198882A1 (en) * | 2003-03-21 | 2006-09-07 | Yechezkel Barenholz | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
WO2004089339A2 (en) | 2003-03-31 | 2004-10-21 | Alza Corporation | Lipid particles having asymmetric lipid coating and method of preparing same |
PT1610820E (en) | 2003-04-04 | 2010-12-16 | Novartis Ag | High concentration antibody and protein formulations |
WO2004091657A2 (en) | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
DK1633440T3 (en) * | 2003-04-15 | 2008-09-08 | Opperbas Holding Bv | Pharmaceutical composition comprising proteins and / or polypeptides and colloidal particles |
WO2004094457A2 (en) * | 2003-04-16 | 2004-11-04 | Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University | Stable rgd peptidomimetic composition |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
CA2522184A1 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Of New York | Desmoglein 4 is a novel gene involved in hair growth |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
MXPA05012314A (en) | 2003-05-12 | 2006-04-18 | Affymax Inc | Spacer moiety for poly(ethylene glycol) -modified peptides. |
WO2004101600A2 (en) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel poly(ethylene glycol) modified compounds and uses thereof |
CA2526080A1 (en) * | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Polypeptides that bind an anti-tissue factor antibody and uses thereof |
BRPI0411200A (en) | 2003-05-30 | 2006-07-18 | Genentech Inc | cancer treatment method, human patient treatment methods, industrialized article and cancer treatment kit |
WO2005002507A2 (en) | 2003-06-03 | 2005-01-13 | Isis Pharmaceuticals, Inc. | Modulation of survivin expression |
EP1629085A2 (en) * | 2003-06-04 | 2006-03-01 | CANJI, Inc. | Transfection agents |
CA2528343A1 (en) | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
JP2007537710A (en) | 2003-06-11 | 2007-12-27 | ワイス | Platelet glycoprotein IBα variant fusion polypeptide and use thereof |
US7939058B2 (en) * | 2003-07-03 | 2011-05-10 | University Of Southern California | Uses of IL-12 in hematopoiesis |
ATE478963T1 (en) | 2003-07-03 | 2010-09-15 | Univ New Jersey Med | GENES AS DIAGNOSTIC TOOLS FOR AUTISM |
EP2784084B2 (en) | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
EP1648519B1 (en) * | 2003-07-16 | 2014-10-08 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
CN100431525C (en) * | 2003-07-17 | 2008-11-12 | 台湾东洋药品工业股份有限公司 | Production method of liposome suspended liquid and products thereof |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050043239A1 (en) * | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
WO2005016349A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Methods of inhibiting leukocyte accumulation |
US8986731B2 (en) * | 2003-08-26 | 2015-03-24 | Biolitec Pharma Marketing Ltd | Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy |
DE602004019546D1 (en) * | 2003-08-26 | 2009-04-02 | Smithkline Beecham Corp | HETEROFUNCTIONAL COPOLYMERS OF GLYCEROL AND POLYETHYLENE GLYCOL, ITS CONJUGATES AND COMPOSITIONS |
US8846079B1 (en) | 2004-12-01 | 2014-09-30 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
US11324698B2 (en) | 2003-08-28 | 2022-05-10 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
CN1867580B (en) * | 2003-09-03 | 2010-09-29 | 协和发酵麒麟株式会社 | Compound modified with glycerol derivative |
US20050233435A1 (en) * | 2003-09-04 | 2005-10-20 | Nyu Medical Center | Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
KR101164256B1 (en) * | 2003-09-15 | 2012-07-10 | 프로티바 바이오쎄라퓨틱스, 인코포레이티드 | Polyethyleneglycol-modified lipid compounds and uses thereof |
NZ545134A (en) | 2003-09-18 | 2009-06-26 | Lilly Co Eli | Modulation of eIF4E expression |
WO2005027901A1 (en) * | 2003-09-25 | 2005-03-31 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US7625707B2 (en) * | 2003-10-02 | 2009-12-01 | Ramot At Tel Aviv University Ltd. | Antibacterial agents and methods of identifying and utilizing same |
EP1678194B1 (en) | 2003-10-10 | 2013-06-26 | Alchemia Oncology Pty Limited | The modulation of hyaluronan synthesis and degradation in the treatment of disease |
WO2005034979A2 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
AU2004283758A1 (en) * | 2003-10-24 | 2005-05-06 | Alza Corporation | Preparation of lipid particles |
WO2005040163A1 (en) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
WO2005046637A2 (en) * | 2003-11-14 | 2005-05-26 | Het Nederlands Kanker Instituut | Pharmaceutical formulations employing short-chain sphingolipids and their use |
US20050129753A1 (en) * | 2003-11-14 | 2005-06-16 | Gabizon Alberto A. | Method for drug loading in liposomes |
ES2493016T3 (en) | 2003-11-17 | 2014-09-11 | Genentech, Inc. | Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or a cytotoxic agent and methods for the treatment of tumors of hematopoietic origin |
US7750123B2 (en) * | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
EP1701979A2 (en) * | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
US9050378B2 (en) * | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
AU2004298483A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
EP2402756A3 (en) * | 2003-12-23 | 2012-02-22 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
TR201815885T4 (en) | 2004-01-07 | 2018-11-21 | Novartis Vaccines & Diagnostics Inc | M-csf specific monoclonal antibodies and their use. |
JP2007520481A (en) * | 2004-01-15 | 2007-07-26 | アルザ・コーポレーシヨン | Liposome composition for delivering therapeutic agents |
JP2007520222A (en) | 2004-01-20 | 2007-07-26 | アイシス ファーマシューティカルズ インコーポレイテッド | Regulation of glucocorticoid receptor expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
US8784881B2 (en) | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
EP1579850A3 (en) * | 2004-03-15 | 2009-12-16 | Nipro Corporation | A pharmaceutical composition containing liposomes for treating a cancer |
US8790919B2 (en) | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
CA2559722A1 (en) * | 2004-03-18 | 2005-09-29 | Transave, Inc. | Administration of cisplatin by inhalation |
KR101245990B1 (en) * | 2004-03-26 | 2013-03-20 | 테루모 가부시키가이샤 | Liposome preparation |
CA2561221C (en) * | 2004-03-26 | 2016-09-20 | Curis, Inc. | Rna interference modulators of hedgehog signaling and uses thereof |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
CA2562024C (en) * | 2004-04-07 | 2014-05-27 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
EP1742660A2 (en) * | 2004-04-16 | 2007-01-17 | Genentech, Inc. | Treatment of disorders |
CA3006109A1 (en) | 2004-05-03 | 2005-11-17 | Ipsen Biopharm Ltd. | Drug delivery liposomes containing anionic polyols or anionic sugars |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
SI2612862T1 (en) | 2004-05-13 | 2017-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
AU2005251691A1 (en) * | 2004-05-17 | 2005-12-22 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
AU2005250369A1 (en) * | 2004-05-18 | 2005-12-15 | Genentech, Inc. | M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein |
US20050260260A1 (en) * | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
JP2008500397A (en) * | 2004-05-21 | 2008-01-10 | トランセイブ, インク. | Treatment of pulmonary and pre-pulmonary disease states |
MXPA06013581A (en) * | 2004-05-25 | 2007-03-15 | Metabolex Inc | Substituted triazoles as modulators of ppar and methods of their preparation. |
EP1755609A1 (en) * | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
JP2008500358A (en) * | 2004-05-25 | 2008-01-10 | メタボレックス インコーポレーティッド | Bicyclic substituted triazoles as modulators of PPARs and methods for their preparation |
CA2568249C (en) * | 2004-05-28 | 2014-12-09 | Human Biomolecular Research Institute | Synthesis of metabolically stable analgesics, pain medications and other agents |
AU2004320622B2 (en) * | 2004-06-03 | 2012-06-14 | Isis Pharmaceuticals, Inc. | Chimeric gapped oligomeric compositions |
US20090048192A1 (en) * | 2004-06-03 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
MXPA06014069A (en) | 2004-06-04 | 2007-04-25 | Genentech Inc | Method for treating multiple sclerosis. |
JP4796062B2 (en) * | 2004-06-07 | 2011-10-19 | プロチバ バイオセラピューティクス インコーポレイティッド | Lipid-encapsulating interfering RNA |
AU2005251403B2 (en) | 2004-06-07 | 2011-09-01 | Arbutus Biopharma Corporation | Cationic lipids and methods of use |
CA2579756C (en) * | 2004-06-19 | 2013-04-30 | Human Biomolecular Research Institute | Modulators of central nervous system neurotransmitters |
AU2005258161B2 (en) | 2004-06-21 | 2011-05-26 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
WO2006002538A1 (en) | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
WO2006014253A2 (en) * | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Factor viia variants |
CA2572765C (en) * | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
WO2006007712A1 (en) * | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
CA2910494C (en) | 2004-07-19 | 2018-10-23 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
EP2361931B1 (en) | 2004-07-20 | 2017-12-06 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
CN101023182B (en) | 2004-07-26 | 2013-04-17 | 健泰科生物技术公司 | Methods and compositions for modulating hepatocyte growth factor activation |
SG190665A1 (en) * | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
US8568637B2 (en) | 2004-08-02 | 2013-10-29 | Ramot At Tel-Aviv University Ltd. | Method of forming a fiber made of peptide nanostructures |
US9132116B2 (en) * | 2004-08-02 | 2015-09-15 | Willowcroft Pharm Inc. | Mast cell stabilizers to prevent or treat laminitis |
JP4934036B2 (en) | 2004-08-17 | 2012-05-16 | タイコ ヘルスケア グループ リミテッド パートナーシップ | Anti-adhesion barrier |
JP2006056807A (en) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | Preparation for use in photodynamic therapy |
ATE539745T1 (en) | 2004-08-19 | 2012-01-15 | Univ Tel Aviv Future Tech Dev | COMPOSITIONS FOR TREATING AMYLOID-ASSOCIATED DISEASES |
JP4715133B2 (en) * | 2004-08-26 | 2011-07-06 | コニカミノルタエムジー株式会社 | Anti-tumor liposome preparation and production method thereof |
JP2006069929A (en) * | 2004-08-31 | 2006-03-16 | Konica Minolta Medical & Graphic Inc | Preparation for treating mycosis and method for producing the same |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
WO2006027780A2 (en) * | 2004-09-08 | 2006-03-16 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
US20080063702A1 (en) * | 2004-09-09 | 2008-03-13 | Yechezkel Barenholz | Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions |
CN101048138B (en) * | 2004-09-09 | 2010-12-08 | 耶路撒冷希伯来大学伊萨姆研发公司 | Use of liposomal glucocorticoids for treating inflammatory states |
EP1797127B1 (en) * | 2004-09-24 | 2017-06-14 | Amgen Inc. | Modified fc molecules |
US6998028B1 (en) * | 2004-09-24 | 2006-02-14 | Superpower, Inc. | Methods for forming superconducting conductors |
US8435948B2 (en) | 2004-09-29 | 2013-05-07 | Mount Sinai School Of Medicine Of New York University | Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody |
ATE514776T1 (en) | 2004-10-05 | 2011-07-15 | California Inst Of Techn | APTAMER-REGULATED NUCLEIC ACIDS AND USES THEREOF |
CA2580271A1 (en) | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
ES2671893T3 (en) * | 2004-10-06 | 2018-06-11 | Mayo Foundation For Medical Education And Research | B7-H1 and PD-1 in the treatment of renal cell carcinoma |
JP2008515929A (en) * | 2004-10-08 | 2008-05-15 | アルザ コーポレイション | A method for inserting a lipid assembly into which a lipid linking part is preformed using microwaves |
TW200612993A (en) * | 2004-10-08 | 2006-05-01 | Alza Corp | Lipopolymer conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
US20090117176A1 (en) * | 2004-10-26 | 2009-05-07 | Pharma Mar, S.A. Sociedad Unipersonal | Anticancer Treatments |
EP1809254A2 (en) * | 2004-10-28 | 2007-07-25 | Alza Corporation | Lyophilized liposome formulations and method |
EP1658848B1 (en) | 2004-10-29 | 2007-08-01 | Pharma Mar S.A., Sociedad Unipersonal | Formulations comprising ecteinascidin and a disaccharide |
JP4990786B2 (en) | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | Compositions and methods for stabilizing drug liposome formulations |
TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
EP1811963A4 (en) * | 2004-11-08 | 2010-01-06 | Transave Inc | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
EP1814910A4 (en) * | 2004-11-11 | 2009-04-29 | Affymax Inc | Novel peptides that bind to the erythropoietin receptor |
CN101102752A (en) * | 2004-11-15 | 2008-01-09 | 耶路撒冷希伯来大学伊萨姆研发公司 | Combination therapy associating preferably a ceramide with acytotoxic drug |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
JP5110880B2 (en) * | 2004-11-18 | 2012-12-26 | テルモ株式会社 | Pharmaceutical compositions, formulations and combination formulations |
ATE544774T1 (en) * | 2004-12-14 | 2012-02-15 | Alnylam Pharmaceuticals Inc | RNAI MODULATION OF MLL-AF4 AND USES THEREOF |
ES2343746T3 (en) | 2005-01-07 | 2010-08-09 | Diadexus, Inc. | OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE. |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
WO2006078307A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
WO2006080452A1 (en) * | 2005-01-28 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Method for producing fine particle surface-modified with water-soluble substance |
EP1853289A4 (en) | 2005-01-31 | 2008-04-09 | Vaxinnate Corp | Novel polypeptide ligands for toll-like receptor 2 (tlr2) |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
PT1853718E (en) | 2005-02-15 | 2015-11-12 | Univ Duke | Anti-cd19 antibodies and uses in oncology |
CA2598409A1 (en) * | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
EP1871807B1 (en) | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
WO2006088245A1 (en) * | 2005-02-18 | 2006-08-24 | The University Of Tokushima | Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative |
US20060188509A1 (en) | 2005-02-23 | 2006-08-24 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
US20060204505A1 (en) * | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
AU2006223498A1 (en) | 2005-03-10 | 2006-09-21 | Genentech, Inc. | Methods and compositions for modulating vascular integrity |
JP2006248978A (en) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
EP1861072A2 (en) * | 2005-03-14 | 2007-12-05 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
US8288438B2 (en) | 2005-03-21 | 2012-10-16 | Metabolex, Inc. | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer |
CN1840193B (en) * | 2005-03-29 | 2010-05-12 | 中国科学院生物物理研究所 | Nanometer capsule of anthracene nucleus anticancer antibiotic with polyethylene glycol-phospholipid |
JP2008537551A (en) | 2005-03-31 | 2008-09-18 | カランド ファーマシューティカルズ, インコーポレイテッド | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
MY148086A (en) * | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
JP5047947B2 (en) | 2005-05-05 | 2012-10-10 | デューク ユニバーシティ | Anti-CD19 antibody treatment for autoimmune disease |
BRPI0611069A2 (en) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma |
PL1899364T3 (en) | 2005-05-17 | 2020-08-24 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
EP1871163A2 (en) | 2005-06-06 | 2008-01-02 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
WO2007005754A2 (en) * | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
KR20080039929A (en) | 2005-07-22 | 2008-05-07 | 와이스 테라퓨틱스 가부시키가이샤 | Anti-cd26 antibodies and methods of use thereof |
WO2007016285A2 (en) * | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
JP5657862B2 (en) * | 2005-07-28 | 2015-01-21 | ノバルティス アーゲー | Use of antibodies against M-CSF |
US20070055199A1 (en) | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Drug delivery device for buccal and aural applications and other areas of the body difficult to access |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
WO2007021423A2 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
EP1973928A2 (en) * | 2005-10-11 | 2008-10-01 | Ramot at Tel-Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
US7875602B2 (en) * | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
AR056142A1 (en) | 2005-10-21 | 2007-09-19 | Amgen Inc | METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY |
PL1978993T3 (en) | 2005-10-31 | 2017-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating cancer based on human fzd receptors |
GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | Modified sirna molecules and uses thereof |
US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
DE102005053066A1 (en) | 2005-11-04 | 2007-05-10 | Basf Ag | Use of copolymers as solubilizers for sparingly water-soluble compounds |
WO2007056264A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
DK2564864T3 (en) | 2005-11-12 | 2015-04-07 | Trustees Of The Leland Board Of | FGF-2 related methods for the diagnosis and treatment of depression |
LT2380592T (en) | 2005-11-14 | 2018-05-10 | Teva Pharmaceuticals International Gmbh | Antagonist antibody directed against calcitonin gene-related peptide |
TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
SI1948798T1 (en) | 2005-11-18 | 2015-09-30 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
EP1966377A2 (en) | 2005-11-21 | 2008-09-10 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
JP2009516514A (en) | 2005-11-21 | 2009-04-23 | ジェネンテック・インコーポレーテッド | Novel gene disruptions, compositions and methods related thereto |
WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
WO2007065027A2 (en) | 2005-12-02 | 2007-06-07 | Dana Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
ES2547689T3 (en) | 2005-12-02 | 2015-10-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling that involve antibodies that bind to IL-22 and IL-22R |
WO2007066335A2 (en) * | 2005-12-08 | 2007-06-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods for affecting liposome composition by ultrasound irradiation |
JP2009523119A (en) * | 2005-12-09 | 2009-06-18 | ビーエーエスエフ ソシエタス・ヨーロピア | Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilizers for compounds that are poorly soluble in water |
WO2007070705A2 (en) | 2005-12-15 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Cationic lipid-mediated vectors |
US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
BRPI0706314A2 (en) | 2006-01-05 | 2011-03-22 | Novartis Ag E Xoma Technology Ltd | method of treating a patient suffering from an osteolytic disorder |
US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
US7951934B2 (en) | 2006-01-26 | 2011-05-31 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
ES2502966T3 (en) | 2006-01-26 | 2014-10-06 | Recopharma Ab | Compositions and methods to inhibit viral adhesion |
US7829097B2 (en) * | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
US9119782B2 (en) | 2006-03-20 | 2015-09-01 | Mary P. McCourt | Drug delivery means |
RS54156B1 (en) | 2006-03-21 | 2015-12-31 | Genentech Inc. | Combinatorial therapy involving alpha5beta1 antagonists |
EP2389951A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
EP2010662A2 (en) | 2006-04-19 | 2009-01-07 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
CA2648481C (en) | 2006-04-21 | 2017-03-07 | Melinda Jane Frost | Pestivirus species |
CA2656990A1 (en) * | 2006-04-28 | 2007-11-08 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
WO2007127428A2 (en) * | 2006-04-28 | 2007-11-08 | University Of Florida Research Foundation, Inc. | Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
WO2008018932A2 (en) * | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
WO2007125173A2 (en) * | 2006-05-03 | 2007-11-08 | Baltic Technology Development, Ltd. | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
US20070264322A1 (en) * | 2006-05-10 | 2007-11-15 | Huang Ken S | Method for making liposomes conjugated with temperature-sensitive ligands |
US20080014205A1 (en) | 2006-05-15 | 2008-01-17 | Lawrence Horowitz | Neutralizing Antibodies to Influenza Viruses |
EP2023813A4 (en) * | 2006-05-15 | 2013-03-13 | Dmitri B Kirpotin | Magnetic microparticles comprising organic substances |
EP2029157A4 (en) * | 2006-05-19 | 2009-11-18 | Georgia Tech Res Inst | Abc transporter ligand |
WO2007137301A2 (en) * | 2006-05-23 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Modulation of chrebp expression |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
WO2007149433A2 (en) | 2006-06-19 | 2007-12-27 | The Johns Hopkins University | Tumor-specific delivery of therapeutic agents via liposomase |
AU2007281876B2 (en) | 2006-06-26 | 2013-09-05 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
EP2037928B1 (en) | 2006-06-26 | 2012-01-11 | Amgen Inc. | Methods for treating atherosclerosis |
JP5072275B2 (en) * | 2006-07-03 | 2012-11-14 | テルモ株式会社 | Method for separating closed vesicles, method for producing preparation and evaluation method |
WO2008054561A2 (en) | 2006-07-11 | 2008-05-08 | University Of Medicine And Dentistry Of New Jersey | Proteins, nucleic acids encoding the same and associated methods of use |
EP2049138A4 (en) * | 2006-07-14 | 2011-11-09 | Georgia Tech Res Inst | Clc channel ligand |
US8343539B2 (en) | 2006-07-14 | 2013-01-01 | Regents Of The University Of Minnesota | Compounds that bind α5β1 integrin and methods of use |
EP2046809B1 (en) | 2006-07-19 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Wsx-1/il-27 as a target for anti-inflammatory responses |
US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
JP4936312B2 (en) * | 2006-07-20 | 2012-05-23 | 株式会社島津製作所 | Novel amphiphile, drug delivery system and molecular imaging system using the same |
WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
JP5406027B2 (en) | 2006-08-04 | 2014-02-05 | ノバルティス アーゲー | EphB3-specific antibodies and uses thereof |
US8586006B2 (en) | 2006-08-09 | 2013-11-19 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
KR101433544B1 (en) | 2006-08-18 | 2014-08-27 | 노바르티스 아게 | Prlr-specific antibody and uses thereof |
EP2423332A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
DK2484696T3 (en) | 2006-08-28 | 2017-10-02 | Kyowa Hakko Kirin Co Ltd | Antagonistic hLIGHT-specific human monoclonal antibodies |
TWI439282B (en) | 2006-08-29 | 2014-06-01 | Genentech Inc | Method of treating stroke with thrombolytic agent |
US8466262B2 (en) | 2006-09-01 | 2013-06-18 | Zymogenetics, Inc. | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
CA2600220C (en) * | 2006-09-07 | 2014-12-09 | Canadian Blood Services | Surface cross-linked lipidic particles, methods of production and uses therefor |
BRPI0717431A2 (en) * | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | CANCER DIAGNOSTIC AND TREATMENT COMPOSITIONS AND METHODS |
CN101557818A (en) | 2006-10-03 | 2009-10-14 | 新泽西医科和牙科大学 | ATAP peptides, nucleic acids encoding the same and associated methods of use |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
US7820623B2 (en) | 2006-10-25 | 2010-10-26 | Amgen Inc. | Conjugated toxin peptide therapeutic agents |
PL2087002T3 (en) | 2006-10-27 | 2015-02-27 | Lpath Inc | Compositions and methods for binding sphingosine-1-phosphate |
CN101687031B (en) | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | Compositions and methods for treating ocular diseases and conditions |
US8158595B2 (en) | 2006-11-09 | 2012-04-17 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
DK2080012T3 (en) * | 2006-11-10 | 2013-06-17 | Dimerix Bioscience Pty Ltd | Methods for analyzing test compounds at associated receptors. |
CA2669399A1 (en) | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
EP2104513B1 (en) | 2006-11-27 | 2015-05-20 | diaDexus, Inc. | Ovr110 antibody compositions and methods of use |
EA200900767A1 (en) | 2006-12-07 | 2009-12-30 | Новартис Аг | ANTAGONISTIC ANTIBODIES AGAINST EPHB3 |
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
EP2114413B1 (en) * | 2006-12-18 | 2014-10-22 | The Johns Hopkins University | Therapeutics for treating cancer using 3-bromopyruvate |
US8834920B2 (en) | 2006-12-21 | 2014-09-16 | Alza Corporation | Liposome composition for targeting egfr receptor |
WO2008079973A2 (en) * | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Egfr binding peptides and uses thereof |
US8278415B2 (en) | 2006-12-21 | 2012-10-02 | Centocor, Inc. | Dimeric high affinity EGFR constructs and uses thereof |
EP2913341A1 (en) | 2006-12-22 | 2015-09-02 | University of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
US8440185B2 (en) * | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
AU2007339762B2 (en) * | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
US20100329664A1 (en) * | 2007-01-23 | 2010-12-30 | Lim Dae-Soon | Shutter device for camera |
US20100093836A1 (en) | 2007-01-29 | 2010-04-15 | Isis Pharmaceuticals, Inc | Compounds and methods for modulating protein expression |
WO2008094275A1 (en) | 2007-01-30 | 2008-08-07 | New York University | Peptides for treatment of conditions associated with nitric oxide |
CN101663407B (en) | 2007-02-22 | 2017-08-08 | 健泰科生物技术公司 | method for detecting inflammatory bowel disease |
PE20090681A1 (en) | 2007-03-02 | 2009-06-10 | Genentech Inc | PREDICTION OF RESPONSE TO A HER INHIBITOR |
AU2008227852B2 (en) * | 2007-03-19 | 2011-02-24 | Fresenius Kabi Oncology Ltd. | Proliposomal and liposomal compositions |
JP4510842B2 (en) * | 2007-03-26 | 2010-07-28 | キヤノン株式会社 | Polyhydroxyalkanoate-coated liposome |
EP2164868B1 (en) | 2007-05-04 | 2015-03-25 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Engineered rabbit antibody variable domains and uses thereof |
EP2737907A3 (en) | 2007-05-07 | 2014-11-05 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
WO2008141278A1 (en) * | 2007-05-11 | 2008-11-20 | Centocor, Inc. | Method for preparing antibody conjugates |
US20090175784A1 (en) | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
US20090196913A1 (en) * | 2007-05-11 | 2009-08-06 | Ken Shi Kun Huang | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
EP2160200B1 (en) | 2007-05-14 | 2013-07-10 | The University of Chicago | Antibody-LIGHT fusion products as cancer therapeutics |
EP2173381B1 (en) | 2007-05-14 | 2013-10-02 | NovImmune SA | Fc receptor-binding polypeptides with modified effector functions |
EP2162540A2 (en) * | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
WO2008148023A2 (en) * | 2007-05-23 | 2008-12-04 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating neurological disorders |
JP2010527618A (en) | 2007-05-24 | 2010-08-19 | アメリカ合衆国 | Nuclear protein transmission through the nucleoside salvage pathway |
AU2008260135A1 (en) | 2007-05-30 | 2008-12-11 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
WO2009029342A2 (en) * | 2007-07-13 | 2009-03-05 | The Johns Hopkins University | B7-dc variants |
US20090082217A1 (en) * | 2007-07-16 | 2009-03-26 | California Institute Of Technology | Selection of nucleic acid-based sensor domains within nucleic acid switch platform |
DK2474557T3 (en) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
ES2528922T3 (en) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Humanized and immunoconjugate anti-CD79b antibodies and methods of use |
CA2693169C (en) * | 2007-07-19 | 2016-01-12 | Metabolex, Inc. | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
EP2489730B1 (en) | 2007-07-26 | 2015-12-30 | Amgen, Inc | Modified lecithin-cholesterol acyltransferase enzymes |
EP2173781A1 (en) * | 2007-07-26 | 2010-04-14 | Basf Se | Process for preparing copolymers obtained by graft polymerization in solution and based on polyethers in solid form |
US7666973B2 (en) | 2007-07-30 | 2010-02-23 | Tyco Healthcare Group Lp | Carbonate copolymers |
HUE025283T2 (en) | 2007-08-02 | 2016-03-29 | Gilead Biologics Inc | Lox and l0xl2 inhibitors and uses thereof |
KR20100046185A (en) * | 2007-08-09 | 2010-05-06 | 다이이찌 산쿄 가부시키가이샤 | Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
US8268958B2 (en) | 2007-08-15 | 2012-09-18 | Tyco Healthcare Group Ip | Phospholipid copolymers |
US20090048423A1 (en) * | 2007-08-15 | 2009-02-19 | Tyco Healthcare Group Lp | Phospholipid Copolymers |
US8367815B2 (en) * | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US20120165387A1 (en) | 2007-08-28 | 2012-06-28 | Smolke Christina D | General composition framework for ligand-controlled RNA regulatory systems |
AU2008296012A1 (en) * | 2007-09-07 | 2009-03-12 | Gencia Corporation | Mitochondrial compositions and uses thereof |
US8865667B2 (en) * | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
CN102203002A (en) * | 2007-09-21 | 2011-09-28 | 细胞免疫科学公司 | Nanotherapeutic colloidal metal compositions and methods |
US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
WO2009039628A1 (en) | 2007-09-27 | 2009-04-02 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
JP2010540498A (en) | 2007-09-28 | 2010-12-24 | ウニヴェルズィテーツシュピタール バーゼル | Immunoliposomes for the treatment of cancer |
MX2010003465A (en) | 2007-10-02 | 2010-07-05 | Amgen Inc | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof. |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
ES2664822T3 (en) * | 2007-10-16 | 2018-04-23 | Biocon Limited | A solid pharmaceutical composition orally administrable and a process thereof |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
US20110152346A1 (en) * | 2007-11-05 | 2011-06-23 | Baltic Technology Development Ltd. | Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids |
EP2219452B1 (en) | 2007-11-05 | 2015-10-14 | MedImmune, LLC | Methods of treating scleroderma |
EP3360567A1 (en) | 2007-11-07 | 2018-08-15 | Genentech, Inc. | Amp for use in treating microbial disorders |
EP2220116B1 (en) * | 2007-11-12 | 2012-09-05 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
US8598165B2 (en) | 2007-11-26 | 2013-12-03 | University Of Kansas | Morpholines as selective inhibitors of cytochrome P450 2A13 |
EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
HUE036548T2 (en) | 2007-12-07 | 2018-08-28 | Zymogenetics Inc | Humanized antibody molecules specific for IL-31 |
US9029524B2 (en) * | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
EP3587450A1 (en) | 2007-12-17 | 2020-01-01 | Pfizer Limited | Treatment of interstitial cystitis with ngf inhibitors |
US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
US20090181094A1 (en) * | 2008-01-15 | 2009-07-16 | Eric Yueh-Lang Sheu | Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents |
AR070141A1 (en) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR |
TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
AU2009210636B2 (en) | 2008-01-31 | 2014-08-28 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
MX2010009885A (en) | 2008-03-10 | 2010-11-30 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections. |
AU2009228058A1 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
PL2280704T3 (en) * | 2008-03-31 | 2015-10-30 | Cymabay Therapeutics Inc | Oxymethylene aryl compounds and uses thereof |
JP2011516065A (en) | 2008-04-04 | 2011-05-26 | カランド ファーマシューティカルズ, インコーポレイテッド | Compositions and uses of EPAS1 inhibitors |
PL2279412T3 (en) | 2008-04-09 | 2017-12-29 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
WO2009126306A2 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
DK2279254T3 (en) | 2008-04-15 | 2017-09-18 | Protiva Biotherapeutics Inc | PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION |
EP2280995A2 (en) * | 2008-04-29 | 2011-02-09 | Wyeth LLC | Methods for treating inflammation |
JP2011519912A (en) * | 2008-05-09 | 2011-07-14 | リコファーマ アーベー | Compositions and methods for inhibiting Shiga toxin and Shiga-like toxin |
WO2009136297A2 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting toxin a from clostridium difficile |
PL2279004T3 (en) | 2008-05-16 | 2015-06-30 | Hoffmann La Roche | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
CN105363034A (en) * | 2008-05-23 | 2016-03-02 | 香港大学 | Combination therapy for the treatment of influenza |
US20110070298A1 (en) | 2008-06-05 | 2011-03-24 | Immunovaccine Technologies Inc. | Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance |
US20110104056A1 (en) | 2008-06-05 | 2011-05-05 | Isao Hara | Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, and molecular imaging system and drug delivery system |
US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
WO2009155431A1 (en) * | 2008-06-18 | 2009-12-23 | University Of Louisville Research Foundation, Inc. | Methods for targeted cancer treatment and detection |
ME02069B (en) | 2008-07-08 | 2015-05-20 | Oncomed Pharm Inc | Notch1 receptor binding agents and methods of use thereof |
EP2310440A4 (en) * | 2008-07-10 | 2013-06-05 | Serina Therapeutics Inc | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
US20100008900A1 (en) * | 2008-07-14 | 2010-01-14 | The University Of Hong Kong | Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
US20110237646A1 (en) * | 2008-08-07 | 2011-09-29 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
CN102186820B (en) | 2008-08-15 | 2013-08-28 | 乔治城大学 | Fluorescent regulators of rassf1a expression and human cancer cell proliferation |
PL2331092T3 (en) * | 2008-08-21 | 2014-08-29 | Univ Johns Hopkins | Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
CN103508936A (en) * | 2008-08-22 | 2014-01-15 | 赛诺菲-安万特 | Intermediate for preparation of indole benzylamine compound |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
EP2328919A2 (en) * | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
AU2009291747B2 (en) | 2008-09-10 | 2016-05-26 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
ES2475065T3 (en) | 2008-10-09 | 2014-07-10 | Tekmira Pharmaceuticals Corporation | Enhanced amino acids and methods for nucleic acid administration |
US9173840B2 (en) | 2008-10-09 | 2015-11-03 | Northeastern University | Multifunctional self-assembling polymeric nanosystems |
KR20110082145A (en) | 2008-10-21 | 2011-07-18 | 메타볼렉스, 인코포레이티드 | Aryl gpr120 receptor agonists and uses thereof |
JP5382380B2 (en) * | 2008-10-21 | 2014-01-08 | インターナショナル ワクチン インスティテュート | Novel Shigella protein antigen and method |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
MX2011004696A (en) * | 2008-11-06 | 2011-10-14 | Glenmark Pharmaceuticals Sa | Treatment with anti-alpha2 integrin antibodies. |
KR101967417B1 (en) | 2008-11-10 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | Novel lipids and compositions for the delivery of therapeutics |
ES2674719T3 (en) | 2008-11-13 | 2018-07-03 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
CA2744158A1 (en) | 2008-11-22 | 2010-05-27 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of breast cancer |
US20110230399A1 (en) * | 2008-11-25 | 2011-09-22 | Bowen Richard L | Methods for Treating Obesity Related Disease |
US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
CA2745811C (en) | 2008-12-04 | 2021-07-13 | Joseph Collard | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
KR101749352B1 (en) | 2008-12-04 | 2017-06-20 | 큐알엔에이, 인크. | Treatment of sirtuin 1(sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
CN102317458B (en) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases |
WO2010068680A1 (en) | 2008-12-10 | 2010-06-17 | Mount Sinai School Of Medicine Of New York University | Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
AR074760A1 (en) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME. |
AR074776A1 (en) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | METHOD TO TREAT MACULAR DEGENERATION; MODULATING THE PATIENT'S IMMUNE SYSTEM |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
NZ593649A (en) * | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
KR101805199B1 (en) | 2009-02-12 | 2017-12-05 | 큐알엔에이, 인크. | Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf |
EP3009150B1 (en) | 2009-02-12 | 2019-11-13 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
EP3424939A1 (en) | 2009-03-02 | 2019-01-09 | Alnylam Pharmaceuticals Inc. | Nucleic acid chemical modifications |
US20110319317A1 (en) | 2009-03-04 | 2011-12-29 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1 |
EP2228059A1 (en) | 2009-03-12 | 2010-09-15 | Universitätsspital Basel | Chemotherapeutic composition for the treatment of cancer |
WO2010107733A2 (en) | 2009-03-16 | 2010-09-23 | Curna, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
SI3260136T1 (en) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv) -neutralizing antibodies |
EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
US8440677B2 (en) | 2009-03-24 | 2013-05-14 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
CN103755808B (en) | 2009-03-25 | 2016-02-10 | 霍夫曼-拉罗奇有限公司 | Anti-alpha 5 beta 1 antibodies and application thereof |
WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
EP2413967A1 (en) | 2009-04-01 | 2012-02-08 | F. Hoffmann-La Roche AG | Treatment of insulin-resistant disorders |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
JP2012524126A (en) * | 2009-04-20 | 2012-10-11 | ギリアド カリストガ リミテッド ライアビリティ カンパニー | Method for treating solid tumors |
EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
CA2759506A1 (en) | 2009-04-23 | 2010-10-28 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
CN102459346B (en) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | The method manufacturing heteromultimers molecule |
EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
US8524784B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
US8524783B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
ES2661787T3 (en) | 2009-05-01 | 2018-04-04 | Curna, Inc. | Treatment of hemoglobin-related diseases (hbf / hbg) by inhibition of natural antisense transcript for hbf / hbg |
CA3045126A1 (en) | 2009-05-05 | 2010-11-11 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
NZ596186A (en) | 2009-05-05 | 2014-03-28 | Alnylam Pharmaceuticals Inc | Lipid compositions |
WO2010128407A2 (en) | 2009-05-05 | 2010-11-11 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
CN103223177B (en) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
KR101722541B1 (en) | 2009-05-06 | 2017-04-04 | 큐알엔에이, 인크. | Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp |
CN102575251B (en) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor |
EP2432499A2 (en) | 2009-05-20 | 2012-03-28 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
AU2010249787A1 (en) | 2009-05-20 | 2011-12-22 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
TWI583692B (en) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
EP2435571B1 (en) | 2009-05-28 | 2016-12-14 | CuRNA, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
KR101766408B1 (en) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | Improved lipid formulation |
WO2010143193A1 (en) | 2009-06-11 | 2010-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Targeted liposomes comprising n-containing bisphosphonates and uses thereof |
EP2443238B1 (en) | 2009-06-16 | 2017-03-22 | CuRNA, Inc. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
JP5944311B2 (en) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | Treatment of collagen gene-related diseases by suppression of natural antisense transcripts against collagen genes |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
CN102597238B (en) | 2009-06-24 | 2016-06-29 | 库尔纳公司 | The relevant disease of TNFR2 is treated by suppressing for the natural antisense transcript of tumor necrosis factor receptor 2 (TNFR2) |
WO2010151674A2 (en) | 2009-06-26 | 2010-12-29 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
WO2010151808A1 (en) | 2009-06-26 | 2010-12-29 | Sea Lane Biotechnologies, Llc | Expression of surrogate light chains |
WO2011000384A1 (en) | 2009-06-30 | 2011-01-06 | Общество С Ограниченной Ответсвенностью "Онкомакс" | Method for suppressing tumor growth by blocking fibroblast growth factor receptor, and method for diagnosing malignant neoplasms |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
JP5766188B2 (en) | 2009-07-01 | 2015-08-19 | プロチバ バイオセラピューティクス インコーポレイティッド | Lipid formulations for delivering therapeutic agents to solid tumors |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
WO2011005715A1 (en) | 2009-07-07 | 2011-01-13 | Genentech, Inc. | Diagnosis and treatment of autoimmune demyelinating diseases |
US8920775B2 (en) | 2009-07-17 | 2014-12-30 | Technical University Of Denmark | Loading technique for preparing radionuclide containing nanoparticles |
KR20120049281A (en) | 2009-07-21 | 2012-05-16 | 길리아드 칼리스토가 엘엘씨 | Treatment of liver disorders with pi3k inhibitors |
WO2011017297A2 (en) | 2009-08-03 | 2011-02-10 | The University Of North Carolina At Chapel Hill | Biodegradable delivery system complexes for the delivery of bioactive compounds |
JP6128848B2 (en) | 2009-08-05 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of insulin gene (INS) -related diseases by suppression of natural antisense transcripts against the insulin gene (INS) |
SG178419A1 (en) | 2009-08-15 | 2012-04-27 | Genentech Inc | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
FR2955324A1 (en) | 2010-01-15 | 2011-07-22 | Sanofi Aventis | DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
WO2011026132A2 (en) | 2009-08-31 | 2011-03-03 | 1/3Acamplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
US20110059111A1 (en) | 2009-09-01 | 2011-03-10 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Mammalian receptors as targets for antibody and active vaccination therapy against mold infections |
CA2772715C (en) | 2009-09-02 | 2019-03-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
JP5909185B2 (en) | 2009-10-01 | 2016-04-26 | シマベイ セラピューティクス, インコーポレーテッド | Substituted tetrazol-1-ylphenoxymethylthiazol-2-ylpiperidinylpyrimidine salt |
WO2011047267A1 (en) * | 2009-10-15 | 2011-04-21 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
EP2488204B1 (en) | 2009-10-16 | 2016-04-06 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
CN102711826B (en) | 2009-10-22 | 2017-03-29 | 霍夫曼-拉罗奇有限公司 | For the method and composition that the HEPSIN for regulating and controlling macrophage-stimulating albumen is activated |
WO2011053468A1 (en) | 2009-10-30 | 2011-05-05 | Sanofi-Aventis | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
ES2651682T3 (en) | 2009-11-05 | 2018-01-29 | Rhizen Pharmaceuticals S.A. | Novelty kinase modulators |
WO2011056234A1 (en) | 2009-11-06 | 2011-05-12 | Fibrogen, Inc. | Treatment for radiation-induced disorders |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
CA2781887C (en) | 2009-11-30 | 2018-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP2509997B1 (en) | 2009-12-07 | 2017-08-30 | i2 Pharmaceuticals, Inc. | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
US8901129B2 (en) | 2009-12-11 | 2014-12-02 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
US20130004490A1 (en) | 2009-12-14 | 2013-01-03 | The United States of America, as represented by the Secretary, Department | Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease |
WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
US8691227B2 (en) | 2009-12-17 | 2014-04-08 | Merck Sharp & Dohme Corp. | Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α |
ES2749426T3 (en) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Nucleic Acid Administration Methods and Compositions |
RU2012131280A (en) | 2009-12-23 | 2014-02-10 | Санофи | [4- (5-AMINOMETHYL-2-fluorophenyl) piperidin-1-yl] - (1H-pyrrolopyridinyl) methanones and their synthesis |
JP5944831B2 (en) | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーSYNIMMUNE GmbH | Anti-FLT3 antibody and method of use thereof |
CN102791702A (en) | 2009-12-23 | 2012-11-21 | 赛诺菲 | Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
CN102869776B (en) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF) |
KR101793753B1 (en) | 2009-12-23 | 2017-11-03 | 큐알엔에이, 인크. | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
WO2011080796A1 (en) | 2009-12-28 | 2011-07-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
WO2011090741A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
US20110159588A1 (en) | 2009-12-30 | 2011-06-30 | Kui Lin | Methods for Modulating a PDGF-AA Mediated Biological Response |
NO2521784T3 (en) | 2010-01-04 | 2018-05-05 | ||
US8912157B2 (en) | 2010-01-06 | 2014-12-16 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
JPWO2011083845A1 (en) * | 2010-01-08 | 2013-05-16 | 富士フイルム株式会社 | Targeting agent for tumor site |
DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
MX2012008085A (en) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Notch1 binding agents and methods of use thereof. |
EP2525808A2 (en) | 2010-01-19 | 2012-11-28 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
WO2011091390A2 (en) | 2010-01-25 | 2011-07-28 | Opko Curna, Llc | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
US8198337B2 (en) * | 2010-01-27 | 2012-06-12 | Momentive Performance Materials Inc. | Demulsifier compositions and methods for separating emulsions using the same |
US20130052259A1 (en) | 2010-02-01 | 2013-02-28 | Yechezkel Barenholz | Liposomes comprising amphipathic drugs and method for their preparation |
WO2011103528A2 (en) | 2010-02-22 | 2011-08-25 | Opko Curna Llc | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
KR20180028561A (en) | 2010-02-23 | 2018-03-16 | 제넨테크, 인크. | Anti-angiogenesis therapy for the treatment of ovarian cancer |
EP2538981B1 (en) | 2010-02-23 | 2017-12-20 | F. Hoffmann-La Roche AG | Compositions and methods for the diagnosis and treatment of tumor |
MX2012009809A (en) | 2010-02-23 | 2012-11-23 | Sanofi Sa | Anti-alpha2 integrin antibodies and their uses. |
US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | Sustained delivery of therapeutic agents to an eye compartment |
AU2011225716A1 (en) | 2010-03-11 | 2012-09-27 | Pfizer Inc. | Antibodies with pH dependent antigen binding |
WO2011119487A2 (en) | 2010-03-22 | 2011-09-29 | Genentech, Inc. | Compositions and methods useful for stabilizing protein-containing formulations |
EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2794745A1 (en) | 2010-03-29 | 2011-10-06 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
SG183947A1 (en) | 2010-03-31 | 2012-10-30 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
KR101715981B1 (en) | 2010-03-31 | 2017-03-13 | 길리애드 파마셋 엘엘씨 | Nucleoside phosphoramidates |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
US9102938B2 (en) | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
US9073990B2 (en) | 2010-04-05 | 2015-07-07 | Bar-Llan University | Protease-activatable pore-forming polypeptides |
US9044494B2 (en) | 2010-04-09 | 2015-06-02 | Curna, Inc. | Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21 |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
EP3085387A1 (en) | 2010-04-26 | 2016-10-26 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
JP5787323B2 (en) * | 2010-04-28 | 2015-09-30 | 国立大学法人北海道大学 | Lipid membrane structure |
WO2011139917A1 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
MX340696B (en) | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies. |
MA34291B1 (en) | 2010-05-03 | 2013-06-01 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR |
BR112012027828A2 (en) | 2010-05-03 | 2016-08-09 | Genentech Inc | matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation |
EP2566966A4 (en) | 2010-05-03 | 2013-12-11 | Curna Inc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
CN103429739B (en) | 2010-05-12 | 2018-11-13 | 哥伦比亚大学纽约管理委员会 | Prepare the method generated with the enteroendocrine cell of excreting insulin |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
WO2011145035A1 (en) | 2010-05-17 | 2011-11-24 | Indian Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases |
EP2571516B1 (en) | 2010-05-18 | 2017-11-15 | Neumedicines, Inc | Il-12 formulations for enhancing hematopoiesis |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
CA2799207C (en) | 2010-05-26 | 2019-03-26 | Curna, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
ES2648885T3 (en) | 2010-06-02 | 2018-01-08 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
DK2575764T3 (en) | 2010-06-03 | 2017-08-07 | Alnylam Pharmaceuticals Inc | BIODEGRADABLE LIPIDS FOR THE ACTIVATION OF ACTIVE AGENTS |
DK2582674T3 (en) | 2010-06-16 | 2014-12-15 | Cymabay Therapeutics Inc | GPR120 receptor agonists and uses thereof. |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
WO2011160110A1 (en) * | 2010-06-19 | 2011-12-22 | Western University Of Health Sciences | Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
CA2802541A1 (en) | 2010-06-23 | 2011-12-29 | Metabolex, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
AU2011270828B2 (en) | 2010-06-24 | 2015-09-24 | Genentech, Inc. | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
CN102309448B (en) * | 2010-06-29 | 2014-07-09 | 中国人民解放军军事医学科学院毒物药物研究所 | Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof |
WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
DK3243526T3 (en) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | SUPPLY OF RNA TO TRACT MULTIPLE IMMUNE SIGNAL WAYS |
PT2591114T (en) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Immunisation of large mammals with low doses of rna |
SI2590676T1 (en) | 2010-07-06 | 2016-11-30 | Glaxosmithkline Biologicals, S.A. | Virion-like delivery particles for self-replicating rna molecules |
CN103153284B (en) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | The liposome of the lipid of RNA delivery is conducive to containing its pKa value |
ES2704223T3 (en) | 2010-07-12 | 2019-03-15 | Pfizer Healthcare Ireland | Conjugates of multifunctional antibodies |
US8980860B2 (en) | 2010-07-14 | 2015-03-17 | Curna, Inc. | Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG |
CN103261225A (en) | 2010-07-23 | 2013-08-21 | 波士顿大学董事会 | Anti-desupr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
WO2012021786A2 (en) | 2010-08-12 | 2012-02-16 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
EP4101462A1 (en) * | 2010-08-31 | 2022-12-14 | GlaxoSmithKline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
ES2920140T3 (en) | 2010-08-31 | 2022-08-01 | Theraclone Sciences Inc | Human immunodeficiency virus (HIV) neutralizing antibodies |
CA2809678A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Small liposomes for delivery of immunogen-encoding rna |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
US8481680B2 (en) | 2010-10-05 | 2013-07-09 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US8993533B2 (en) | 2010-10-06 | 2015-03-31 | Curna, Inc. | Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4 |
ES2716243T3 (en) | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Antigen Supply Platforms |
CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
EP2633317A1 (en) | 2010-10-25 | 2013-09-04 | Genentech, Inc. | Treatment of gastrointestinal inflammation and psoriasis a |
CN103201387B (en) | 2010-10-27 | 2018-02-02 | 库尔纳公司 | IFRD1 relevant diseases are treated by suppressing the natural antisense transcript of interferon correlative development regulatory factor 1 (IFRD1) |
EA030436B1 (en) | 2010-11-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | ANTI-IL-23p19 ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF, USE THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THESE ANTIBODIES, METHOD FOR PRODUCING SAME, ISOLATED POLYNUCLEOTIDES, EXPRESSION VECTORS AND CELLS FOR PRODUCING ANTIBODIES |
WO2012061811A2 (en) | 2010-11-05 | 2012-05-10 | Fibrogen, Inc. | Treatment method for lung remodeling diseases |
US9518114B2 (en) | 2010-11-12 | 2016-12-13 | Purdue Research Foundation | Treating bladder tumor cells using fibronectin attachment protein as a target |
US20140199682A1 (en) | 2010-11-17 | 2014-07-17 | Sea Lane Biotechnologies, Llc | Influenza neutralizing agents |
CN103561726A (en) | 2010-11-18 | 2014-02-05 | 通用医疗公司 | Novel compositions and uses of anti-hypertension agents for cancer therapy |
WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
EP3042910B1 (en) | 2010-11-30 | 2019-01-09 | Gilead Pharmasset LLC | 2'-spiro-nucleosides for use in the therapy of hepatitis c |
KR20140092226A (en) | 2010-12-14 | 2014-07-23 | 테크니칼 유니버시티 오브 덴마크 | Entrapment of radionuclides in nanoparticle compositions |
EP2468259A1 (en) * | 2010-12-23 | 2012-06-27 | Traslational Cancer Drugs Pharma, S.L. | Pharmaceutical compositions of pyridinium and quinolinium derivatives |
CA2834968C (en) | 2011-01-05 | 2018-01-09 | Livon Laboratories | Methods of making liposomes, liposome compositions made by the methods, and methods of using the same |
EP4215194A1 (en) | 2011-01-11 | 2023-07-26 | Dimerix Bioscience Pty Ltd | Combination therapy |
DK3202760T3 (en) | 2011-01-11 | 2019-11-25 | Alnylam Pharmaceuticals Inc | PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY |
RU2440142C1 (en) | 2011-02-07 | 2012-01-20 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibody, stopping or retarding tumour growth (versions), method of suppressing tumour growth, method of diagnosing malignant lesions |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
EP2675478A4 (en) | 2011-02-14 | 2015-06-10 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza |
PL226015B1 (en) * | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposome preparation containing anticancer active substance, process for the preparation thereof and pharmaceutical compositions containing thereof |
JP6211931B2 (en) | 2011-03-09 | 2017-10-11 | セル・シグナリング・テクノロジー・インコーポレイテツド | Methods and reagents for producing monoclonal antibodies |
BR112013023576A2 (en) | 2011-03-15 | 2016-12-06 | Theraclone Sciences Inc | compositions and methods for influenza therapy and diagnosis |
JP2014509859A (en) | 2011-03-16 | 2014-04-24 | アムジエン・インコーポレーテツド | Potent and selective inhibitors of 17NAV1.3 and NAV1.7 |
US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
US9181308B2 (en) | 2011-03-28 | 2015-11-10 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
AU2012236304C1 (en) | 2011-03-31 | 2017-01-05 | Genentech, Inc. | Methods of administering beta7 integrin antagonists |
EP2508176A1 (en) | 2011-04-08 | 2012-10-10 | Lipotarg Gmbh | Novel combination treatment of cancer |
CN103547588B (en) | 2011-04-13 | 2016-06-29 | Isis制药公司 | The antisense that PTP1B expresses regulates |
JP6072771B2 (en) | 2011-04-20 | 2017-02-01 | メディミューン,エルエルシー | Antibodies and other molecules that bind to B7-H1 and PD-1 |
KR101589135B1 (en) | 2011-04-20 | 2016-01-29 | 주식회사 셀앤바이오 | Humanized anti-EMAPII antibodies and uses thereof |
ES2710874T3 (en) | 2011-05-04 | 2019-04-29 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
JP6400470B2 (en) | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | Multispecific Fab fusion proteins and methods of use |
RU2620980C2 (en) | 2011-06-09 | 2017-05-30 | Курна, Инк. | Treatment of diseases associated with frataxin (fxn), by inhibiting natural antisense fxn transcript |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2721156B1 (en) | 2011-06-16 | 2016-12-21 | Ionis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
US20150045540A1 (en) | 2011-06-28 | 2015-02-12 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
PL2731591T3 (en) | 2011-07-13 | 2021-05-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomes co-encapsulating a bisphosphonate and an amphipathic agent |
US20140161821A1 (en) | 2011-07-14 | 2014-06-12 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
FR2979239A1 (en) * | 2011-08-25 | 2013-03-01 | Trophos | LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE |
WO2013033069A1 (en) | 2011-08-30 | 2013-03-07 | Theraclone Sciences, Inc. | Human rhinovirus (hrv) antibodies |
PT2751279T (en) | 2011-08-31 | 2017-12-29 | St Jude Children`S Res Hospital | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use |
MY170725A (en) | 2011-09-09 | 2019-08-27 | Univ Osaka | Dengue-virus serotype neutralizing antibodies |
CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
AU2012312654B2 (en) | 2011-09-19 | 2017-04-13 | Gencia Corporation | Modified creatine compounds |
EP3401401B1 (en) | 2011-09-20 | 2020-04-15 | Ionis Pharmaceuticals, Inc. | Antisense modulation of gcgr expression |
US9399678B2 (en) | 2011-09-23 | 2016-07-26 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Anti-tumor necrosis factor-alpha agents and uses thereof |
EP2758438A1 (en) | 2011-09-23 | 2014-07-30 | Amgen Research (Munich) GmbH | Bispecific binding molecules for 5t4 and cd3 |
HUE061002T2 (en) | 2011-09-23 | 2023-04-28 | Mereo Biopharma 5 Inc | Vegf/dll4 binding agents and uses thereof |
CA2849476A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
CA2850187C (en) | 2011-09-29 | 2021-12-07 | Plx Pharma Inc. | Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
CN113876945A (en) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | Liposome composition comprising adjuvant for activating or increasing TLR2 activity and application thereof |
ES2687951T3 (en) | 2011-10-14 | 2018-10-30 | F. Hoffmann-La Roche Ag | Anti-HtrA1 antibodies and procedures for use |
US8883989B2 (en) | 2011-10-18 | 2014-11-11 | Regents Of The University Of Minnesota | Fractalkine binding polynucleotides and methods of use |
CN103906838A (en) | 2011-10-25 | 2014-07-02 | Isis制药公司 | Antisense modulation of GCCR expression |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
MX2014004991A (en) | 2011-10-28 | 2014-05-22 | Genentech Inc | Therapeutic combinations and methods of treating melanoma. |
DK3091029T3 (en) | 2011-10-31 | 2023-01-30 | Hoffmann La Roche | Anti-IL13 antibody formulations |
TWI619496B (en) * | 2011-11-03 | 2018-04-01 | 台灣微脂體股份有限公司 | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
BR112014011331A2 (en) | 2011-11-11 | 2017-04-25 | Rinat Neuroscience Corp | trop-2 specific antibodies and their uses |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
PL2780373T3 (en) | 2011-11-16 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies |
AU2012352454A1 (en) | 2011-12-15 | 2014-07-17 | The University Of Chicago | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
EP2794659A1 (en) | 2011-12-22 | 2014-10-29 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
EP3539982A3 (en) | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
EP3447071A1 (en) | 2012-01-09 | 2019-02-27 | Pfizer Healthcare Ireland | Mutant antibodies and conjugation thereof |
EP2804620A4 (en) | 2012-01-18 | 2016-04-13 | Neumedicines Inc | Il-12 for radiation protection and radiation-induced toxicity mitigation |
JP2015505537A (en) | 2012-01-20 | 2015-02-23 | シー レーン バイオテクノロジーズ, エルエルシー | Binding molecule conjugate |
US20150004219A1 (en) | 2012-02-02 | 2015-01-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Stable liposomes for drug delivery |
EP3578569A1 (en) | 2012-02-06 | 2019-12-11 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
AU2013221292A1 (en) * | 2012-02-17 | 2014-09-11 | Celsion Corporation | Thermosensitive nanoparticle formulations and method of making the same |
US20150037334A1 (en) | 2012-03-01 | 2015-02-05 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
US8865730B2 (en) | 2012-03-05 | 2014-10-21 | Gilead Calistoga Llc | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
JP2015511494A (en) | 2012-03-15 | 2015-04-20 | キュアナ,インク. | Treatment of BDNF-related diseases by inhibition of natural antisense transcripts against brain-derived neurotrophic factor (BDNF) |
PL2831117T3 (en) | 2012-03-29 | 2018-03-30 | Novimmune Sa | Anti-tlr4 antibodies and uses thereof |
SG11201406185WA (en) | 2012-03-30 | 2014-11-27 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
JP2015516400A (en) | 2012-04-24 | 2015-06-11 | ユニバーシティー オブ マイアミUniversity Of Miami | Perforin 2 protection against invasive and multi-drug resistant pathogens |
EP3326649B1 (en) | 2012-05-03 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
JP6411329B2 (en) | 2012-05-04 | 2018-10-24 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Affinity matured anti-CCR4 humanized monoclonal antibody and methods of use |
CA2872519C (en) | 2012-05-04 | 2017-09-05 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
BR112014031421A2 (en) | 2012-06-15 | 2017-06-27 | Brigham & Womens Hospital Inc | cancer treatment compositions and methods for producing them |
WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
JP2015524410A (en) * | 2012-07-18 | 2015-08-24 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | Liposome composition of epoxy ketone-based proteasome inhibitor |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
CN110464709A (en) | 2012-08-10 | 2019-11-19 | 德克萨斯州大学系统董事会 | For treating the neuroprotective liposome composition and method of apoplexy |
EP2885319B1 (en) | 2012-08-14 | 2019-10-09 | Nanyang Technological University | Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
ES2848025T3 (en) | 2012-09-04 | 2021-08-05 | Eleison Pharmaceuticals LLC | Prevention of lung cancer recurrence with lipid-complexed cisplatin |
US20160136159A1 (en) | 2012-09-17 | 2016-05-19 | Chemedest Ltd. | Method for Treating Peripheral Neuropathy |
US9828434B2 (en) | 2012-10-04 | 2017-11-28 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-PD-L1 antibodies and methods of use |
MX2015003932A (en) | 2012-10-05 | 2015-07-23 | Genentech Inc | Methods for diagnosing and treating inflammatory bowel disease. |
CA2887711A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
JP6371294B2 (en) | 2012-10-31 | 2018-08-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods and monitoring of treatment with DLL4 antagonists |
EP3725807A1 (en) | 2012-12-03 | 2020-10-21 | NovImmune SA | Anti-cd47 antibodies and methods of use thereof |
KR20150095809A (en) | 2012-12-12 | 2015-08-21 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Compositions and methods for treatment of cancer |
CN105072981B (en) | 2012-12-19 | 2017-10-24 | 纽约州立大学研究基金会 | The composition and method of inclusion are discharged for induced with laser nanoparticle |
AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
ES2875957T3 (en) | 2012-12-20 | 2021-11-11 | Amgen Inc | APJ receptor agonists and their uses |
GB201223053D0 (en) | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
EP2935332B1 (en) | 2012-12-21 | 2021-11-10 | MedImmune, LLC | Anti-h7cr antibodies |
US9920121B2 (en) | 2013-01-25 | 2018-03-20 | Amgen Inc. | Antibodies targeting CDH19 for melanoma |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
SG11201506132PA (en) | 2013-02-06 | 2015-09-29 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
WO2014126921A1 (en) | 2013-02-12 | 2014-08-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that neutralize norovirus |
EP2970408B1 (en) | 2013-03-12 | 2018-01-10 | Amgen Inc. | Potent and selective inhibitors of nav1.7 |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
JP2016513712A (en) | 2013-03-14 | 2016-05-16 | ジェローム, ジェイ. シェンターク, | Cholestosome vesicles for uptake of molecules into chylomicrons |
EP3689902B1 (en) | 2013-03-15 | 2023-06-28 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
WO2014140368A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza m2 and cd3 |
WO2014144017A2 (en) | 2013-03-15 | 2014-09-18 | Gencia Corporation | Compositions and methods for treating conditions that affect epidermis |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
WO2014152497A2 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
JP2016513682A (en) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | Anti-plasma kallikrein antibody |
WO2014145654A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Method for the site-specific covalent cross-linking of antibodies to surfaces |
US10159688B2 (en) * | 2013-03-15 | 2018-12-25 | M. Alphabet 3, L.L.C. | Methods and compositions for enhancing oxygen levels in tissues |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
EP3653642A1 (en) | 2013-03-15 | 2020-05-20 | Amgen Research (Munich) GmbH | Single chain binding molecules comprising n-terminal abp |
KR102175688B1 (en) | 2013-03-27 | 2020-11-06 | 제넨테크, 인크. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
DK2983787T3 (en) | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Procedure for the treatment of post-traumatic stress disorder |
US20140329889A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
WO2014182676A2 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
SG11201508264UA (en) | 2013-05-07 | 2015-11-27 | Rinat Neuroscience Corp | Anti-glucagon receptor antibodies and methods of use thereof |
WO2014183052A1 (en) | 2013-05-09 | 2014-11-13 | The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
BR112015029395A2 (en) | 2013-05-24 | 2017-09-19 | Medimmune Llc | ANTI-B7-H5 ANTIBODIES AND THEIR USES |
RU2687044C2 (en) | 2013-05-31 | 2019-05-06 | Дженентек, Инк. | Antibodies against teichoic acid conjugate and their conjugates |
PE20160715A1 (en) | 2013-05-31 | 2016-08-01 | Genentech Inc | ANTIBODIES AGAINST WALL AND CONJUGATED TEICOIC ACIDS |
ES2891755T3 (en) | 2013-06-06 | 2022-01-31 | Pf Medicament | Anti-C10orf54 antibodies and uses thereof |
AU2014280847B2 (en) | 2013-06-13 | 2019-07-04 | Antisense Therapeutics Ltd | Combination therapy |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
AU2014292924B2 (en) | 2013-07-25 | 2019-11-21 | Cytomx Therapeutics, Inc | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
US20160193148A1 (en) * | 2013-08-01 | 2016-07-07 | University Of Georgia Research Foundation, Inc. | Liposomal formulations for the treatment of bacterial infections |
TWI623551B (en) | 2013-08-02 | 2018-05-11 | 輝瑞大藥廠 | Anti-cxcr4 antibodies and antibody-drug conjugates |
EA201690213A1 (en) | 2013-08-12 | 2016-07-29 | Дженентек, Инк. | COMPOSITIONS AND METHOD FOR TREATMENT OF CONNECTED STATES |
US10077304B2 (en) | 2013-08-14 | 2018-09-18 | The Governing Council Of The University Of Toronto | Antibodies against frizzled receptor |
WO2015031536A1 (en) * | 2013-08-27 | 2015-03-05 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
ES2779302T3 (en) | 2013-09-04 | 2020-08-14 | Cold Spring Harbor Laboratory | Reduction of mRNA degradation with nonsense mediation |
AU2014317961B2 (en) | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
TWI688401B (en) | 2013-09-13 | 2020-03-21 | 美商安進公司 | Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia |
PT3046537T (en) * | 2013-09-16 | 2021-10-07 | Glycomine Inc | Pharmaceutical preparation of carbohydrates for therapeutic use |
DE102013015334A1 (en) * | 2013-09-17 | 2015-03-19 | Fresenius Medical Care Deutschland Gmbh | Magnesium-liposome complexes |
US10036020B2 (en) | 2013-09-19 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for inhibiting JC virus (JCV) |
RU2020106752A (en) | 2013-09-25 | 2020-03-11 | Сайтомкс Терапьютикс, Инк. | SUBSTRATES OF MATRIX METALLOPROTEINASES AND OTHER DISSOLIDABLE FRAGMENTS AND METHODS FOR USING THEM |
ES2714708T3 (en) | 2013-10-01 | 2019-05-29 | Mayo Found Medical Education & Res | Procedures for the treatment of cancer in patients with elevated levels of Bim |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3070167A4 (en) | 2013-11-06 | 2017-06-07 | Osaka University | Antibody having broad neutralizing activity in group 1 influenza a virus |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
JP2017505756A (en) | 2013-12-13 | 2017-02-23 | ザ ジェネラル ホスピタル コーポレイション | Soluble high molecular weight (HMW) tau species and uses thereof |
WO2015095601A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
JP2017500319A (en) | 2013-12-20 | 2017-01-05 | ギリアード カリストガ エルエルシー | Polymorphic form of the hydrochloride salt of (S) -2- (1- (9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one |
CA2936940C (en) | 2014-01-14 | 2023-07-04 | The Johns Hopkins University | Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof |
EP4176896A1 (en) | 2014-01-31 | 2023-05-10 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
EA033604B1 (en) | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Anti-baff antibody molecule, pharmaceutical composition comprising this molecule, methods of using same and isolated polynucleotide encoding same |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
EP3102197B1 (en) | 2014-02-04 | 2018-08-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US10272117B2 (en) | 2014-02-24 | 2019-04-30 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
EP4043489A1 (en) | 2014-03-19 | 2022-08-17 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
EP3119431B1 (en) | 2014-03-21 | 2024-01-24 | Teva Pharmaceuticals International GmbH | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
AU2015235986B2 (en) | 2014-03-27 | 2020-12-03 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
US10426753B2 (en) | 2014-04-03 | 2019-10-01 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
EP3134111B1 (en) | 2014-04-25 | 2022-06-08 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
LT3137114T (en) | 2014-04-30 | 2021-03-25 | Pfizer Inc. | Anti-ptk7 antibody-drug conjugates |
EP3139955B1 (en) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Fusion proteins for treating cancer and related methods |
WO2015171918A2 (en) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
US10392438B2 (en) | 2014-05-16 | 2019-08-27 | Pfizer Inc. | Bispecific antibodies |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
EA028614B1 (en) | 2014-05-22 | 2017-12-29 | Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" | Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer |
US10584171B2 (en) | 2014-05-30 | 2020-03-10 | Henlix Biotech Co., Ltd. | Anti-epidermal growth factor receptor (EGFR) antibodies |
CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
WO2015191362A1 (en) | 2014-06-11 | 2015-12-17 | Gilead Sciences, Inc. | Methods for treating cardiovascular diseases |
CA2952012A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
EP3157945A4 (en) | 2014-06-20 | 2017-11-22 | F. Hoffmann-La Roche AG | Chagasin-based scaffold compositions, methods, and uses |
EP3160503B1 (en) | 2014-06-26 | 2021-02-17 | The Trustees of Columbia University in the City of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
JP7020909B2 (en) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス,インコーポレイティド | Anti-CD3 antibody, activating anti-CD3 antibody, multispecific anti-CD3 antibody, multispecific activating anti-CD3 antibody, and how to use them. |
UY36245A (en) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
US11661462B2 (en) | 2014-07-31 | 2023-05-30 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody contructs |
WO2016020798A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016034968A1 (en) | 2014-09-02 | 2016-03-10 | Pfizer Inc. | Therapeutic antibody |
EP3197492A1 (en) | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
EP3201232A1 (en) | 2014-10-03 | 2017-08-09 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
WO2016057488A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
DK3212233T3 (en) | 2014-10-31 | 2020-07-27 | Oncomed Pharm Inc | COMBINATION THERAPY FOR TREATMENT OF DISEASE |
EP3218005B1 (en) | 2014-11-12 | 2023-01-04 | Seagen Inc. | Glycan-interacting compounds and methods of use |
WO2016077566A1 (en) | 2014-11-12 | 2016-05-19 | Research Institute At Nationwide Children's Hospital | Modulation of alternative mdm2 splicing |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
US11191811B2 (en) | 2014-11-19 | 2021-12-07 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for frailty associated with aging |
WO2016090038A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
JP6751393B2 (en) | 2014-12-03 | 2020-09-02 | ジェネンテック, インコーポレイテッド | Anti-STAPHYLOCOCCUS AUREUS antibody rifamycin conjugate and use thereof |
US10072070B2 (en) | 2014-12-05 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Potent anti-influenza A neuraminidase subtype N1 antibody |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
PT3800202T (en) | 2014-12-11 | 2023-01-05 | Pf Medicament | Anti-c10orf54 antibodies and uses thereof |
CN107278151A (en) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | Sutent preparation and its application method in treatment glaucoma |
MA41374A (en) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF |
CA2974715C (en) | 2015-01-27 | 2020-05-05 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
WO2016123329A2 (en) | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
JP2018506526A (en) | 2015-01-29 | 2018-03-08 | ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティBoard Of Trustees Of Michigan State University | Cryptic polypeptides and uses thereof |
CA2976912A1 (en) * | 2015-02-17 | 2016-08-25 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
PL3258951T3 (en) | 2015-02-19 | 2020-07-27 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
AU2016222683A1 (en) | 2015-02-26 | 2017-07-13 | Genentech, Inc. | Integrin beta7 antagonists and methods of treating crohn's disease |
BR112017015880A2 (en) | 2015-03-03 | 2018-07-31 | Kymab Ltd | antibodies, uses and methods |
EP3265059A4 (en) | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
CN107530291A (en) * | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | Double heavy duty liposomal pharmaceutical preparations |
WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
AU2016233143B2 (en) | 2015-03-17 | 2021-03-25 | Alberto Gabizon | Methods for the treatment of bladder cancer |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
EP3280730B1 (en) | 2015-04-08 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
KR102405104B1 (en) | 2015-04-13 | 2022-06-07 | 화이자 인코포레이티드 | Therapeutic antibodies and their uses |
KR20180023892A (en) | 2015-04-17 | 2018-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | The bispecific antibody constructs for CDH3 and CD3 |
CN107849134B (en) | 2015-05-01 | 2022-05-03 | 达纳-法伯癌症研究所公司 | Methods of mediating cytokine expression with anti-CCR 4 antibodies |
CN107922490A (en) | 2015-05-04 | 2018-04-17 | 西托姆克斯治疗公司 | Anti- ITGa3 antibody, can activate anti-ITGa3 antibody and its application method |
HUE057720T2 (en) | 2015-05-04 | 2022-06-28 | Cytomx Therapeutics Inc | Activatable anti-cd71 antibodies, and methods of use thereof |
PT3292150T (en) | 2015-05-04 | 2020-06-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
EP3294334B1 (en) | 2015-05-11 | 2020-07-08 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
EP3294887A1 (en) | 2015-05-14 | 2018-03-21 | CNIC Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | Mirna compositions for the treatment of mature b-cell neoplasms |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
AU2016271142A1 (en) | 2015-05-29 | 2017-11-23 | Genentech, Inc. | PD-L1 promoter methylation in cancer |
MA50829A (en) | 2015-06-01 | 2018-04-11 | Sarepta Therapeutics Inc | EXCLUSION OF EXON INDUCED BY ANTISEN TECHNOLOGY IN TYPE VII COLLAGEN |
MX2017016024A (en) | 2015-06-10 | 2018-08-15 | Elysium Health Inc | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders. |
CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
DK3322733T3 (en) | 2015-07-13 | 2021-10-18 | Compugen Ltd | HIDE1 COMPOSITIONS AND METHODS |
US10913802B2 (en) | 2015-07-21 | 2021-02-09 | Dyax Corp. | Monoclonal antibody inhibitor of factor XIIA |
BR112018001762A2 (en) | 2015-07-29 | 2018-09-18 | Allergan Inc | heavy chain only antibodies to ang-2 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
JP2018523673A (en) | 2015-08-14 | 2018-08-23 | アラーガン、インコーポレイテッドAllergan,Incorporated | Heavy chain only antibody against PDGF |
CN108348480A (en) | 2015-08-20 | 2018-07-31 | 益普生生物制药有限公司 | Use liposome Irinotecan and PARP inhibitor combination treatment use for cancer treatment |
ES2826826T3 (en) | 2015-08-21 | 2021-05-19 | Ipsen Biopharm Ltd | Pharmaceutical combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for the treatment of metastatic pancreatic cancer |
HUE063528T2 (en) | 2015-09-01 | 2024-01-28 | Boehringer Ingelheim Int | Use of anti-cd40 antibodies for treatment of lupus nephritis |
AU2016323447B2 (en) | 2015-09-15 | 2023-03-30 | Scholar Rock, Inc. | Anti-pro/latent-Myostatin antibodies and uses thereof |
TWI799366B (en) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | Cystine knot scaffold platform |
CA2999160A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
US10954300B2 (en) | 2015-09-28 | 2021-03-23 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
KR20180075537A (en) | 2015-10-06 | 2018-07-04 | 제넨테크, 인크. | Methods for treating multiple sclerosis |
WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
SG10201912568PA (en) | 2015-10-16 | 2020-02-27 | Ipsen Biopharm Ltd | Stabilizing camptothecin pharmaceutical compositions |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
SI3368578T1 (en) | 2015-10-30 | 2021-08-31 | F. Hoffmann-La Roche Ag | Anti-htra1 antibodies and methods of use thereof |
WO2017075670A1 (en) | 2015-11-05 | 2017-05-11 | Children's Hospital Los Angeles | "mobilizing leukemia cells" |
EP3370712A4 (en) | 2015-11-06 | 2019-10-09 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
AU2016352874B2 (en) | 2015-11-10 | 2021-06-24 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
CA3004886A1 (en) | 2015-11-12 | 2017-05-18 | Graybug Vision, Inc. | Aggregating microparticles for medical therapy |
MX2018005061A (en) | 2015-11-12 | 2019-02-28 | Siamab Therapeutics Inc | Glycan-interacting compounds and methods of use. |
TWI778491B (en) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
TWI812873B (en) | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | Antibodies and antibody fragments for site-specific conjugation |
ES2861449T3 (en) | 2015-12-02 | 2021-10-06 | Stcube & Co Inc | Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses |
WO2017096017A1 (en) | 2015-12-02 | 2017-06-08 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
MA43415A (en) | 2015-12-09 | 2018-10-17 | Modernatx Inc | MODIFIED RNA CODING FOR A URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE AND ASSOCIATED USES |
US10548844B2 (en) | 2015-12-14 | 2020-02-04 | Massachusetts Institute Of Technology | pH-responsive mucoadhesive polymeric encapsulated microorganisms |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
WO2017110772A1 (en) | 2015-12-21 | 2017-06-29 | 富士フイルム株式会社 | Liposome and liposome composition |
WO2017117218A1 (en) | 2015-12-30 | 2017-07-06 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
EP3400240A2 (en) | 2016-01-08 | 2018-11-14 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
TWI797073B (en) | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | Pharmaceutical composition comprising bispecific antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
EP4039709A1 (en) | 2016-02-03 | 2022-08-10 | Amgen Research (Munich) GmbH | Bcma and cd3 bispecific t cell engaging antibody constructs |
IL260920B (en) | 2016-02-03 | 2022-09-01 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs, compositions comprising same and uses thereof |
AU2017213826A1 (en) | 2016-02-04 | 2018-08-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
EP3426306A1 (en) * | 2016-03-07 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
JP7157981B2 (en) | 2016-03-07 | 2022-10-21 | チャールストンファーマ, エルエルシー | anti-nucleolin antibody |
PL3365368T3 (en) | 2016-03-11 | 2023-08-21 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
CN109476756B (en) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | Multi-specificity Fab fusion protein and application thereof |
CN109414511B (en) | 2016-04-18 | 2023-05-23 | 萨勒普塔医疗公司 | Antisense oligomers for treating diseases associated with acid alpha-glucosidase genes and methods of use thereof |
US10973748B2 (en) | 2016-04-21 | 2021-04-13 | Versitech Limited | Compositions and methods for lightening skin and reducing hyperpigmentation |
US11365256B2 (en) | 2016-06-08 | 2022-06-21 | Xencor, Inc. | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases |
ITUA20164630A1 (en) | 2016-06-23 | 2017-12-23 | Paolo Blasi | PHARMACOLOGICAL ADIUVANTS FOR TUMOR THERMAL WELDING |
EP3474886B1 (en) | 2016-06-27 | 2021-08-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children and adolescents |
US11246832B2 (en) | 2016-06-28 | 2022-02-15 | Verily Life Sciences Llc | Serial filtration to generate small cholesterol-containing liposomes |
RU2019104896A (en) | 2016-07-22 | 2020-08-24 | Дана-Фарбер Кэнсер Инститьют, Инк. | ANTIBODIES TO THE GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND METHODS OF THEIR USE |
CN109862896A (en) | 2016-08-03 | 2019-06-07 | 西玛贝医药公司 | For treating the Oxymethylene aryl compound of inflammatory gastrointestinal disease or gastrointestinal disorder |
TWI754659B (en) | 2016-08-08 | 2022-02-11 | 台灣微脂體股份有限公司 | Delivery vehicle, method and kit for preparing a liposomal composition containing mild acidic agent |
US10870694B2 (en) | 2016-09-02 | 2020-12-22 | Dana Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
EP3509633A1 (en) | 2016-09-06 | 2019-07-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
TW201825511A (en) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | Oncolytic virus expressing immune checkpoint modulators |
JP2019534858A (en) | 2016-09-09 | 2019-12-05 | ジェネンテック, インコーポレイテッド | Selective peptide inhibitor of FRIZZLED |
AU2017325839A1 (en) | 2016-09-14 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | Proximity-based sortase-mediated protein purification and ligation |
WO2018052818A1 (en) | 2016-09-16 | 2018-03-22 | Henlix, Inc. | Anti-pd-1 antibodies |
WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
EA201990548A1 (en) | 2016-09-23 | 2019-09-30 | Тева Фармасьютикалз Интернэшнл Гмбх | TREATMENT OF CLUSTER HEAD PAIN |
KR20190086681A (en) | 2016-10-26 | 2019-07-23 | 모더나티엑스, 인크. | Messenger ribonucleic acid and method of use thereof for improving immune response |
MX2019004783A (en) | 2016-11-02 | 2019-08-12 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin). |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
JP2020503256A (en) | 2016-11-04 | 2020-01-30 | ノビミューン エスアー | Anti-CD19 antibodies and methods of using them |
CN109996809A (en) | 2016-11-14 | 2019-07-09 | 诺华股份有限公司 | Composition relevant to fusogenic protein MINION, method and therapeutical uses |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
US10772926B2 (en) | 2016-12-16 | 2020-09-15 | Nutragen Health Innovations, Inc. | Natural drugs for the treatment of inflammation and melanoma |
RS63849B9 (en) | 2016-12-16 | 2023-06-30 | Pfizer | Glp-1 receptor agonists and uses thereof |
JP7157744B2 (en) | 2017-01-06 | 2022-10-20 | スカラー ロック インコーポレイテッド | Isoform-specific, context-tolerant TGFβ1 inhibitors and uses thereof |
PL3565592T3 (en) | 2017-01-06 | 2023-08-21 | Scholar Rock, Inc. | Treating metabolic diseases by inhibiting myostatin activation |
PT3565592T (en) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Methods for treating metabolic diseases by inhibiting myostatin activation |
WO2018144775A1 (en) | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
BR112019018043A2 (en) | 2017-03-03 | 2020-04-07 | Seattle Genetics Inc | cancer treatment method, and, antibody-drug conjugate |
SG11201907835YA (en) | 2017-03-03 | 2019-09-27 | Rinat Neuroscience Corp | Anti-gitr antibodies and methods of use thereof |
KR20190134654A (en) | 2017-03-09 | 2019-12-04 | 싸이톰스 테라퓨틱스, 인크. | CD147 antibody, activatable CD147 antibody, and how to make and use it |
CN110461877A (en) | 2017-03-27 | 2019-11-15 | 勃林格殷格翰国际有限公司 | The anti-antibody combined treatment of IL-36R |
WO2018191153A1 (en) | 2017-04-09 | 2018-10-18 | The Cleveland Clinic Foundation | Cancer treatment by malat1 inhibition |
WO2018189611A1 (en) | 2017-04-12 | 2018-10-18 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
EP3612625A4 (en) | 2017-04-21 | 2021-08-18 | Mellitus, LLC | Methods and antibodies for diabetes-related applications |
EP3615569A1 (en) | 2017-04-25 | 2020-03-04 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
KR20190141243A (en) | 2017-05-05 | 2019-12-23 | 암젠 인크 | Pharmaceutical compositions comprising bispecific antibody constructs for improved storage and administration |
US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
AU2018265415A1 (en) | 2017-05-10 | 2019-10-31 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
WO2018209288A1 (en) | 2017-05-12 | 2018-11-15 | Massachusetts Institute Of Technology | Argonaute protein-double stranded rna complexes and uses related thereto |
SG11201909751TA (en) | 2017-05-12 | 2019-11-28 | Augusta University Research Institute Inc | Human alpha fetoprotein-specific t cell receptors and uses thereof |
EP3630167A1 (en) | 2017-05-26 | 2020-04-08 | NovImmune SA | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
US20200131266A1 (en) | 2017-05-31 | 2020-04-30 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
KR20200015602A (en) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Antibodies and molecules immunospecifically binding to BTN1A1 and therapeutic uses thereof |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
KR20200026209A (en) | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
US20190015473A1 (en) | 2017-07-13 | 2019-01-17 | Massachusetts Institute Of Technology | Targeting the hdac2-sp3 complex to enhance synaptic funcation |
KR20200027971A (en) | 2017-07-14 | 2020-03-13 | 싸이톰스 테라퓨틱스, 인크. | Anti-CD166 antibodies and uses thereof |
WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
US20210025877A1 (en) | 2017-07-20 | 2021-01-28 | CytomX Therapeutices, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anti-nucleolin antibody |
MA49634A (en) | 2017-07-21 | 2020-05-27 | Modernatx Inc | MODIFIED RNA CODING FOR A PROPIONYL-COA-CARBOXYLASE AND ASSOCIATED USES |
EP3658672A1 (en) | 2017-07-24 | 2020-06-03 | Modernatx, Inc. | Modified mrna encoding a glucose-6-phosphatase and uses thereof |
CN116271012A (en) | 2017-07-27 | 2023-06-23 | 瑞颂医药公司 | High concentration anti-C5 antibody formulations |
US20200231682A1 (en) | 2017-07-28 | 2020-07-23 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
US11135187B2 (en) | 2017-08-22 | 2021-10-05 | National Institutes Of Health (Nih) | Compositions and methods for treating diabetic retinopathy |
US20190117789A1 (en) | 2017-08-30 | 2019-04-25 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
CN111133005A (en) | 2017-09-07 | 2020-05-08 | 奥古斯塔大学研究所公司 | Programmed cell death protein 1 antibodies |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
JP2020536967A (en) | 2017-10-12 | 2020-12-17 | イミュノウェイク インコーポレイテッド | VEGFR-antibody light chain fusion protein |
CA3078911A1 (en) | 2017-10-14 | 2019-04-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
SG11202003434SA (en) | 2017-10-17 | 2020-05-28 | Rhizen Pharmaceuticals Sa | Crac channel modulators for treating esophageal cancer |
JP7394753B2 (en) | 2017-10-18 | 2023-12-08 | サレプタ セラピューティクス, インコーポレイテッド | antisense oligomer compounds |
WO2019082124A1 (en) | 2017-10-26 | 2019-05-02 | Rhizen Pharmaceuticals Sa | Composition and method for treating diffuse large b-cell lymphoma |
CN111556876A (en) | 2017-10-27 | 2020-08-18 | 辉瑞公司 | Antibodies and antibody-drug conjugates specific for CD123 and uses thereof |
EA202090682A1 (en) | 2017-10-30 | 2020-10-15 | Ризен Фармасьютикалз Са | CALCIUM CHANNEL MODULATORS ACTIVATED BY CALCIUM RELEASE FOR TREATMENT OF HEMATOLOGICAL AND SOLID CANCER DISEASES |
WO2019086626A1 (en) | 2017-11-03 | 2019-05-09 | Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) | MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS |
US20200289520A1 (en) | 2017-12-06 | 2020-09-17 | Rhizen Pharmaceuticals Sa | Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma |
US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
US20210163592A1 (en) | 2017-12-11 | 2021-06-03 | Amgen Inc | Continuous manufacturing process for bispecific antibody products |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
US20190254973A1 (en) | 2018-02-22 | 2019-08-22 | Verily Life Sciences Llc | Combining orthogonal chemistries for preparation of multiplexed nanoparticles |
RU2020128440A (en) | 2018-02-28 | 2022-03-28 | Пфайзер Инк. | IL-15 OPTIONS AND THEIR APPLICATIONS |
EP3762420A1 (en) | 2018-03-09 | 2021-01-13 | CytomX Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
CA3093330A1 (en) | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
AU2019235033A1 (en) | 2018-03-14 | 2020-07-30 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
CA3093723A1 (en) | 2018-03-21 | 2019-09-26 | Colorado State University Research Foundation | Cancer vaccine compositions and methods of use thereof |
US10722528B2 (en) | 2018-03-28 | 2020-07-28 | Augusta University Research Institute, Inc. | Compositions and methods for inhibiting metastasis |
CN112334485A (en) | 2018-04-06 | 2021-02-05 | 百进生物科技公司 | Anti-tetraspanin 33agents and compositions thereof and methods of making and using |
CN116536272A (en) | 2018-04-06 | 2023-08-04 | 儿童医疗中心有限公司 | Compositions and methods for somatic reprogramming and imprinting |
US20210115156A1 (en) | 2018-04-13 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fc-engineered anti-human ige antibodies and methods of use |
US20210171610A1 (en) | 2018-05-02 | 2021-06-10 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
PE20210127A1 (en) | 2018-05-23 | 2021-01-19 | Pfizer | CD3 SPECIFIC ANTIBODIES AND THEIR USES |
US11525010B2 (en) | 2018-05-23 | 2022-12-13 | Pfizer Inc. | Antibodies specific for GUCY2c and uses thereof |
CA3045370A1 (en) | 2018-06-08 | 2019-12-08 | Pfizer Inc. | Methods of treating metabolic disease |
TWI707683B (en) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1 receptor agonists and uses thereof |
MX2020013624A (en) | 2018-06-15 | 2022-08-11 | Pfizer | Glp-1 receptor agonists and uses thereof. |
WO2019245817A1 (en) | 2018-06-19 | 2019-12-26 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
US11827877B2 (en) | 2018-06-28 | 2023-11-28 | Crispr Therapeutics Ag | Compositions and methods for genomic editing by insertion of donor polynucleotides |
EA202190094A1 (en) | 2018-06-29 | 2021-04-21 | Бёрингер Ингельхайм Интернациональ Гмбх | ANTIBODIES AGAINST CD40 FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE |
TWI709562B (en) | 2018-07-06 | 2020-11-11 | 美商輝瑞股份有限公司 | Manufacturing process and intermediates for a pyrrolo〔2,3-d〕pyrimidine compound and use thereof |
CA3105988A1 (en) | 2018-07-11 | 2020-01-16 | Abhishek Datta | High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof |
EP4019046A1 (en) | 2018-07-11 | 2022-06-29 | Scholar Rock, Inc. | Isoform selective tgfbeta1 inhibitors and use thereof |
TW202019957A (en) | 2018-07-11 | 2020-06-01 | 美商供石公司 | Tgfβ1 inhibitors and use thereof |
MA53160A (en) | 2018-07-20 | 2021-05-26 | Pf Medicament | RECEIVER FOR VISTA |
US20220023450A1 (en) * | 2018-09-11 | 2022-01-27 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
WO2020068557A1 (en) | 2018-09-25 | 2020-04-02 | BioLegend, Inc. | Anti-tlr9 agents and compositions and methods for making and using the same |
EP3856206A1 (en) | 2018-09-27 | 2021-08-04 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
WO2020065409A2 (en) | 2018-09-28 | 2020-04-02 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof |
MA53859A (en) | 2018-10-10 | 2022-01-19 | Boehringer Ingelheim Int | METHOD OF MEMBRANE GAS TRANSFER IN A HIGH-DENSITY BIOREACTOR CULTURE |
WO2020077212A1 (en) | 2018-10-11 | 2020-04-16 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
US11427591B2 (en) | 2018-10-17 | 2022-08-30 | Insilico Medicine Ip Limited | Kinase inhibitors |
US20210380669A1 (en) | 2018-10-23 | 2021-12-09 | Scholar Rock, Inc. | Rgmc-selective inhibitors and use thereof |
CN112955252B (en) * | 2018-10-26 | 2023-11-21 | 康涅狄格大学 | Continuous processing system and method for internal and external modification of nanoparticles |
MX2021005116A (en) | 2018-11-02 | 2021-07-15 | Cytomx Therapeutics Inc | Activatable anti-cd166 antibodies and methods of use thereof. |
EP3883928A4 (en) | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
MX2021006429A (en) | 2018-12-06 | 2021-07-15 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof. |
US11793834B2 (en) | 2018-12-12 | 2023-10-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
EP3914694A1 (en) | 2019-01-22 | 2021-12-01 | Massachusetts Institute of Technology | In vitro human blood brain barrier |
JP2020117502A (en) | 2019-01-28 | 2020-08-06 | ファイザー・インク | Method of treating signs and symptoms of osteoarthritis |
TW202043267A (en) | 2019-01-30 | 2020-12-01 | 美商供石公司 | Ltbp complex-specific inhibitors of tgfβ and uses thereof |
AU2020222083B2 (en) | 2019-02-15 | 2022-11-17 | Pfizer Inc. | Crystalline pyrimidinyl-3,8-diazabicyclo(3.2.1)octanylmethanone compound and use thereof |
US20220135663A1 (en) | 2019-02-18 | 2022-05-05 | Pfizer Inc. | Method of treatment of Chronic Low Back Pain |
CN113874394B (en) | 2019-02-20 | 2024-01-19 | 和铂抗体有限公司 | Antibodies to |
US11739078B2 (en) | 2019-02-22 | 2023-08-29 | Insilico Medicine Ip Limited | Methods of inhibiting kinases |
EP3930761A1 (en) | 2019-02-26 | 2022-01-05 | CytomX Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
US20200283796A1 (en) | 2019-03-05 | 2020-09-10 | Massachusetts Institute Of Technology | Dna launched rna replicon system (drep) and uses thereof |
BR112021017637A8 (en) | 2019-03-08 | 2022-08-16 | Massachusetts Inst Technology | SYNTHETIC ONCOLYTIC VIRUS, PHARMACEUTICAL COMPOSITION, AND METHOD TO TREAT CANCER |
EP3947441A1 (en) | 2019-03-27 | 2022-02-09 | UMC Utrecht Holding B.V. | Engineered iga antibodies and methods of use |
AR118536A1 (en) | 2019-04-01 | 2021-10-20 | Genentech Inc | COMPOSITIONS AND METHODS TO STABILIZE FORMULATIONS CONTAINING PROTEIN |
EP3947367A1 (en) | 2019-04-02 | 2022-02-09 | Array Biopharma, Inc. | Protein tyrosine phosphatase inhibitors |
EP3990452A1 (en) | 2019-06-28 | 2022-05-04 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
TW202115086A (en) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk inhibitors |
LT6699B (en) | 2019-07-15 | 2020-02-10 | UAB "Valentis" | Method for production of proliposomes by using up to 5% ethanol and the use thereof for encapsulation of lipophilic substances |
CN112300279A (en) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
US10758329B1 (en) | 2019-08-20 | 2020-09-01 | Raymond L. Wright, III | Hydrating mouth guard |
CN114650844A (en) | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | anti-CD 47 antibodies, activatable anti-CD 47 antibodies, and methods of use thereof |
WO2021062092A1 (en) | 2019-09-26 | 2021-04-01 | Massachusetts Institute Of Technology | Trans-activated functional rna by strand displacement and uses thereof |
WO2021062323A1 (en) | 2019-09-26 | 2021-04-01 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
WO2021062096A1 (en) | 2019-09-26 | 2021-04-01 | Massachusetts Institute Of Technology | Microrna-based logic gates and uses thereof |
WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
TWI771766B (en) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | Diacylglycerol acyltransferase 2 inhibitor |
CA3153932A1 (en) | 2019-10-07 | 2021-04-15 | Jonathan Kipnis | Modulating lymphatic vessels in neurological disease |
WO2021072277A1 (en) | 2019-10-09 | 2021-04-15 | Stcube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
US20240092935A1 (en) | 2019-10-11 | 2024-03-21 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
JP2023501912A (en) | 2019-10-21 | 2023-01-20 | ライゼン ファーマシューティカルズ アーゲー | Compositions containing DHODH inhibitors for the treatment of acute myeloid leukemia |
CA3163979A1 (en) | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
IL294650A (en) | 2020-01-11 | 2022-09-01 | Scholar Rock Inc | Tgfbeta inhibitors and use thereof |
WO2021142448A2 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
US20230076768A1 (en) | 2020-01-14 | 2023-03-09 | Synthekine, Inc. | IL2 Orthologs and Methods of Use |
CN115427447A (en) | 2020-01-17 | 2022-12-02 | 百进生物科技公司 | anti-TLR 7 agents and compositions and methods of making and using the same |
WO2021151079A1 (en) | 2020-01-24 | 2021-07-29 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
JP2022058085A (en) | 2020-02-24 | 2022-04-11 | ファイザー・インク | Combination of inhibitors of diacylglycerol acyltransferase 2 and inhibitors of acetyl-coa carboxylase |
AU2021232062A1 (en) | 2020-03-06 | 2022-09-29 | Colorado State University Research Foundation | Production of vaccines comprising inactivated SARS-CoV-2 viral particles |
CA3174908A1 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
GB202003632D0 (en) | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
US20230095383A1 (en) | 2020-03-17 | 2023-03-30 | Dst Pharma, Inc. | Methods and compositions for treating viral infections |
KR20220158031A (en) | 2020-03-26 | 2022-11-29 | 피엘엑스 옵코 인코포레이티드 | Pharmaceutical carrier capable of pH dependent reconstitution and method of manufacturing and using the same |
BR112022017578A2 (en) | 2020-03-27 | 2022-10-18 | Pfizer | TREATMENT OF TYPE 2 DIABETES OR OBESITY OR OVERWEIGHT WITH 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-IL}PIPERIDIN-1-IL)METHYL]-1-[ (2S)-OXETAN-2-ILMETHYL]-1H-BENZIMIDAZOL-6-CARBOXYLIC OR A PHARMACEUTICAL SALT THEREOF |
EP4132931A1 (en) | 2020-04-08 | 2023-02-15 | Pfizer Inc. | Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof |
CN115605229A (en) | 2020-04-24 | 2023-01-13 | 米伦纽姆医药公司(Us) | anti-CD 19 antibodies and uses thereof |
EP4146688A1 (en) | 2020-05-06 | 2023-03-15 | CRISPR Therapeutics AG | Mask peptides and masked anti-ptk7 antibodies comprising such |
AU2021271317A1 (en) | 2020-05-15 | 2023-01-19 | Crispr Therapeutics Ag | Messenger RNA encoding Cas9 for use in genome-editing systems |
JP2023527997A (en) | 2020-05-27 | 2023-07-03 | キル・レガー・セラピューティクス・インコーポレーテッド | Salts and crystal forms of GLP-1R agonists and uses thereof |
CA3186348A1 (en) | 2020-06-09 | 2021-12-16 | Pfizer Inc. | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof |
CA3187966A1 (en) | 2020-06-26 | 2021-12-30 | Pfizer Inc. | Methods of treating inflammatory bowel disease with tl1a antibodies |
WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
PE20231565A1 (en) | 2020-07-17 | 2023-10-04 | Pfizer | THERAPEUTIC ANTIBODIES AND THEIR USES |
WO2022020811A1 (en) | 2020-07-24 | 2022-01-27 | Strand Therapeutics, Inc. | Lipidnanoparticle comprising modified nucleotides |
EP4188552A2 (en) | 2020-07-28 | 2023-06-07 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic raf inhibitors and methods for use thereof |
IL300110A (en) | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Chiral synthesis of fused bicyclic raf inhibitors |
JP2023537005A (en) | 2020-08-05 | 2023-08-30 | シンセカイン インコーポレイテッド | IL10 receptor binding molecules and methods of use |
EP4192863A2 (en) | 2020-08-05 | 2023-06-14 | Synthekine, Inc. | Il2rg binding molecules and methods of use |
US20230272090A1 (en) | 2020-08-05 | 2023-08-31 | Sandro Vivona | Il2rb binding molecules and methods of use |
WO2022031869A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Gp130 binding molecules and methods of use |
AR123156A1 (en) | 2020-08-06 | 2022-11-02 | Qilu Regor Therapeutics Inc | GLP-1R AGONISTS AND THEIR USES |
WO2022036041A1 (en) | 2020-08-14 | 2022-02-17 | Kite Pharma, Inc | Improving immune cell function |
AU2021340793A1 (en) | 2020-09-14 | 2023-05-11 | Vor Biopharma Inc. | Single domain antibodies against cd33 |
US20220089759A1 (en) | 2020-09-21 | 2022-03-24 | Boehringer Ingelheim International Gmbh | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
EP4225794A1 (en) | 2020-10-06 | 2023-08-16 | Xencor, Inc. | Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle) |
CN116710446A (en) | 2020-10-14 | 2023-09-05 | 上海齐鲁锐格医药研发有限公司 | Crystal forms of GLP-1R agonist and application thereof |
WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
JP2024505790A (en) | 2020-12-18 | 2024-02-08 | モメンタ ファーマシューティカルズ インコーポレイテッド | Antibodies against integrin alpha 11 beta 1 |
CN116917309A (en) | 2021-01-08 | 2023-10-20 | 斯特兰德生物科技公司 | Expression constructs and uses thereof |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
EP4288457A2 (en) | 2021-02-05 | 2023-12-13 | Boehringer Ingelheim International GmbH | Anti-il1rap antibodies |
JP2024508818A (en) | 2021-02-24 | 2024-02-28 | インシリコ メディシン アイピー リミテッド | Analogs for the treatment of diseases |
AU2022234333A1 (en) | 2021-03-11 | 2023-09-28 | Kite Pharma, Inc. | Improving immune cell function |
WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
EP4314065A1 (en) | 2021-03-22 | 2024-02-07 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
IL305828A (en) | 2021-03-22 | 2023-11-01 | Novimmune Sa | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022215054A1 (en) | 2021-04-09 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
AU2022261124A1 (en) | 2021-04-22 | 2023-10-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
WO2022232035A1 (en) | 2021-04-26 | 2022-11-03 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
IL307939A (en) | 2021-04-26 | 2023-12-01 | Millennium Pharm Inc | Anti-clec12a antibodies and uses thereof |
WO2022235940A1 (en) | 2021-05-06 | 2022-11-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
WO2022245859A1 (en) | 2021-05-17 | 2022-11-24 | Curia Ip Holdings, Llc | Sars-cov-2 spike protein antibodies |
US20230115257A1 (en) | 2021-05-17 | 2023-04-13 | Curia Ip Holdings, Llc | Sars-cov-2 spike protein antibodies |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
CA3221555A1 (en) | 2021-06-23 | 2022-12-29 | Kimberly LONG | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
US20230048743A1 (en) | 2021-07-12 | 2023-02-16 | Genentech Inc. | Structures for Reducing Antibody-Lipase Binding |
WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
GB202111759D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
GB202111758D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
GB202111757D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
WO2023031741A1 (en) | 2021-08-31 | 2023-03-09 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
WO2023034901A1 (en) | 2021-09-01 | 2023-03-09 | The Broad Institute, Inc. | Tumor avatar vaccine compositions and uses thereof |
GB202112935D0 (en) | 2021-09-10 | 2021-10-27 | Harbour Antibodies Bv | Sars-cov-2 (sars2, covid-19) heavy chain only antibodies |
WO2023036982A1 (en) | 2021-09-10 | 2023-03-16 | Harbour Antibodies Bv | Anti-sars2-s antibodies |
TW202330612A (en) | 2021-10-20 | 2023-08-01 | 日商武田藥品工業股份有限公司 | Compositions targeting bcma and methods of use thereof |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
WO2023081471A1 (en) | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2023105371A1 (en) | 2021-12-08 | 2023-06-15 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
WO2023111817A1 (en) | 2021-12-17 | 2023-06-22 | Pfizer Inc. | Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
WO2023201238A1 (en) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023212618A1 (en) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
WO2023235852A1 (en) | 2022-06-03 | 2023-12-07 | Zenas Biopharma, Inc. | Methods and compositions for treating igg4- related diseases |
WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0072111A1 (en) * | 1981-07-20 | 1983-02-16 | Lipid Specialties, Inc. | Synthetic phospholipid compounds and their preparation |
EP0118316A2 (en) * | 1983-03-07 | 1984-09-12 | Lipid Specialties, Inc. | Synthetic phospholipid compounds, their preparation and use |
GB2185397A (en) * | 1986-01-17 | 1987-07-22 | Cosmas Damian Ltd | Drug delivery system |
WO1988004924A1 (en) * | 1986-12-24 | 1988-07-14 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0354855A2 (en) * | 1988-08-11 | 1990-02-14 | Terumo Kabushiki Kaisha | Liposomes on which adsorption of proteins is inhibited |
WO1990004384A1 (en) * | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | Liposomes |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
JPS60100516A (en) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
IE58981B1 (en) * | 1985-10-15 | 1993-12-15 | Vestar Inc | Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles |
US4797285A (en) * | 1985-12-06 | 1989-01-10 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Lipsome/anthraquinone drug composition and method |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4863739A (en) * | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
JPH0696636B2 (en) * | 1988-03-30 | 1994-11-30 | 富士写真フイルム株式会社 | 2,4-bis (o-methoxypolyethylene glycol) -6-cholesteryl-S-triazine compound |
AU616040B2 (en) * | 1988-08-11 | 1991-10-17 | Terumo Kabushiki Kaisha | Agents for inhibiting adsorption of proteins on the liposome surface |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
-
1989
- 1989-10-20 US US07/425,224 patent/US5013556A/en not_active Expired - Lifetime
-
1990
- 1990-10-19 DK DK91900513.2T patent/DK0496835T3/en active
- 1990-10-19 DE DE69019366T patent/DE69019366T2/en not_active Expired - Lifetime
- 1990-10-19 DE DE19675048C patent/DE19675048I2/en active Active
- 1990-10-19 ES ES91900513T patent/ES2071976T3/en not_active Expired - Lifetime
- 1990-10-19 KR KR1019920700918A patent/KR0134982B1/en not_active IP Right Cessation
- 1990-10-19 AU AU66374/90A patent/AU642679B2/en not_active Expired
- 1990-10-19 AU AU68982/91A patent/AU654120B2/en not_active Expired
- 1990-10-19 WO PCT/US1990/006211 patent/WO1991005546A1/en active IP Right Grant
- 1990-10-19 JP JP3501034A patent/JP2667051B2/en not_active Expired - Lifetime
- 1990-10-19 CA CA002067133A patent/CA2067133C/en not_active Expired - Lifetime
- 1990-10-19 CA CA002067178A patent/CA2067178C/en not_active Expired - Lifetime
- 1990-10-19 WO PCT/US1990/006034 patent/WO1991005545A1/en not_active Application Discontinuation
- 1990-10-19 AT AT91900513T patent/ATE122229T1/en active
- 1990-10-19 EP EP91900513A patent/EP0496835B1/en not_active Expired - Lifetime
- 1990-10-19 KR KR1019920700919A patent/KR920703013A/en not_active Application Discontinuation
- 1990-10-19 EP EP90916409A patent/EP0496813B1/en not_active Revoked
- 1990-10-19 JP JP51523890A patent/JP3571335B2/en not_active Expired - Fee Related
- 1990-10-19 DE DE69015207T patent/DE69015207T2/en not_active Revoked
- 1990-10-19 AT AT90916409T patent/ATE115401T1/en not_active IP Right Cessation
- 1990-10-21 IL IL9606990A patent/IL96069A/en not_active IP Right Cessation
- 1990-10-21 IL IL9607090A patent/IL96070A/en not_active IP Right Cessation
-
1991
- 1991-01-15 US US07/642,321 patent/US5213804A/en not_active Expired - Lifetime
-
1992
- 1992-03-27 NO NO920996A patent/NO304637B1/en not_active IP Right Cessation
- 1992-03-27 NO NO92921213A patent/NO921213L/en unknown
- 1992-04-21 FI FI921763A patent/FI921763A0/en not_active Application Discontinuation
- 1992-04-21 FI FI921764A patent/FI105151B/en active Protection Beyond IP Right Term
-
1995
- 1995-08-09 GR GR950402186T patent/GR3017060T3/en unknown
-
1996
- 1996-12-13 LU LU88854C patent/LU88854I2/en unknown
- 1996-12-18 NL NL960031C patent/NL960031I2/en unknown
-
1997
- 1997-02-05 HK HK14097A patent/HK14097A/en not_active IP Right Cessation
- 1997-03-17 JP JP9063661A patent/JP2889549B2/en not_active Expired - Lifetime
-
1999
- 1999-02-23 NO NO1999003C patent/NO1999003I1/en unknown
-
2001
- 2001-01-11 JP JP2001004291A patent/JP3921050B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0072111A1 (en) * | 1981-07-20 | 1983-02-16 | Lipid Specialties, Inc. | Synthetic phospholipid compounds and their preparation |
EP0118316A2 (en) * | 1983-03-07 | 1984-09-12 | Lipid Specialties, Inc. | Synthetic phospholipid compounds, their preparation and use |
GB2185397A (en) * | 1986-01-17 | 1987-07-22 | Cosmas Damian Ltd | Drug delivery system |
WO1988004924A1 (en) * | 1986-12-24 | 1988-07-14 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0354855A2 (en) * | 1988-08-11 | 1990-02-14 | Terumo Kabushiki Kaisha | Liposomes on which adsorption of proteins is inhibited |
WO1990004384A1 (en) * | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | Liposomes |
Non-Patent Citations (2)
Title |
---|
Derwent File Supplier WPIL, 1989, AN 89-335922 (46), Derwent Publications, Ltd. (London, GB), & JP-A-1249798 (FUJI PHOTO FILM CO., LTD), 5 October 1989 * |
Patent Abstracts of Japan, volume 13, no. 592 (C-671)(3940), 26 December 1989; & JP-A-1249717 (FUJI PHOTO FILM CO., LTD.) 5 October 1989 * |
Cited By (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
WO1994007537A1 (en) * | 1992-10-05 | 1994-04-14 | Stichting Voor De Technische Wetenschappen | Pharmaceutical composition for site-specific release of a clot-dissolving protein |
WO1994007466A1 (en) * | 1992-10-07 | 1994-04-14 | Liposome Technology, Inc. | Compositions for treatmewnt of inflamed tissues |
WO1994020073A1 (en) * | 1993-03-03 | 1994-09-15 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
WO1994026251A1 (en) * | 1993-05-07 | 1994-11-24 | Sequus Pharmaceuticals, Inc. | Subcutaneous liposome delivery method |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5993846A (en) * | 1993-08-13 | 1999-11-30 | Pharmos Corporation | Bioadhesive emulsion preparations for enhanced drug delivery |
WO1996010391A1 (en) * | 1994-09-30 | 1996-04-11 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US6673364B1 (en) | 1995-06-07 | 2004-01-06 | The University Of British Columbia | Liposome having an exchangeable component |
US6096720A (en) * | 1995-08-01 | 2000-08-01 | Novartis Ag | Liposomal oligonucleotide compositions |
US6165501A (en) * | 1995-12-11 | 2000-12-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
WO1997021429A1 (en) * | 1995-12-11 | 1997-06-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid |
US6271208B1 (en) | 1996-08-26 | 2001-08-07 | Transgene S.A. | Process of making cationic lipid-nucleic acid complexes |
WO1998008489A1 (en) * | 1996-08-26 | 1998-03-05 | Transgene S.A. | Cationic lipid-nucleic acid complexes |
WO1998016202A2 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome composition and method |
US6224903B1 (en) | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
AU715063B2 (en) * | 1996-10-11 | 2000-01-13 | Alza Corporation | Fusogenic liposome composition and method |
WO1998016202A3 (en) * | 1996-10-11 | 1998-07-16 | Sequus Pharm Inc | Fusogenic liposome composition and method |
US6316024B1 (en) | 1996-10-11 | 2001-11-13 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
US6083923A (en) * | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
WO1999027908A1 (en) * | 1997-12-04 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
WO2000066126A3 (en) * | 1999-04-29 | 2001-04-05 | Alza Corp | Liposome compositions for improved drug retention |
WO2000066126A2 (en) * | 1999-04-29 | 2000-11-09 | Alza Corporation | Liposome compositions for improved drug retention |
WO2001011069A1 (en) | 1999-08-06 | 2001-02-15 | Celltech R&D Limited | Freeze/thawed lipid complexes and their preparation |
EP2329830A2 (en) | 2000-01-18 | 2011-06-08 | ISIS Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2003207A2 (en) | 2000-01-18 | 2008-12-17 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2213291A1 (en) | 2000-01-18 | 2010-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2246443A1 (en) | 2001-05-14 | 2010-11-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP2365094A1 (en) | 2001-05-14 | 2011-09-14 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP2270024A1 (en) | 2001-06-21 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP2221376A2 (en) | 2001-06-21 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP2280019A1 (en) | 2001-07-25 | 2011-02-02 | ISIS Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
EP2332955A2 (en) | 2001-07-30 | 2011-06-15 | ISIS Pharmaceuticals, Inc. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
EP2336145A1 (en) | 2001-08-01 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2174945A1 (en) | 2001-08-01 | 2010-04-14 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2272985A1 (en) | 2001-08-07 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (A) expression |
EP2316968A1 (en) | 2001-08-07 | 2011-05-04 | ISIS Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (A) expression |
EP2270230A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2270231A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2388318A1 (en) | 2001-12-10 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
US7358068B2 (en) | 2002-09-13 | 2008-04-15 | Replicor, Inc. | Antiviral oligonucleotides |
US8008270B2 (en) | 2002-09-13 | 2011-08-30 | Replicor Inc. | Antiviral oligonucleotides targeting viral families |
US8008269B2 (en) | 2002-09-13 | 2011-08-30 | Replicor Inc. | Antiviral oligonucleotides |
US8067385B2 (en) | 2002-09-13 | 2011-11-29 | Replicor, Inc. | Antiviral oligonucleotides targeting HBV |
EP2330194A2 (en) | 2002-09-13 | 2011-06-08 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
EP2336318A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2336319A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP1651187A4 (en) * | 2003-07-31 | 2009-03-11 | Univ Texas | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
EP1651187A2 (en) * | 2003-07-31 | 2006-05-03 | The Board Of Regents, The University Of Texas System | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
EP2284267A2 (en) | 2003-08-18 | 2011-02-16 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US8338381B2 (en) | 2003-10-24 | 2012-12-25 | ADER Enterprise, Inc. | Composition and method for the treatment of eye disease |
US7960350B2 (en) | 2003-10-24 | 2011-06-14 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
EP2527444A2 (en) | 2004-02-06 | 2012-11-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of stat3 expression |
EP2468865A1 (en) | 2004-02-06 | 2012-06-27 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of stat3 expression |
US8293719B2 (en) | 2004-03-12 | 2012-10-23 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
EP2944646A1 (en) | 2005-09-29 | 2015-11-18 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
WO2007115168A2 (en) | 2006-03-31 | 2007-10-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 gene |
US7718629B2 (en) | 2006-03-31 | 2010-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
EP2392583A1 (en) | 2006-05-19 | 2011-12-07 | Alnylam Europe AG. | RNAi modulation of Aha and therapeutic uses thereof |
EP2584051A1 (en) | 2006-05-22 | 2013-04-24 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expressions of IKK-B gene |
US7888498B2 (en) | 2006-05-22 | 2011-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
EP2905336A1 (en) | 2007-03-29 | 2015-08-12 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
US9476052B2 (en) | 2007-06-15 | 2016-10-25 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US8119612B2 (en) | 2007-06-15 | 2012-02-21 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US9074212B2 (en) | 2007-06-15 | 2015-07-07 | Arrowhead Research Corporation | RNAi inhibition of alpha-ENaC expression |
US8168606B2 (en) | 2007-06-15 | 2012-05-01 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US7943592B2 (en) | 2007-06-15 | 2011-05-17 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US10544418B2 (en) | 2007-06-15 | 2020-01-28 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US9914927B2 (en) | 2007-06-15 | 2018-03-13 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US7718632B2 (en) | 2007-06-15 | 2010-05-18 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US7939508B2 (en) | 2007-06-15 | 2011-05-10 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US11208662B2 (en) | 2007-06-15 | 2021-12-28 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
EP2848688A1 (en) | 2007-12-10 | 2015-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
EP2617828A1 (en) | 2007-12-10 | 2013-07-24 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of factor VII gene |
EP2712926A2 (en) | 2008-03-05 | 2014-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
US8148344B2 (en) | 2008-03-27 | 2012-04-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for mediating RNAi in vivo |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
EP2140872A2 (en) | 2008-07-02 | 2010-01-06 | Kenneth Wileford | Composition for the treatment of skin conditions comprising sea water with additional magnesium |
EP3081648A1 (en) | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
WO2010042281A2 (en) | 2008-08-25 | 2010-04-15 | Excaliard Pharmaceuticals | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2690175A2 (en) | 2008-09-02 | 2014-01-29 | Alnylam Pharmaceuticals | Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression |
EP3208337A1 (en) | 2008-09-02 | 2017-08-23 | Alnylam Pharmaceuticals, Inc. | Compositions for combined inhibition of mutant egfr and il-6 expression |
EP3109321A1 (en) | 2008-09-25 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
EP3584320A1 (en) | 2008-09-25 | 2019-12-25 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
EP3354733A1 (en) | 2008-10-20 | 2018-08-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
EP3848461A1 (en) | 2008-10-20 | 2021-07-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
EP2937418A1 (en) | 2008-10-20 | 2015-10-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
WO2010068816A1 (en) | 2008-12-10 | 2010-06-17 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
EP3225281A1 (en) | 2008-12-10 | 2017-10-04 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
US8926955B2 (en) | 2008-12-22 | 2015-01-06 | Creabilis S.A. | Synthesis of polymer conjugates of indolocarbazole compounds |
WO2010099341A1 (en) | 2009-02-26 | 2010-09-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of mig-12 gene |
WO2010105209A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
EP2810643A2 (en) | 2009-08-14 | 2014-12-10 | Alnylam Pharmaceuticals Inc. | Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus |
EP4089169A1 (en) | 2009-10-12 | 2022-11-16 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
EP3252068A2 (en) | 2009-10-12 | 2017-12-06 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
EP3329924A1 (en) | 2010-03-29 | 2018-06-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
EP3456827A2 (en) | 2010-06-02 | 2019-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
WO2012064824A1 (en) | 2010-11-09 | 2012-05-18 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
WO2012078967A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (epo) production |
WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
EP3674409A1 (en) | 2011-03-29 | 2020-07-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of tmprss6 gene |
EP3354343A1 (en) | 2011-06-02 | 2018-08-01 | President and Fellows of Harvard College | Methods and uses for ex vivo tissue culture systems |
WO2012166903A1 (en) | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
EP3693464A2 (en) | 2011-06-21 | 2020-08-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
EP3564393A1 (en) | 2011-06-21 | 2019-11-06 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
WO2012177906A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
EP3388068A1 (en) | 2011-06-21 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | Composition and methods for inhibition of expression of protein c (proc) genes |
WO2012177947A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
WO2012177949A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
EP3597750A1 (en) | 2011-06-23 | 2020-01-22 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
EP4134433A1 (en) | 2011-06-23 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
EP3366312A1 (en) | 2011-06-23 | 2018-08-29 | Alnylam Pharmaceuticals, Inc. | Serpina 1 sirnas: compositions of matter and methods of treatment |
WO2013003112A1 (en) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
US9138492B2 (en) * | 2012-02-23 | 2015-09-22 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
US20130224121A1 (en) * | 2012-02-23 | 2013-08-29 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
EP3868883A1 (en) | 2012-04-10 | 2021-08-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
EP3284824A1 (en) | 2012-04-10 | 2018-02-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2013155204A2 (en) | 2012-04-10 | 2013-10-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2014107731A1 (en) | 2013-01-07 | 2014-07-10 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
EP3708184A1 (en) | 2013-03-27 | 2020-09-16 | The General Hospital Corporation | Methods and agents for treating alzheimer s disease |
WO2014160871A2 (en) | 2013-03-27 | 2014-10-02 | The General Hospital Corporation | Methods and agents for treating alzheimer's disease |
WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
WO2015050990A1 (en) | 2013-10-02 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
EP3693463A1 (en) | 2013-10-04 | 2020-08-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
WO2016094897A1 (en) | 2014-12-12 | 2016-06-16 | The Jackson Laboratory | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
WO2016100716A1 (en) | 2014-12-18 | 2016-06-23 | Vasant Jadhav | Reversirtm compounds |
EP3797789A1 (en) | 2015-01-20 | 2021-03-31 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
US10485764B2 (en) | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
WO2017015109A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
EP3919619A1 (en) | 2015-07-17 | 2021-12-08 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017048843A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
US11214802B2 (en) | 2017-07-06 | 2022-01-04 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
WO2020037125A1 (en) | 2018-08-16 | 2020-02-20 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2020113135A1 (en) | 2018-11-29 | 2020-06-04 | Flagship Pioneering Innovations V, Inc. | Methods of modulating rna |
WO2021046122A1 (en) | 2019-09-03 | 2021-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
WO2021087325A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
WO2021163066A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
WO2021207167A1 (en) | 2020-04-06 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU642679B2 (en) | Liposome microreservoir composition and method | |
US5225212A (en) | Microreservoir liposome composition and method | |
EP0632719B1 (en) | Method of treatment of infected tissues | |
EP0662820B1 (en) | Compositions for treatmewnt of inflamed tissues | |
US4844904A (en) | Liposome composition | |
JP2001510451A (en) | Ion carrier carrying weakly basic drug-liposome in the middle | |
US20030113369A1 (en) | Liposomes with enhanced circulation time and method of treatment | |
AU2004218489A1 (en) | Liposome composition for reduction of liposome-induced complement activation | |
US20010051183A1 (en) | Liposomes with enhanced circulation time and method of treatment | |
WO2001041738A2 (en) | Lipid carrier compositions with protected surface reactive functions | |
WO2000009071A2 (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
WO2005021012A1 (en) | Drug carrier having gemcitabine enclosed therein | |
JPH04244017A (en) | Liposome preparation | |
WO2003022250A2 (en) | Unilamellar vesicles stabilized with short chain hydrophilic polymers | |
ZA200507816B (en) | Liposome composition for reduction of liposome-induced complement activation | |
KR100768265B1 (en) | Heparin coated liposomes to prolong circulation time in bloodstream and preparation method thereof | |
Scherphof et al. | In Vivo Uptake and Processing of Liposomes by Parenchymal and Non-Parenchymal Liver Cells; Application to Immunotherapeutic Treatment of Hepatic Metastases | |
WO1999065481A1 (en) | Liposomal formulations of busulphan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2067133 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 921763 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990916409 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990916409 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990916409 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990916409 Country of ref document: EP |